See discussions, stats, and author profiles for this publication at: https://www.researchgate.net/publication/299769281

Towards understanding and predicting suicidality in women: Biomarkers and clinical risk assessment

Article in Molecular Psychiatry · April 2016

DOI: 10.1038/mp.2016.31

| CITATIONS | S | READS | |
|-----------|---|-------|--|
| 21 autho | ors , including: | | |
| | Anantha Shekhar Indiana University School of Medicine 263 PUBLICATIONS 9,346 CITATIONS SEE PROFILE | | Sunil Kurian The Scripps Research Institute 124 PUBLICATIONS 2,305 CITATIONS SEE PROFILE |
| | George Sandusky Indiana University Bloomington 218 PUBLICATIONS 14,139 CITATIONS SEE PROFILE | | Alexander Niculescu Indiana University School of Medicine 90 PUBLICATIONS 2,975 CITATIONS SEE PROFILE |

Some of the authors of this publication are also working on these related projects:





Protein Structure / Function View project

All content following this page was uploaded by Daniel F Levey on 19 October 2017.

www.nature.com/mp

IMMEDIATE COMMUNICATION

Towards understanding and predicting suicidality in women: biomarkers and clinical risk assessment

DF Levey^{1,2,8}, EM Niculescu^{1,8}, H Le-Niculescu¹, HL Dainton¹, PL Phalen³, TB Ladd^{1,2}, H Weber³, E Belanger³, DL Graham³, FN Khan¹, NP Vanipenta¹, EC Stage^{1,2}, A Ballew⁴, M Yard⁵, T Gelbart⁶, A Shekhar¹, NJ Schork⁷, SM Kurian⁶, GE Sandusky⁵, DR Salomon⁶ and AB Niculescu^{1,2,3}

Women are under-represented in research on suicidality to date. Although women have a lower rate of suicide completion than men, due in part to the less-violent methods used, they have a higher rate of suicide attempts. Our group has previously identified genomic (blood gene expression biomarkers) and clinical information (apps) predictors for suicidality in men. We now describe pilot studies in women. We used a powerful within-participant discovery approach to identify genes that change in expression between no suicidal ideation (no SI) and high suicidal ideation (high SI) states (n = 12 participants out of a cohort of 51 women psychiatric participants followed longitudinally, with diagnoses of bipolar disorder, depression, schizoaffective disorder and schizophrenia). We then used a Convergent Functional Genomics (CFG) approach to prioritize the candidate biomarkers identified in the discovery step by using all the prior evidence in the field. Next, we validated for suicidal behavior the top-ranked biomarkers for SI, in a demographically matched cohort of women suicide completers from the coroner's office (n = 6), by assessing which markers were stepwise changed from no SI to high SI to suicide completers. We then tested the 50 biomarkers that survived Bonferroni correction in the validation step, as well as top increased and decreased biomarkers from the discovery and prioritization steps, in a completely independent test cohort of women psychiatric disorder participants for prediction of SI (n = 33) and in a future follow-up cohort of psychiatric disorder participants for prediction of psychiatric hospitalizations due to suicidality (n = 24). Additionally, we examined how two clinical instruments in the form of apps, Convergent Functional Information for Suicidality (CFI-S) and Simplified Affective State Scale (SASS), previously tested in men, perform in women. The top CFI-S item distinguishing high SI from no SI states was the chronic stress of social isolation. We then showed how the clinical information apps combined with the 50 validated biomarkers into a broad predictor (UP-Suicide), our apriori primary end point, predicts suicidality in women. UP-Suicide had a receiver-operating characteristic (ROC) area under the curve (AUC) of 82% for predicting SI and an AUC of 78% for predicting future hospitalizations for suicidality. Some of the individual components of the UP-Suicide showed even better results. SASS had an AUC of 81% for predicting SI, CFI-S had an AUC of 84% and the combination of the two apps had an AUC of 87%. The top biomarker from our sequential discovery, prioritization and validation steps, BCL2, predicted future hospitalizations due to suicidality with an AUC of 89%, and the panel of 50 validated biomarkers (BioM-50) predicted future hospitalizations due to suicidality with an AUC of 94%. The best overall single blood biomarker for predictions was PIK3C3 with an AUC of 65% for SI and an AUC of 90% for future hospitalizations. Finally, we sought to understand the biology of the biomarkers. BCL2 and GSK3B, the top CFG scoring validated biomarkers, as well as PIK3C3, have anti-apoptotic and neurotrophic effects, are decreased in expression in suicidality and are known targets of the anti-suicidal mood stabilizer drug lithium, which increases their expression and/or activity. Circadian clock genes were overrepresented among the top markers. Notably, PER1, increased in expression in suicidality, had an AUC of 84% for predicting future hospitalizations, and CSNK1A1, decreased in expression, had an AUC of 96% for predicting future hospitalizations. Circadian clock abnormalities are related to mood disorder, and sleep abnormalities have been implicated in suicide. Docosahexaenoic acid signaling was one of the top biological pathways overrepresented in validated biomarkers, which is of interest given the potential therapeutic and prophylactic benefits of omega-3 fatty acids. Some of the top biomarkers from the current work in women showed co-directionality of change in expression with our previous work in men, whereas others had changes in opposite directions, underlying the issue of biological context and differences in suicidality between the two genders. With this study, we begin to shed much needed light in the area of female suicidality, identify useful objective predictors and help understand gender commonalities and differences. During the conduct of the study, one participant committed suicide. In retrospect, when the analyses were completed, her UP-Suicide risk prediction score was at the 100 percentile of all participants tested.

Molecular Psychiatry advance online publication, 5 April 2016; doi:10.1038/mp.2016.31

¹Department of Psychiatry, Indiana University School of Medicine, Indianapolis, IN, USA; ²Stark Neuroscience Research Institute, Indiana University School of Medicine, Indianapolis, IN, USA; ³Indianapolis Veterans' Affairs Medical Center, Indianapolis, IN, USA; ⁴Marion County Coroner's Office, Indianapolis, IN, USA; ⁵Indiana Center for Biomarker Research in Neuropsychiatry, Indiana University School of Medicine, Indianapolis, IN, USA; ⁶Department of Molecular and Experimental Medicine, The Scripps Research Institute, La Jolla, CA, USA and ⁷J. Craig Venter Institute, La Jolla, CA, USA. Correspondence: Professor AB Niculescu, Psychiatry and Medical Neuroscience, Indiana University School of Medicine, Indianapolis Veterans' Affairs Medical Center, Indiana Center for Biomarker Research in Neuropsychiatry and Laboratory of Neurophenomics, Neuroscience Research Building 200B, 320W. 15th Street, Indianapolis, IN 46202, USA.

E-mail: anicules@iupui.edu

⁸These authors contributed equally to this work.

Received 22 November 2015; revised 27 January 2016; accepted 11 February 2016

2

INTRODUCTION

'Is there no way out of the mind?' -Sylvia Plath

Predicting suicidality (suicidal ideation (SI), suicide attempts and suicide completion) in individuals is a difficult task, which is even more challenging in an understudied population like women. Although women have a lower rate of suicide completion than men, due in part to the less-violent methods used, they have a higher rate of suicide attempts.¹ It is reasonable to assume that genetic and biological differences may exist in suicidality between men and women. Studies by gender are a first step toward individualized medicine. We have previously shown in men with psychiatric disorders how blood biomarkers for suicide, alone or in combination with quantitative phenomic data for anxiety and mood, the Simplified Affective State Scale (SASS), and with a risk profile scale we have developed, Convergent Functional Information for Suicide (CFI-S), collected in the form of apps, could have predictive ability for SI, and for future hospitalizations for suicidality.² We now present data for discovery, prioritization, validation and testing of blood biomarkers for suicidality in women, across psychiatric diagnoses. We also show the utility of SASS and CFI-S in predicting suicidality in women. Both these type of tools, biomarkers and phenomic data apps, do not directly ask about SI. We demonstrate how our apriori primary end point, a comprehensive universal predictor for suicide (UP-Suicide), composed of the combination of 50 top Bonferroni validated biomarkers, along with SASS, and CFI-S, predicts in independent test cohorts SI and future psychiatric hospitalizations for suicidality. Finally, we uncover biological pathways involved in suicide in women, and potential therapeutics.

MATERIALS AND METHODS

Human participants

We derived our data from four cohorts: one live psychiatric participants discovery cohort; one postmortem coroner's office validation cohort; and two live psychiatric participants test cohorts —one for predicting SI and one for predicting future hospitalizations for suicidality (Figure 1).

The live psychiatric participants are part of a larger longitudinal cohort that we are continuously collecting. Participants are recruited from the patient population at the Indianapolis Veterans' Affairs (VA) Medical Center and Indiana University School of Medicine through referrals from care providers, the use of brochures left in plain sight in public places and mental health clinics and through word of mouth. All participants understood and signed informed consent forms detailing the research goals, procedure, caveats and safeguards, per institutional review boardapproved protocol. Participants completed diagnostic assessments by an extensive structured clinical interview—Diagnostic Interview for Genetic Studies—at a baseline visit, followed by up to six testing visits, 3-6 months apart or whenever a new psychiatric hospitalization occurred. At each testing visit, they received a series of psychiatric rating scales, including the Hamilton Rating Scale for Depression-17, which includes a SI rating item (Figure 2a), and the blood was drawn. Whole blood (10 ml) was collected in two RNA-stabilizing PAXgene tubes, labeled with an anonymized ID number, and stored at - 80 °C in a locked freezer until the time of future processing. Whole-blood (predominantly lymphocyte) RNA was extracted for microarray gene expression studies from the PAXgene tubes, as detailed below. We focused this study on a female population. We have recently described a similar study in males,² and data from that study are used for gender comparison purposes in this paper.

Our within-participant discovery cohort, from which the biomarker data were derived, consisted of 12 female participants with psychiatric disorders and multiple visits in our laboratory,



Figure 1. Cohorts used in study depicting, flow of discovery, prioritization, validation and testing of biomarkers from each step.

who each had at least one diametric change in SI scores from no SI to high SI from one testing visit to another. There were 7 participants with 3 visits each, and 5 participants with 2 visits each, resulting in a total of 31 blood samples for subsequent microarray studies (Figure 2 and Supplementary Table S1).

Our postmortem cohort, in which the top biomarker findings were validated for behavior, consisted of a demographically matched cohort of six female violent suicide completers obtained through the Marion County coroner's office (Table 1 and Supplementary Table S1). We required a last observed alive postmortem interval of 24 h or less, and the cases selected had completed suicide by means other than overdose, which could affect gene expression. Five participants completed suicide by gunshot to head or chest, and one by asphyxiation. Next of kin signed informed consent at the coroner's office for donation of blood for research. The samples were collected as part of our INBRAIN initiative (Indiana Center for Biomarker Research in Neuropsychiatry).

Our independent test cohort for predicting SI (Table 1) consisted of 33 female participants with psychiatric disorders, demographically matched with the discovery cohort, with one or multiple testing visits in our laboratory, with either no SI, intermediate SI or high SI, resulting in a total of 74 blood samples in whom whole-genome blood gene expression data were obtained (Table 1 and Supplementary Table S1).

Our test cohort for predicting future hospitalizations (Table 1 and Supplementary Table S1) consisted of 24 female participants in whom whole-genome blood gene expression data were obtained by us at testing visits over the years as part of our longitudinal study. If the participants had multiple testing visits, then the visit with the highest marker (or combination of markers) levels was selected for the analyses (so-called 'high watermark' or index visit). The participants' subsequent number of psychiatric hospitalizations, with or without suicidality (ideation or attempt), was tabulated from electronic medical records. Participants were evaluated for the presence of future hospitalizations for suicidality, and for the frequency of such hospitalizations. A hospitalization was deemed to be without suicidality if suicidality was not listed as a reason for admission, and no SI was described in the admission and discharge medical notes. Conversely, a hospitalization was deemed to be because of suicidality if suicidal acts or

intent was listed as a reason for admission, and/or SI was described in the admission and discharge medical notes.

Medications

The participants in the discovery cohort were all diagnosed with various psychiatric disorders (Table 1). Their psychiatric medications were listed in their electronic medical records, and documented by us at the time of each testing visit. The participants were on a variety of different psychiatric medications: mood stabilizers, antidepressants, antipsychotics, benzodiazepines and others (data not shown). Medications can have a strong influence on gene expression. However, our discovery of differentially expressed genes was based on within-participant analyses, which factor out not only genetic background effects but also medication effects, as the participants had no major medication changes between visits. Moreover, there was no consistent pattern in any particular type of medication, or between any change in medications and SI, in the rare instances where there were changes in medications between visits.

Human blood gene expression experiments and analyses

RNA extraction. Whole blood (2.5–5 ml) was collected into each PaxGene tube by routine venipuncture. PaxGene tubes contain proprietary reagents for the stabilization of RNA. RNA was extracted and processed as previously described.³

 $\it Microarrays.$ Microarray work was carried out using previously described methodology. 4

Analysis. We have used the participant's SI scores at the time of blood collection (0—no SI compared with 2 and above—high SI). We looked at gene expression differences between the no SI and the high SI visits, using a within-participant design, then an across-participants summation (Figure 2).

Gene expression analyses in the discovery cohort

We analyzed the data in two ways: an Absent-Present (AP) approach, and a differential expression (DE) approach, as in previous work by us on suicide biomarkers.^{2,3} The AP approach may capture turning on and off of genes, and the DE approach may capture gradual changes in expression. For the AP approach, we used Affymetrix Microarray Suite Version 5.0 (MAS5) to generate Absent (A), Marginal (M) or Present (P) calls for each probeset on the chip (Affymetrix U133 Plus 2.0 GeneChips) for all participants in the discovery cohort (Affymetrix, Santa Clara, CA, USA). For the DE approach, we imported all Affymetrix microarray data as .cel files into Partek Genomic Suites 6.6 software package (Partek, St Louis, MO, USA). Using only the perfect match values, we ran a robust multi-array analysis (RMA), background corrected with quantile normalization and a median polish probeset summarization, to obtain the normalized expression levels of all probesets for each chip. RMA was performed independently for each of the four diagnoses used in the study, to avoid potential artifacts due to different ranges of gene expression in different diagnoses.⁵ Then, the participants normalized data were extracted from these RMAs and assembled for the different cohorts used in the study.

A/P analysis. For the longitudinal within-participant AP analysis, comparisons were made within-participant between sequential visits to identify changes in gene expression from Absent to Present that track changes in phene expression (SI) from no SI to high SI. For a comparison, if there was a change from A to P tracking a change from no SI to high SI, or a change from P to A tracking a change from high SI to no SI, that was given a score of +1 (increased biomarker in High SI). If the change was in opposite



direction in the gene vs the phene (SI), that was given a score of -1 (decreased biomarker in High SI). If there was no change in gene expression between visits despite a change of phene expression (SI), or a change in gene expression between visits despite no change in phene expression (SI), that was given a score of 0 (not tracking as a biomarker). If there was no change in gene expression and no change in SI between visits, that was given a score of +1 if there was concordance (P-P with High SI-High SI or A-A with No SI-No SI), or a score of -1 if there was the opposite (A-A with High SI-High SI or P-P with No SI-No SI). If the changes were to M (moderate) instead of P, then the values used were 0.5 or -0.5. These values were then summed up across the comparisons in each participant, resulting in an overall score for each gene/ probeset in each participant. We also used a perfection bonus. If the gene expression perfectly tracked the SI in a participant that had at least two comparisons (three visits), that probeset was rewarded by a doubling of its overall score. Additionally, we used a non-tracking correction. If there was no change in gene expression in any of the comparisons for a particular participant, that overall score for that probeset in that participant was zero.

DE analysis. For the longitudinal within-participant DE analysis, fold changes (FC) in gene expression were calculated between sequential visits within each participant. Scoring methodology was similar to that used above for AP. Probesets that had a $FC \ge 1.2$ were scored +1 (increased in high SI) or -1 (decreased in high SI). FC \ge 1.1 were scored +0.5 or – 0.5. FC lower than 1.1 were considered no change. The only difference between the DE and the AP analyses was when scoring comparisons where there was no phene expression (SI) change between visits and no change in gene expression between visits (FC lower than 1.1). In that case, the comparison received the same score as the nearest preceding comparison where there was a change in SI from visit to visit. If no preceding comparison with a change in SI was available, then it was given the same score as the nearest subsequent comparison where there was a change in SI. For DE also, we used a perfection bonus and a non-tracking correction. If the gene expression perfectly tracked the SI in a participant that had at least two comparisons (3 visits), that probeset was rewarded by a doubling of its score. If there was no change in gene expression in any of the comparisons for a particular participant, that overall score for that probeset in that participant was zero.

Internal score. Once scores within each participant were calculated, an algebraic sum across all participants was obtained, for each probeset. Probesets were then given internal points based upon these algebraic sum scores. Probesets with scores above the 33.3% of the maximum score (for increased probesets and decreased probesets) received 1 point, those above 50% received 2 points and those above 80% received 4 points. For AP analyses, we have 30 probesets which received 4 points, 647 probesets with 2 points and 2596 probesets with 1 point, for a total of 3273 probesets. For DE analyses, we have 95 probesets which received 4 points, 2215 probesets with 2 points and 7520 probesets with 1 point, for a total of 9829 probesets. The overlap between the two discovery methods for probesets with an internal score of 1 is shown in Figure 2d. Different probesets may be found by the two methods due to differences in scope (DE capturing genes that are present in both visits of a comparison, that is, PP, but are changed in expression), thresholds (what makes the 33.3% change cutoff across participants varies between methods), and technical detection levels (what is considered in the noise range varies between the methods).

Gene names for the probesets were identified using NetAffyx (Affymetrix) for Affymetrix HG-U133 Plus 2.0 GeneChips, followed by GeneCards to confirm the primary gene symbol. In addition, for those probesets that were not assigned a gene name by NetAffyx, we used the UCSC Genome Browser to directly map them to known genes, with the following limitations: (1) in case the



Figure 2. Biomarker discovery, prioritization and validation. Discovery cohort: longitudinal within-participant analysis. Phchp### is study ID for each participant. V# denotes visit number (1, 2 or 3). (a) Suicidal ideation (SI) scoring. (b) Participants and visits. (c) PhenoChipping: two-way unsupervised hierarchical clustering of all participant visits in the discovery cohort vs 18 quantitative phenotypes measuring affective state and suicidality. SASS, Simplified Affective State Scale. A—Anxiety items (Anxiety, Uncertainty, Fear, Anger, Average). M—Mood items (Mood, Motivation, Movement, Thinking, Self-esteem, Interest, Appetite, Average). STAI-STATE is State Trait Anxiety Inventory, State Subscale. YMRS is Young Mania Rating Scale. (d) Discovery—number of probesets carried forward from the Absent-Present (AP) and differential expression (DE) analyses, with an internal score of 1 and above. Red—increased in expression in high SI and blue—decreased in expression in high SI; (e) Prioritization—CFG genes, with a total score of 4 and above, validated in the cohort of suicide completers. All the genes shown were significantly changed and survived Bonferroni correction in ANOVA from no SI to high SI to suicide completers.

probeset fell in an intron, that particular gene was assumed to be implicated; (2) only one gene was assigned to each probeset. Genes were then scored using our manually curated Convergent Functional Genomics (CFG) databases as described below (Figure 2).

Convergent functional genomics

Databases. We have established in our laboratory (Laboratory of Neurophenomics, Indiana University School of Medicine, www. neurophenomics.info) manually curated databases of all the human gene expression (postmortem brain, blood and cell cultures), human genetics (association, copy number variations and linkage), and animal model gene expression and genetic studies published to date on psychiatric disorders. Only the findings deemed significant in the primary publication, by the study authors, using their particular experimental design and thresholds, are included in our databases. Our databases include only primary literature data and do not include review papers or other secondary data integration analyses to avoid redundancy and circularity. These large and constantly updated databases have been used in our CFG cross-validation and prioritization (Figure 2). For this study, data from 442 papers on suicide were present in the databases at the time of the CFG analyses (genetic studies—164, brain studies—192, peripheral fluids—86).

Human postmortem brain gene expression evidence. Converging evidence was scored for a gene if there were published reports of human postmortem data showing changes in expression of that gene or changes in protein levels in brains from participants who died from suicide.

Human blood and other peripheral tissue gene expression data. Converging evidence was scored for a gene if there were published reports of human blood, lymphoblastoid cell lines, cerebrospinal fluid or other peripheral tissue data showing changes in expression of that gene or changes in protein levels



| | Participants | Diagnosis | Ethnicity | Age mean (s.d.) | T-test fo | or age |
|--|--------------|--|---|---|---|--|
| Discovery cohort (within-participant changes in suicidal ideation) | 12 | BP = 4 $MDD = 4$ $SZA = 3$ $SZ = 1$ | EA = 9 AA = 2 Asian = 1 | All = 44.39 (11.65) No SI = 44.56 High SI = 44.15 | T-test for age between no SI and high SI 0.926 | |
| Independent validation cohort for gene expression (suicide completers) | 6 | BP = 1 $MDD = 3$ $PTSD = 1$ Non- | EA = 5 AA = 1 | 43.5 (14.24) | | T-test for age with discovery cohort P=0.890 |
| Independent testing cohort for state predictions (suicidal ideation) | 33 | psychiatric = 1 <u>All</u> BP = 17 MDD = 7 SZA = 7 SZ = 2 <u>No SI</u> BP = 13 MDD = 4 SZA = 6 SZ = 2 <u>Intermediate SI</u> BP = 3 SZA = 1 <u>High SI</u> BP = 3 MDD = 3 SZA = 1 | EA = 26 AA = 5 Asian = 1 Mixed = 1 | All = 44.05 (8.81) No SI = 43.98 High SI = 41.28 | T-test for age between no SI and high SI 0.553 | T-test for age with discovery cohort P = 0.887 |
| Combined discovery and testing cohort for state (suicidal ideation) used for CFI-S analysis (Figure 3) | 45 | AIIBP = 21MDD = 11SZA = 10SZ = 3No SIBP = 17MDD = 8SZA = 9SZ = 3Intermediate SIBP = 3SZA = 1High SIBP = 7MDD = 7SZA = 4SZ = 1 | EA = 35 AA = 7 Asian = 2 Mixed = 1 | All = 44.15 (9.68) No SI = 44.12 High SI = 43.15 | T-test for age between no SI and high SI 0.727 | |
| Testing cohort for trait predictions (future hospitalizations for suicidality) | 24 | JZ = 1 AII $BP = 10$ $MDD = 9$ $SZA = 3$ $SZ = 2$ $No Hosp for SI$ $BP = 8$ $MDD = 8$ $SZA = 1$ $SZ = 2$ $Hosp for SI$ $BP = 2$ $MDD = 1$ $SZA = 2$ $SZ = 0$ | EA = 19 AA = 4 Mixed = 1 | All = 46.51 (6.66) No Hosp for SI = 47.2 Hosp for SI = 43.4 | T-test for age between no Hosp for SI and Hosp for SI 0.0430 | T-test for age with discovery cohort P = 0.354 |

in participants who had a history of suicidality or who died from suicide.

Human genetic evidence (association and linkage). To designate convergence for a particular gene, the gene had to have

independent published evidence of association or linkage for suicide. For linkage, the location of each gene was obtained through GeneCards (http://www.genecards.org), and the sex averaged cM location of the start of the gene was then obtained through http://compgen.rutgers.edu/mapinterpolator. For linkage

| Gene symbol/Gene Name | Probeset L | Discovery (change) method/score | Prior human genetic evidence | Prior human brain expression evidence | Prior human peripheral expression evidence | Prioritization total CFG score for suicide | Validation ANOVA P-value | Predictions ROC/P-value | Clock function |
|---|---|--|---|---|--|--|---|--|--|
| Best predictive biomarkers out of validated b. BCL2 DCL2 | iomarkers (Bonfer 203684_s_at | oni) (49 genes, 50 ₁ (D) DE/2 | <i>probesets)</i> Linkage ³⁸ | (D) PFC ³⁹ | (D) Blood ⁴ | 00.6 | 3.95E – 06 | SI: 0.48/0.56 Hosp: | |
| B-ceil CLL/Lympnoma 2 <u>ALDH3A2</u> Aldehyde dehydrogenase 3 family, | 202053_s_at | (D) DE/2 | | (I) PFC, Thalamus ⁴⁰ | (D) Blood ⁴ | 8.00 | 1.62E – 06 | 0.89/0.00/ SI: 0.63/0.14 Hosp: 0.6/0.29 | |
| MOB3B | 229568_at | (D) DE/1 | | (I) ACC ¹³ | (I) Blood ⁴ | 7.00 | 4.69E – 06 | SI: 0.55/0.35 Hosp: | |
| Provide states activator 35 | 202861_at | (I) DE/1 | | (D) PFC ¹³ | (D) Blood ⁴ | 7.00 | 5.32E – 12 | CIU.U/CSU SI: 0.45/0.66 Hosp: | Clock Core |
| Period circadian clock I HAVCR2 ULAVCR2 | 1555629_at | (I) DE/4 | | | (D) Blood ⁴ | 6.00 | 1.69E – 12 | 0.84/0.018 SI: 0.62/0.15 Hosp: | |
| Hepatitis A virus cellular receptor 2 ARHGAP15 | 1561489_at | (I) DE/1 | Suicide ⁴¹ | | (I) Blood ⁴ | 5.00 | 3.05E – 06 | 0.8/0.022 SI: 0.55/0.34 Hosp: | |
| han orrase acuvaung protein 15 HTRA1 HtrA serine peptidase 1 | 201185_at | (I) AP/1 | | (I) NAC ¹³ | | 5.00 | 3.17E – 07 | 0./9/0.041 SI: 0.36/0.89 Hosp: 0.84/0.01 | Clock Distant |
| EPB41L5 erythrocyte membrane protein | 229292_at | (I) DE/1 | Linkage ⁴² | | (I) Blood ⁴ | 4.00 | 4.58E – 14 | SI: 0.68/0.062 Hosp: | Output |
| GF3C2 general transcription factor IIIC, | 210620_s_at | (D) DE/2 | | | (D) Blood ⁴ | 4.00 | 1.68E-07 | SI: 0.64/0.12 Hosp: | |
| Polypeptide 2, beta 110kUa PDXDC1 Pyridoxal-dependent decarboxylase | 1560013_at | (I) DE/2 | | | (I) Blood ⁴ | 4.00 | 1.03E – 05 | U.81/0.05 SI: 0.51/0.46 Hosp:0.81/0.018 | |
| oomain containing 1 <u>PIK3C3</u> Phosphatidylinositol 3-kinase, catalytic subunit type 3 | 232086_at | (D) DE/1 | Suicide, Antidepressant: 43 | s | (I) Blood ⁴ | 4.00 | 3.14E – 08 | SI: 0.65/0.098 Hosp: 0.9/0.011 | |
| Best predictive biomarkers out of top discove LRRC8B Leucine-rich repeat containing 8 family, | ry and prioritizati 212976_at | on biomarkers (non (D) DE/4 | -Bonferroni validated, 65 g | enes) (I) PFC ⁴⁴ | | 8.00 | 0.231881 | SI: 0.60/0.19 Hosp: 0.69/0.14 | |
| ACTR3 ACTR3 ART83 ART83 Actin-related protein 3 homolog | 213102_at | (D) DE/4 | Linkage ⁴² | | (I) Blood ⁴ | 7.00 | 0.0045239 | SI: 0.62/0.15 Hosp: 0.73/0.12 | |
| ASPH | 242037_at | (I) DE/4 | | | (I) Blood ⁴ | 6.00 | 0.01087 | SI: 0.65/.098 Hosp: | |
| aspartate beta-nyarioxytase <u>CSNK1A1</u> Casein kinase 1, alpha 1 | 235464_at | (D) DE/4 | | | (D) Blood ⁴ | 6.00 | NC | 0.8/.022 SI: 0.56/0.32 Hosp: 0.96/0.0007 | Clock Immediate |
| DPCD Deleted in primary ciliary dyskinesia | 226009_at | (I) DE/4 | | | (D) Blood ⁴ | 6.00 | NC | SI: 0.67/0.067 Hosp: 0.76/0.044 | Input |
| GTF3C3 GTF3C3 General transcription factor IIIC, | 1555439_at | (I) AP/4 | | | (I) Blood ⁴ | 6.00 | NC | SI: 0.67/0.075 Hosp: 0.75/.067 | |
| polypepride 3, rozkud KLHL28 Kelch-lika family member 28 | 220374_at | (I) AP/4 | | | (I) Blood ⁴ | 6.00 | NC | SI: 0.64/0.11 Hosp: 0.01/0.002 | |
| LARP4 Laribonucleoprotein domain family, | 214155_s_at | (D) DE/4 | | | (D) Blood ⁴ | 6.00 | 0.014911 | 0.9/0.005 0.9/0.005 | |
| NUDT6 NUDT6 Nudix (nucleoside diphosphate linked | 220183_s_at | (D) AP/4 | | | (D) Blood ⁴ | 6.00 | NC | SI: 0.62/0.16 Hosp: 0.71/0.14 | |
| Molety A)-type mour o SNX27 Sorting pavin family member 27 | 244349_at | (I) AP/4 | | | (I) Blood ⁴ | 6.00 | NC | SI: 0.63/0.13 Hosp: 0.85/0.015 | |
| UIMCI 11bicuitin interaction motif containing 1 | 233596_at | (I) DE/4 | | | (I) Blood ⁴ | 6.00 | NC | SI: 0.41/0.76 Hosp: 0.86/0.006 | |
| Zinc finger protein 548 | 1553718_at | (D) DE/4 | | | (D) Blood ⁴ | 6.00 | 0.000461 | SI: 0.40/0.82 Hosp: 0.83/0.012 | |
| Abbreviations: ACC, anterior cingulate characteristic. The 3 best predictive mi in order of Total CFG score (3 × 2 × 2 × biomarkers listed here (70%) are co-di probeset in men, not necessarily the os | the cortex; AP, Ak arkers, increase 2 = 24 possible irectional in mu | ssent-Present; CF d and decreased p: in fact 23 as o en for the exact women. Two hay | EG, Convergent Functi d, for suicidal ideation one (PIK3C3) is shared : same probeset. Evide | onal Genomics; DE, dif (SI) and for hospitalizat between SI and Hosp. ence in human periphe ence in the field In vult | fferential expression; N. tions (Hosp), from Valid, <u>Underlined</u> means cha eral expression evidenc | AC, nucleus accumber ated group and from 7 nged in the same dire e from column from 0 | ns; PFC, pre-fron Top Discovery an ection as in priol Niculescu <i>et al.</i> ⁴ | tal cortex; ROC, receive de Prioritization groups, r studies in men. ² 16 ol scommalus circlion of cha | er-operating , are shown, ut of the 23 inge of best |

Understanding and predicting suicidality in women DF Levey *et al*



| Table 3. Biological pathways and c | dise | Ises | | | | | | | | | | |
|--|-----------|--|---------------------------------|--|--|-----------------|---|--|--|--|---|---|
| A. | | Ingenuity pathways | | | KF | EGG pathwc | ski | | GeneGO path | iways | | |
| | # | Top canonical pathways | P-value | Ratio | Pathway name | Ra | tio Enrichm P-valı | nent Pr ue | ocess networks | Rat | io F | -value |
| Prioritization | - | B-cell receptor signaling- | 2.88E – 13 | 22.9% | Morphine addictio | n 19/. | 239 9.27E- | -06 In | mune response_BCR pathway | 42/1 | 137 4.3 | 332E-11 |
| ררט score ≥4 (<i>n</i> = 14/1 genes) | 7 | Protein kinase A signaling | 3.61E – 13 | 16.6% | Phosphatidylinosit | ol 18/. | 245 4.20E - | -05 A | poptosis_Anti-Apoptosis mediated | by 45/1 | 1.0 | 070E-08 |
| | m | PI3K signaling in B lymphocytes | 5.80E – 12 | 24.8% | signaling system Neurotrophin sign | aling 29/: | 545 7.23E - | e) -05 R€ | sternal signals via MAPK and JAK's sproduction_Gonadotropin regulat | tion 48/1 | 1.4 | 452E-08 |
| | 4 | IGF-1 signaling | 7.76E – 12 | 23/133 28.3% | pathway Amoebiasis | 22/. | 363 9.46E - | -05 Cé | ell cycle_G1-S Growth factor regula | ation 47/1 | 195 2.7 | 115E-08 |
| | ŝ | Glucocorticoid receptor signaling | 1.96E – 11 | 17.8% | Insulin signaling | 27/: | 520 0.0001 | 855 D(| evelopment_Hemopoiesis, | 37/1 | 136 2.3 | 393E-08 |
| Validation Stepwise in Suicide Completers | - | Glucocorticoid receptor signaling | 2.86E – 06 | 50/281 7.8% 22/281 | pathway Morphine addictio | 2/6 u | .49 0.0006 | er 493 Ré | ythropoletin pathway eproduction_Gonadotropin regulat | tion 24/1 | 66 66 | 343E-07 |
| (<i>n</i> = 589 genes) | 7 | IGF-1 signaling | 7.18E – 06 | 12.1% | Colorectal cancer | 2/6 | 87 0.0016 | 932 R¢ | eproduction_GnRH signaling pathv | vay 20/1 | 166 8.3 | 256E-06 |
| | m | Renin-angiotensin signaling | 8.72E – 06 | 11.0% | Cocaine addiction | 6/1 | 55 0.0037. | 291 R€ | eproduction_Progesterone signalin | ig 23/2 | 214 1. | 194E-05 |
| | 4 | Protein kinase A signaling | 1.02E – 05 | 6.5% | Insulin signaling | 12/: | 535 0.0047. | 284 Si | gnal transduction_NOTCH signalin | g 24/2 | 236 1.9 | 962E-05 |
| | S | Melanocyte development and | 1.02E – 05 | 20/398 12.8% | patnway Inositol phosphate | s 6/1 | 93 0.0101 | 986 Si | gnal transduction_Androgen recep | otor 12/ | 72 2.: | 241E-05 |
| Validation Nominally significant In | - | pigmentation signaling Neurotrophin/TRK signaling | 3.48E – 06 | 11/80 12.5% 9/72 | Cocaine addiction | 6/1 | 55 0.0004 | 154 Ré | gnaiing cross-taik eproduction_Gonadotropin regulat | tion 16/1 | .7 661 | 748E-05 |
| suicide completers (n=390 genes) | 2 | Glucocorticoid receptor signaling | 2.68E – 05 | 5.7% | Colorectal cancer | 7/2 | 89 0.0022 | :26 R€ | eproduction_GnRH signaling pathv | vay 14/1 | 1.9 | 323E-04 |
| | c | Melanocyte development and | 1.06E – 04 | 9.3% 8/86 | Wnt signaling path | hway 9/4 | 195 0.0036 | 575 R€ | eproduction_Progesterone signalin | ig 16/2 | 214 1.8 | 322E-04 |
| | 4 | pigmentation signaling G-Protein coupled receptor | 1.79E – 04 | 5.3% | Notch signaling | 5/1 | 70 0.0043 | 315 Si | gnal transduction_NOTCH signalin | ig 16/2 | 236 5.4 | 195E-04 |
| | 5 | signaling Corticotropin releasing hormone | 2.23E – 04 | 14/ 204 7.4% 9/121 | patnway Adherens junction | , 7/5 | 40 0.0053 | 315 Si | gnal transduction_WNT signaling | 13/1 | 177 8. | 738E-04 |
| Validation Bonferroni significant in | - | signaling IL-17 signaling | 1.34E – 05 | 5.6% 4/72 | Inositol phosphat | te 3/1 | 96 0.0003 | 383 Ce | ell cycle_G1-S Interleukin regulati | ion 6/1 | 28 6. | 400E-06 |
| suicide Completers (<i>n</i> = 49 genes) | 7 | p53 signaling | 4.52E – 05 | 4.1% 4/98 | metabolism Phosphatidylinosi | itol 3/2 | 0.000 | 363 Irr | 1mune response_BCR pathway | 5/1 | 37 1.3 | 387E-04 |
| | m | Role of osteoblasts, osteoclasts and chondrocytes in rheumatoid | 8.71E – 05 | 2.2% 5/225 | signaling system Colorectal cancer | 3/2 | 93 0.0012 | 214 In cy | nmune response_Th17-derived rtokines | 5/4 | 98 4. | 589E-04 |
| | 4 | artnitus Docosahexaenoic acid (DHA) | 1.02E – 04 | 6.7 % 3/45 | Tryptophan | 2/1 | 32 0.0042 | 29 In | flammation_IL-2 signaling | 4/1 | 04 5. | 752E-04 |
| | 5 | signaling Ovarian cancer signaling | 1.48E – 04 | 3.0 % 4/133 | metabolism Neurotrophin signaling pathwa; | y 3/5 | 571 0.007£ | 344 Cč | ell cycle_G1-S Growth factor regul: | ation 5/1 | 95 7. | 127E-04 |
| B. | | 1 | igenuity | | | | | | GeneGO | | | |
| | # | Diseases and Disorders | | P-value | # Mole | scules | Diseases | | | Ratio | P-v | alue |
| Prioritization CFG score ≥ 4 ($n = 1471$ genes) | - 7 m 4 v | Cancer Organismal Injury and Abnormal Gastrointestinal Disease Reproductive System Disease Infectious Diseases | ities 2.2 1.0 1.4 8.3(| 5E - 06-2.211 5E - 06-2.211 2E - 06-5.071 3E - 06-5.071 3E - 06-2.31E 0E - 07-1.15E | E - 45 124 E - 45 124 E - 31 90! E - 24 61] E - 24 24! | 6 4 v v o | Mental Disorr Psychiatry an Depressive D Central Nervo Depressive D | ders d Psych isorder, ous Syst isorder | nology Major tem Diseases | 256/1610 284/1904 120/543 379/3060 120/557 | 1.890 2.194 2.660 8.770 3.125 | 1E - 35 1E - 34 1E - 29 1E - 29 1E - 28 |
| Validation Stepwise in Suicide Completers (n = 589 genes) | - | Cancer | 6.5 | 7E – 04–6.34I | E – 17 48: | 7 | Breast Neopli | asms | | 356/8894 | 3.727 | 'E-15 |

Understanding and predicting suicidality in women DF Levey *et al*

© 2016 Macmillan Publishers Limited



| B. | | Ingenui | ity | | GeneGO | | |
|--|------------------|---|---|--------------------------------|---|--|---|
| | # | Diseases and Disorders | P-value | # Molecules | Diseases | Ratio | P-value |
| | 0 0 4 5 | Organismal Injury and Abnormalities Gastrointestinal Disease Reproductive System Disease Infectious Diseases | 6.57E - 04-6.34E - 17 6.23E - 04-2.76E - 10 6.50E - 04-8.34E - 09 6.57E - 04-6.95E - 08 | 492 355 240 104 | Breast Diseases Psychiatry and Psychology Pathological Conditions, Signs and Symptoms Mental Disorders | 356/8895 115/1904 207/4433 101/1610 | 3.798E - 15 2.268E - 14 1.078E - 13 1.146E - 13 |
| Validation Nominally significant In Suicide Completers (<i>n</i> = 396 genes) | - 0 m 4 n | Cancer Organismal Injury and Abnormalities Tumor Morphology Developmental Disorder Gastrointestinal Disease | 2.36E - 03-1.87E - 10 2.47E - 03-1.87E - 10 2.29E - 03-1.17E - 07 2.47E - 03-1.40E - 06 2.44E - 03-2.43E - 06 | 325 330 36 230 230 | Depressive Disorder, Major Pathological Conditions, Signs and Symptoms Depressive Disorder Breast Neoplasms Breast Diseases | 40/543 150/4433 40/557 245/8894 245/8895 | 1.045E-12 2.002E-12 2.333E-12 2.770E-11 2.806E-11 |
| Validation Bonferroni significant in Suicide Completers ($n = 49$ genes) | м 7 – | Immunological Disease Cancer Dermatological Diseases and | 4.03E - 03-1.27E - 06 4.15E - 03-3.97E - 06 4.03E - 03-3.97E - 06 | 14 10 10 | Lymphoma, Mantle-Cell Psychiatry and Psychology Lymphoma, Non-Hodgkin | 8/196 19/1904 12/726 | 3.430E – 08 1.209E – 07 2.323E – 07 |
| | 4 ∿ | Conductors Hematological Disease Organismal Injury and Abnormalities | 4.03E - 03-3.97E - 06 4.15E - 03-3.97E - 06 | 5 42 | Mental Disorders Leukemia, Myeloid | 17/1610 16/1436 | 3.079E – 07 3.667E – 07 |
| Abbreviations: CFG, Convergent Fu | inction | al Genomics; KEGG, Kyoto Encyclopedia | of Genes and Genomes. | Bold values signi | fy pathways of interest. | | |

convergence, the start of the gene had to map within 5 cM of the location of a marker linked to the disorder.

CFG scoring. For CFG analysis (Figure 2e), the external crossvalidating lines of evidence were weighted such that findings in human postmortem brain tissue, the target organ, were prioritized over peripheral tissue findings and genetic findings, by giving them twice as many points. Human brain expression evidence was given 4 points, whereas human peripheral evidence was given 2 points and human genetic evidence was given a maximum of 2 points for association, and 1 point for linkage. Each line of evidence was capped in such a way that any positive findings within that line of evidence result in maximum points, regardless of how many different studies support that single line of evidence. to avoid potential popularity biases. In addition to our external CFG score, we also prioritized genes based upon the initial gene expression analyses used to identify them. Probesets identified by gene expression analyses could receive a maximum of 4 points. Thus, the maximum possible total CFG score for each gene was 12 points (4 points for the internal score and 8 points for the external CFG score) (Table 2 and Supplementary Table S2). The scoring system was decided upon before the analyses were carried out. We sought to give twice as much weight to external score as to internal in order to increase generalizability and avoid fit to cohort of the prioritized genes.⁶ It has not escaped our attention that other ways of scoring the lines of evidence may give slightly different results in terms of prioritization, if not in terms of the list of genes per se. Nevertheless, we feel this simple scoring system provides a good separation of genes based on gene expression evidence and on independent cross-validating evidence in the field (Figure 2). In the future, with multiple large data sets, machine learning approaches could be used and validated to assign weights to CFG.

Clock gene database

We compiled a database of genes associated with circadian function, by using a combination of review papers^{7.8} and searches of existing databases CircaDB (http://circadb.hogeneschlab.org), GeneCards (http://www.genecards.org) and GenAtlas (http://gena tlas.medecine.univ-paris5.fr). Using the data we compiled from these sources we identified a total of 1468 genes that show circadian functioning. We further classified genes into 'core' clock genes, that is, those genes that are the main engine driving circadian function (n = 18), 'immediate' clock genes, that is, the genes that directly input or output to the core clock (n = 331) and 'distant' clock genes, that is, genes that directly input or output to the immediate clock genes (n = 1119).

Pathway analyses

IPA (Ingenuity Pathway Analyses, version 24390178, Qiagen, Hilden, Germany), GeneGO MetaCore (Thompson Reuters, New York, NY, USA) and KEGG (Kyoto Encyclopedia of Genes and Genomes) (through the Partek Genomics Suite 6.6 software package) were used to analyze the biological roles, including top canonical pathways, and diseases, of the candidate genes resulting from our work, as well as to identify genes in our data set that are the target of existing drugs (Table 3 and Supplementary Tables S4 and S5). We ran the pathway analyses together for all the AP and DE probesets with a total CFG score of \geq 4, then for those of them who showed stepwise change in the suicide completers validation cohort, then for those of them who survived Bonferroni correction (Table 3).

Validation analyses

For the AP analyses, we imported the Affymetrix microarray .chp data files from the participants in the validation cohort of suicide

completers into MAS5 Affymetrix Expression Console, alongside the data files from the participants in the discovery cohort, to compare expression levels of biomarkers in the validation cohort with those in the no SI and high SI groups in the discovery cohort. We then transferred the AP data to an Excel sheet and transformed A into 0, M into 0.5 and P into 1.

For the DE analyses, we imported Affymetrix microarray .cel files from the participants in the validation cohort of suicide completers into Partek Genomic Suites. We then ran an RMA, background corrected with quantile normalization, and a median polish probeset summarization of all the chips from the validation cohort to obtain the normalized expression levels of all probesets for each chip. Partek normalizes expression data into a log base of 2 for visualization purposes. We non-logtransformed expression data by taking 2 to the power of the transformed expression value. We then used the non-logtransformed expression data to compare expression levels of biomarkers in the validation cohort with those in the no SI and high SI groups in the discovery cohort. We then transferred the expression data to an Excel sheet.

For validation analyses of our candidate biomarker genes, we examined which of the top candidate genes (Total CFG score of 4 or above), separately from AP and from DE, were stepwise changed in expression from the no SI group to the high SI group to the suicide completers group. We used an empirical cutoff of 33.3% of the maximum possible CFG score of 12, which also permits the inclusion of potentially novel genes with maximal internal score but no external evidence score. We imported the Excel sheets with the raw expression data from AP and DE into Partek, and statistical analyses were performed using a one-way ANOVA for the stepwise changed probesets, and stringent Bonferroni corrections for all the probesets tested (stepwise and non-stepwise).

Clinical measures

The SASS is an 11-item scale for measuring mood and anxiety, previously developed and described by us.^{4,9} The SASS has a set of 11 visual analog scales (7 for mood and 4 for anxiety) that ends up providing a number ranging from 0 to 100 for mood state, and the same for anxiety state. We have developed an Android app version (Supplementary Figure S2).

CFI-S (Figure 3 and Supplementary Figure S2) is a 22-item scale and Android app for suicide risk,⁴ which integrates, in a simple binary manner (Yes—1 and No—0), similar to a polygenic risk score, information about known life events, mental health, physical health, stress, addictions and cultural factors that can influence suicide risk.^{10,11} The scale was administered at participant testing visits (n = 39), or scored based on retrospective electronic medical record information and Diagnostic Interview for Genetic Testing information (n = 48). When information was not available for an item, it was not scored (NA).

Combining gene expression biomarkers and clinical measures

The Universal Predictor for Suicide (UP-Suicide) construct, our primary end point, was decided upon as part of our apriori study design to be broad spectrum, and combine our top Bonferroni validated biomarkers with the phenomic (clinical) markers (SASS and CFI-S). It is calculated as the average of three increased markers (BioM-18 averaged increased Bonferroni biomarkers, Anxiety, CFI-S) minus the average of two decreased markers (BioM-32 averaged decreased Bonferroni biomarkers, Mood). All individual markers are Z-scored by diagnosis, to account for different ranges and be able to combine them into a composite predictor.



Testing analyses

The test cohort for SI and the test cohort for future hospitalizations analyses were assembled out of data that was RMA normalized by diagnosis. Phenomic (clinical) and gene expression markers used for predictions were z-scored by diagnosis, to be able to combine different markers into panels and to avoid potential artifacts due to different ranges of phene expression and gene expression in different diagnoses. Markers were combined by computing the average of the increased risk markers minus the average of the decreased risk markers. Predictions were performed using R-studio.

Predicting SI. Receiver-operating characteristic (ROC) analyses between genomic and phenomic marker levels and SI were performed by assigning participants with an HAMD-SI score of 2 and greater into the high SI category. We used the pROC function of the R-studio. We used the z-scored biomarker and app scores, running them in this ROC generating program against the 'diagnostic' groups in the independent test cohort (high SI vs the rest of subjects). Additionally, ANOVA was performed between no SI (HAMD-SI 0), intermediate (HAMD-SI 1) and high SI participants (HAMD-SI 2 and above) and Pearson *R* (one-tail) was calculated between HAMD-SI scores and marker levels (Table 4 and Figure 4).

Predicting future hospitalizations for suicidality. We conducted analyses for hospitalizations in the years following testing (on average 2.75 years, range 0.3-7.5 years; see Supplementary Table S1). For each participant in the test cohort for future hospitalizations, the study visit with highest levels for the marker or combination of markers was selected as index visit (or with the lowest levels, in the case of decreased markers). ROC analyses between genomic and phenomic marker levels and future hospitalizations were performed as described above, based on assigning if participants had been hospitalized for suicidality (ideation, attempts) or not following the index testing visit. Additionally, a one tailed t-test with unequal variance was performed between groups of participants with and without hospitalizations for suicidality. Pearson R (one-tail) correlation was performed between hospitalization frequency (number of hospitalizations for suicidality divided by duration of follow-up) and marker scores. We conducted correlation analyses for hospitalizations frequency for all future hospitalizations due to suicidality as this calculation, unlike the ROC and *t*-test, accounts for the actual length of follow-up at our VA, which varied from participant to participant. The ROC and t-test might in fact, if anything, underrepresent the power of the markers to predict, as the more severe psychiatric patients are more likely to move geographically and/or be lost to follow-up.

RESULTS

Discovery of biomarkers for SI

We conducted whole-genome gene expression profiling in the blood samples from a longitudinally followed cohort of female participants with psychiatric disorders that predispose to suicidality. The samples were collected at repeated visits, 3–6 months apart. State information about SI was collected from a questionnaire (HAMD) administered at the time of each blood draw (Supplementary Table S1). Out of 51 female psychiatric participants (with a total of 123 visits) followed longitudinally in our study, with a diagnosis of BP, MDD, schizophrenia and schizoaffective disorder, there were 12 participants that switched from a no SI (SI score of 0) to a high SI state (SI score of 2 and above) at different visits, which was our intended discovery group (Figure 2). We used a powerful within-participant design to analyze data from these 12 participants and their 31 visits. A within-participant design factors out genetic variability, as well as 10



| Predicto | or | ROC AUC | AUC p-value | ANOVA | Correlat | ion R C | orrelation p-value |
|---------------|-------|---|---------------------------------------|--|----------------------|----------------------|---|
| CFI-S | | 0.817 | 1.29e-05 | 7.9e-5 | 0.44 | 1 | 9.35e-06 |
| CFI-S Item | | | Descriptio | n | | Correct direction | T-test (one tailed) High SI vs. No SI p-value |
| 16 | Cł | nronic stress: lack | of positive rela | ationships, social | isolation | Y | 0.0040 |
| 12 | | Ci | urrent substand | ce abuse | | Y | 0.0071 |
| 17 | ŀ | listory of excessiv (including rage, a | e extroversion | and impulsive b fights, seeking re | ehaviors venge) | Y | 0.0147 |
| 14 | | L | ack of religious | beliefs | | Y | 0.0175 |
| 13 | | Past his | tory of suicidal | acts/gestures | | Y | 0.0253 |
| 15 | | Acute stress | : Rejection (wit | thin last 3 month | is) | Y | 0.0294 |
| 20 | Hi | story of comman | d hallucination | s of self-directed | violence | Y | 0.0453 |
| 10 | | Dissatisfactio | on with life at t | his moment in tir | ne | Y | 0.0583 |
| 8 | Chror | ic stress: perceive | d uselessness, extended k | not feeling neede in. | ed, burden to | Y | 0.0635 |
| 4 | | Personally know | Y | 0.0733 | | | |
| 7 | | Acute stress: | Y | 0.0748 | | | |
| 3 | | Family his | Y | 0.1422 | | | |
| 21 | | Age: | Y | 0.2374 | | | |
| 2 | | 0.2477 | | | | | |
| 6 | Ac | ute/severe medica stand this pair | al illness, includ n anymore.") (w | ling acute pain (" vithin last 3 mont | l just can't :hs) | Y | 0.2714 |
| 5 | | History of abuse | e: physical, sexu | ial, emotional, ne | eglect | Y | 0.3348 |
| 9 | His | story of excessive pla | introversion, co anned suicide a | onscientiousness ttempts) | (including | Y | 0.3388 |
| 18 | Lack | of coping skills wh | en faced with | stress (cracks und | der pressure) | Y | 0.3723 |
| 19 | Lack | of children. If has | children, not in of them. | touch /not help | ing take care | N | 0.0714 |
| 1 | | Psychiatri | c illness diagno | sed and treated | | All have d | x All have dx |
| 11 | | Lao | ck of hope for t | he future | | No differen | ce 1 |
| 22 | | | Gender: Ma | ale | | All female | s All females |

Figure 3. Convergent Functional Information for Suicide (CFI-S) scale testing in women. Prediction of high suicidal ideation in women in a larger cohort that combines the discovery and test cohorts used for biomarker work. CFI-S was developed independently of any data from this study, by compiling known socio-demographic and clinical risk factors for suicide. It is composed of 22 items that assess the influence of mental health factors, as well as of life satisfaction, physical health, environmental stress, addictions, cultural factors known to influence suicidal behavior, and two demographic factors, age and gender. Table depicts individual items and their ability to differentiate between no SI and high SI.

some medications, lifestyle and demographic effects on gene expression, permitting identification of relevant signal with Ns as small as 1.¹² Another benefit of a within-participant design may be accuracy/consistency of self-report of psychiatric symptoms ('phene expression'), similar in rationale to the signal detection benefits it provides in gene expression.

For discovery, we used two methodologies: Absent/Present (reflecting on/off of transcription) and Differential Expression (reflecting more subtle gradual changes in expression levels). The genes that tracked SI in each participant were identified in our analyses. We used three thresholds for increase in expression genes and for decrease in expression genes: \geq 33.3% (low), \geq 50% (medium) and \geq 80% (high) of the maximum scoring increased and decreased gene across participants. Such a restrictive

approach was used as a way of minimizing false positives, even at the risk of having false negatives. For example, there were genes on each of the two lists, from AP and DE analyses, that had clear prior evidence for involvement in suicidality, such as AKAP10 (ref. 13) (31.7%) and MED28 (ref. 13) (31.8%) from AP, and S100B^{13,14} (31.7%) and SKA2 (ref. 15) (31.4%) for DE, but were not included in our subsequent analyses because they did not meet our apriori set 33.3% threshold. Notably, SKA2 reproduces our results in males,² as well as the work from Kaminsky and colleagues.^{15,16}

Prioritization of biomarkers based on prior evidence in the field These differentially expressed genes were then prioritized using a Bayesian-like CFG approach (Figure 2) integrating all the

| Table 4. Prediction of suicidal ideation | and future hospitaliza | tions for suicidality | | | | | |
|--|---|---|---|--|---|--|---|
| | Marker | Participants with high SI | l/Participants total | ROC AUC/P-value | Pearson's Correla | tion R/P-value | Student's t-test P-value |
| Suicidal ideation independent cohort, n=33 Best blood biomarker predictors | Out of validated biom EPB41L5 HAVCR2 ARHGAP15 ARHGAP15 GTF3C3 ALDH3A2 Out of top discovery i | arkers (Bonferroni) (49 gent 133 7133 7133 7133 7133 7133 7133 | es, 50 probesets) s (Non-Bonferroni Valida | 0.68/0.06 0.62/0.15 0.55/0.14 0.55/0.1 0.65/0.1 0.64/0.115 0.62/0.142 tted, 65 genes) | 0.22/0 0.17/0 0.12/0 0.12/0 - 0.21/(- 0.21/2 | 0.03 2.07 2.07 2.175 2.037 2.036 | 0.09 0.18 0.22 0.08368 0.07208 0.1421 |
| | DPCD GTF3C3 ASPH ACTR3 NUDT6 LRRC8B Panels of Validated Bi | 7133 7133 7133 7133 7133 7133 7133 7133 | sed, Combined) | 0.67/0.07 0.67/0.07 0.62/0.15 0.62/0.15 0.62/0.15 0.60/0.19 | 0.23/0 0.23/0 0.07/0 0.07/0 0.15/ 0.15/ 0.15/ | 0.04 20.02 0.05 0.11 0.11 | 0.12 0.11 0.13 0.13 0.13 0.13 |
| Clinical measures Combined | BIOM-18 BIOM-18 BIOM-50 Anxiety Mood SASS CFI-S + SASS CFI-S + SASS UP-Suicide | 7133 7133 7133 7133 7133 7129 7129 7129 | | 0.37/0.87 0.43/0.72 0.570.029 0.72(0.028 0.38/0.0078 0.84/0.0035 0.84/0.0035 0.82/0.0038 0.82/0.003 | 0.0200 0.0200 0.0200 0.33700 0.33700 0.48/0.0 0.43/0.0 | 1/0.49 1/0.49 .011 .0005 .0013 .0013 .0003 | 0.59 0.66 0.465 0.002 5.042-05 5.042-05 0.00027 0.001467 |
| Marker Future hospitalizations for suicidality cohort, n = Best Blood Biomarker Out of Valic Predictors | r Participants ho participant = 24 participants idated Biomarkers (Bonfer | s hospitalized for suicidality/ s hospitalized total roni) (49 genes, 50 probese | ROC AUC/P-value ts) | Pearson's correlation R/ P-value | Student's t-test P-value | Cox regression hazard ratio | Cox regression P-value |
| HTRA1 PER1 PDXDC | discovery and prioritizati | 5124 4124 5124 3124 4124 4124 5124 5124 4124 4124 4124 4 | 0.84/0.01 0.84/0.018 0.81/0.018 0.81/0.018 0.89/0.007 0.85/0.015 0.85/0.005 0.85/0.002 0.86/0.0007 0.9/0.005 0.9/0.0012 | 0.62/0.00058 0.39/0.029 0.64/0.0004 - 0.35/0.047 - 0.35/0.047 - 0.34/0.08 0.47/0.08 0.50/0.007 0.73/2.5E-05 - 0.37/0.10 - 0.3/0.08 | 0.02 0.1314 0.04187 0.05385 0.05385 0.05385 0.0462 0.04 0.04 0.05 0.005 0.0005 0.0005 0.0008 | 4.55 1.535 2.4436 5.943 5.943 5.9436 5.948 9.572 4.27 6.205 37.01 15.94 | 0.01 0.1615 0.1503 0.1503 0.09 0.03 0.03 0.03 0.01 0.02 |
| Clinical measures BioM-18 BioM-18 BioM-18 BioM-18 BioM-50 BioM-50 BioM-50 BioM-50 BioM-50 BioM-50 Clinical measures Anxiety Anxiety CFI-5 SAS CFI-5 SAS Combined UP-Suicide | ssin | 4124 4124 5124 3124 3124 3124 3124 5124 5124 5124 | 0.88/0.0088 0.71/11 0.94/0.002 0.86/0.01 0.88/0.18 0.83/0.02 0.52 0.74/0.08 0.78/0.032 | 0.46/0.011 - 0.34/0.053 0.54/0.003 0.44/0.01 - 0.22/0.16 0.39/0.03 0.24/0.12 0.24/0.12 0.51/0.003 0.51/0.003 | 0.033 0.16 0.005813 0.00399 0.239 0.034 0.033 0.033 0.0330 | 27.6 10.57 89.459 14.4 33.4 3.72 1.17 4.68 9.6068 | 0.021 0.23 0.061 0.066 0.1 0.1 0.0 0.01 |
| Abbreviations: AUC, area under the curve predictive biomarkers ($n = 23$) from Table 2. measures/apps and by the combined genoi (BioM-18 and BioM-32), along with clinical 1 towards significance. <i>T</i> -tests are between h | e; CFI-S, Convergent Fur are shown, out of the to mic and clinical predict measures app scores fro high SI and no SI, and b | tctional Information for S tal tested ($n = 115$) from S tal tested ($n = 115$) from S or, UP-Suicide, for a total or m CFL-S and from SASS (h etween hospitalized for s | uicidality; ROC, receivuitipplementary Table S2 upplementary Table S2 of $n = 124$ predictors tee Mood and Anxiety). Rec uicidality vs not hospit | er-operating characteristi 2. Also shown are predictiv sted. UP-Suicide is compo d—increased marker and talized for suicidality. | c; SASS, Simplified A ons by the panels of 1 ised of the panels of i blue—decreased ma | Affective State Scale; SI, Bonferroni validated bioi increased and decreasec irker. Bold—nominally si | suicidal ideation. Top markers, by the clinical 1 validated biomarkers gnificant. Italic—trend |

© 2016 Macmillan Publishers Limited

Understanding and predicting suicidality in women DF Levey *et al*



Figure 4. UP-Suicide predicting suicidal ideation in the independent test cohort, and predicting future hospitalizations due to suicidality. UP-Suicide is composed of the 50 Bonferroni validated biomarkers along with CFI-S scores and SASS (Mood and Anxiety scores). *n* = number of testing visits. (a) *Top left*: Receiver operating curve identifying participants with suicidal ideation against participants with no SI or intermediate SI. *Top right*: Y axis contains the average UP-Suicide scores with standard error of mean for no SI, intermediate SI and high SI. *Bottom right*: Scatter plot depicting HAMD-SI score on the Y axis and UP-Suicide score on the X axis with linear trend line. *Bottom*: Table summarizing descriptive statistics. (b) *Top left*: Receiver operating curve identifying participants with future hospitalizations due to suicidality. *Top right*: Y axis contains the average UP-Suicide is core on the X axis with linear trend line. *Bottom*: Table summarizing the true hospitalizations due to suicidality and participants with future hospitalizations due to suicidality. *Scatter* plot depicting frequency of future hospitalizations due to suicidality on the Y axis and UP-Suicide score on the X axis with linear trend line. *Bottom*: Table summarizing descriptive statistics.

previously published human genetic evidence, postmortem brain gene expression evidence and peripheral fluids evidence for suicide in the field available at the time of our analyses (September 2015). This is a way of identifying and prioritizing disease relevant genomic biomarkers, extracting generalizable signal out of potential cohort-specific noise and genetic heterogeneity. We have built in our laboratory manually curated databases of the psychiatric genomic and proteomic literature to date, for use in CFG analyses. The CFG approach is thus a *de facto* field-wide collaboration. We use in essence, in a Bayesian manner, the whole body of knowledge in the field to leverage findings from our discovery data sets.

12

For validation in suicide completers, we used 1471 genes that had a CFG score of 4 and above, from AP and DE, reflecting either maximum internal score from discovery or additional external literature cross-validating evidence. Out of these, 882 did not show any stepwise change in suicide completers (NC, nonconcordant). As such, they may be involved primarily in ideation and not in behavior (Supplementary Table S5). The remaining 589 genes (40.0%) had levels of expression that were changed stepwise from no SI to high SI to suicide completion. In all, 396 of these genes (26.9%) were nominally significant, and 49 genes (50 probesets—two for JUN) (3.33%) survived Bonferroni correction for multiple comparisons (Figure 2f). These genes are likely involved in SI and suicidal behavior. (A person can have SI without suicidal behavior, but cannot have suicidal behavior without SI.)

Selection of biomarkers for testing of predictive ability

For testing, we decided apriori to focus on the Bonferroni validated biomarkers (49 genes, 50 probesets). We also examined in a secondary analysis the top scoring biomarkers from both discovery and prioritization (65 genes), so as to avoid potential false negatives in the validation step due to possible postmortem artifacts or extreme stringency of statistical cutoff (Supplementary Figure S1). The top CFG scoring genes after the Bonferroni validation step were BCL2 and GSK3B. The top CFG scoring genes from the discovery and prioritization steps were FAM214A, CLTA, HSPD1 and ZMYND8. Notably, all have co-directional gene expression changes evidence in brains of suicide completers in studies from other groups (Figure 2, Table 2 and Supplementary Table S2).

Biological understanding

We also sought to understand the biology represented by the biomarkers identified by us, and derive some mechanistic and practical insights. We conducted: (1) unbiased biological pathway analyses and hypothesis-driven mechanistic queries, (2) overall disease involvement and specific neuropsychiatric disorders queries and (3) overall drug modulation along with targeted queries for omega-3, lithium and clozapine (Table 3 and Supplementary Tables S3 and S4). Administration of omega-3s in particular may be a mass-deployable therapeutic and preventive strategy.^{18,19}

The sets of biomarkers identified have biological roles in inflammation, neurotrophins, inositol signaling, stress response, and perhaps overall the switch between cell survival and proliferation vs apoptosis (Table 3 and Supplementary Table S5).

We also examined evidence for the involvement of these biomarkers for suicidality in other psychiatric disorders, permitting us to address issues of context and specificity (Supplementary Table S3). FAM214A, MOB3B, ZNF548 and ARHGAP35 seem to be relatively specific for suicide, based on the evidence to date in the field. BCL2, GSK3B, HSPD1 and PER1 are less specific for suicide, having equally high evidence for involvement in suicide and in other psychiatric disorders.

These boundaries and understanding will likely change as additional evidence in the field accumulates. For example, HSPD1, discovered in this work as a top biomarker increased in expression in suicidality, is also increased in expression in the blood following anti-depressant treatment,^{20,21} and thus might be a useful biomarker for treatment-emergent suicidal ideation.

A number of the genes are changed in expression in opposite direction in suicide in this study vs high mood in our previous mood biomarker study²²—SSBP2, ZNF596 (Supplementary Table S3), suggesting that suicidal participants are in a low mood state. Also, some of the top suicide biomarkers are changed in expression in the same direction as in high psychosis participants

12

in a previous psychosis biomarker study of ours²³—HERC4, PIP5K1B, SLC35B3, SNX27, KIR2DL4 and NUDT10 (Supplementary Table S3), suggesting that suicidal participants may be in a psychosis-like state. Taken together, the data indicate that suicidality could be viewed as a psychotic dysphoric state. This molecularly informed view is consistent with the emerging clinical evidence in the field.²⁴

A number of top biomarkers identified by us have biological roles that are related to the core circadian clock (such as PER1), or modulate the circadian clock (such as CSNK1A1), or show at least some circadian pattern (such as HTRA1). To be able to ascertain all the genes in our data set that were circadian and do estimates for enrichment, we compiled from the literature a database of all the known genes that fall into these three categories, numbering a total of 1468 genes. Using an estimate of about 21 000 genes in the human genome, that gives about 7% of genes having some circadian pattern. Out of our 49 Bonferroni validated biomarker genes, 7 had circadian evidence (14.3%) (Supplementary Table S3), suggesting a two-fold enrichment for circadian genes. Circadian clock abnormalities are related to mood disorders,^{8,25} and sleep abnormalities have been implicated in suicide.²⁶

Finally, we conducted biological pathway analyses on the genes that, after discovery and prioritization, were stepwise changed in suicide completers (n = 882) and may be involved in ideation and behavior, vs those that were not stepwise changed (n = 589), and that may only be involved in ideation (Supplementary Table S5). The genes involved in ideation map to pathways related to PI3K signaling. The genes involved in behavior map to pathways related to glucocorticoid receptor signaling. This is consistent with ideation without behavior being related to neurotrophic factors, and ideation with behavior being related to stress.

Clinical information

We used a simple new 22-item scale and app for suicide risk, CFI-S. which scores in a simple binary manner and integrates information about known life events, mental health, physical health, stress, addictions and cultural factors that can influence suicide risk.^{10,4,11} Clinical risk predictors and scales are of high interest in the military²⁷ and in the general population at large.²⁸ Our scale aims for comprehensiveness, simplicity and quantification similar to a polygenic risk score, and may provide context to the blood biomarker signals. We analyzed which items of the CFI-S scale were the most significantly different between no and high SI live participants (Figure 3). We identified seven items that were significantly different: lack of positive relationships/social isolation (P = 0.004), substance abuse (P = 0.0071), history of impulsive behaviors (P = 0.015), lack of religious beliefs (P = 0.018), past history of suicidal acts/gestures (P = 0.025), rejection (P = 0.029) and history of command auditory hallucinations (P = 0.045). Social isolation increases vulnerability to stress, which is independently consistent with our biological marker results.

We also used an 11-item scale for measuring mood and anxiety, the SASS.⁴ The SASS is a set of 11 visual analog scales (7 for mood and 4 for anxiety) that ends up providing a number ranging from 0 to 100 for mood state, and the same for anxiety state.

Testing for predictive ability

The best single increased (risk) biomarker predictor for SI state is EPB41L5 (ROC area under the curve (AUC) 0.68, *P*-value 0.06; Pearson Correlation 0.22, *P*-value 0.03), an increase in expression, Bonferroni validated biomarker (Tables 2 and 4). This biomarker was also identified co-directionally in our previous male work,⁴ and has no evidence for involvement in other psychiatric disorders. The best single decreased (protective) biomarker predictor for SI is PIK3C3 (ROC AUC 0.65, *P*-value 0.1; Pearson Correlation -0.21, *P*-value 0.037), a decrease in expression,

Bonferroni validated biomarker (Tables 2 and 4). PIK3C3 is also decreased in expression in postmortem brains in depression.²⁹

The best single increased (risk) biomarker predictor for future hospitalizations for suicidality is HTRA1 (ROC AUC 0.84, *P*-value 0.01; Cox regression hazard ratio 4.55, *P*-value 0.01), an increase in expression, Bonferroni validated biomarker (Tables 2 and 4). HTRA1 is also increased in expression in the blood of schizophrenics.³⁰ The best single decreased (protective) biomarker predictor for future hospitalizations for suicidality is CSNK1A1 (ROC AUC 0.96, *P*-value 0.0007; Cox Regression Hazard Ratio 620.5, *P*-value 0.02), a top discovery and prioritization, non-Bonferroni validated biomarker (Tables 2 and 4). This biomarker was also identified co-directionally in our previous male work.⁴ CSNK1A1 (casein kinase 1, alpha 1) is a circadian clock gene, part of the input into the core clock. It is decreased in expression in suicidality in our work, and decreased in postmortem brains of alcoholics.³¹ Interestingly, it is increased in expression by mood stabilizers³² and by omega-3 fatty acids.³³ PIK3C3 is also a good predictor for future hospitalizations for suicidality (ROC AUC 0.9, *P*-value 0.011).

BCL2, the top CFG scoring biomarker from validation, has good accuracy at predicting future hospitalizations for suicidality (ROC AUC 0.89, *P*-value 0.007; Cox regression hazard ratio 3.08, *P*-value 0.01). The panel of 50 validated biomarkers, BioM-50, had even better accuracy at predicting future hospitalizations for suicidality (ROC AUC 0.94, *P*-value 0.002; Cox regression hazard ratio 89.46, *P*-value 0.02). Overall, in women, blood biomarkers seemed to perform better for predicting future hospitalizations for suicidality (trait) than for predicting SI (state). This is different from the trend we saw in men,⁴ where blood biomarkers were somewhat better predictors of state than of trait. These gender differences are interesting, and merit exploration in additional future comparative studies.

CFI-S has very good accuracy (ROC AUC 0.84, *P*-value 0.002; Pearson Correlation 0.39, *P*-value 0.001) at predicting SI in psychiatric participants across diagnostic groups. The other app, SASS, also has very good accuracy (ROC AUC 0.81, *P*-value 0.003; Pearson Correlation 0.38, *P*-value 0.0005) at predicting SI in women psychiatric participants. The combination of the apps is synergistic (ROC AUC 0.87, *P*-value 0.0009; Pearson Correlation 0.48, *P*-value 0.0001). Thus, even without the benefit of potentially more costly, invasive and labor intensive blood biomarker testing, clinically useful predictions could be made with the apps.

Our apriori primary end point was a combined universal predictor for suicide (UP-Suicide), composed of the scores in CFI-S and in SASS (Mood, Anxiety), along with the Bonferroni validated biomarkers (n = 50) resulting from the sequential discovery for ideation, prioritization with CFG, and validation for behavior in suicide completers steps. UP-Suicide is a good predictor of SI (ROC AUC 0.82, P-value 0.003; Pearson Correlation 0.43, P-value 0.0003) (Table 4 and Figure 4). UP-Suicide also has good predictive ability for future psychiatric hospitalizations for suicidality (ROC AUC 0.78, P-value 0.032; Cox Regression Hazard Ratio 9.61, P-value 0.01). Overall, while there may post hoc appear to be better individual predictors for SI and for future hospitalizations (Table 4), our apriori primary broad-spectrum end point (UP-Suicide) has been successful, may be more robust to effects of fit to cohort, and might be more generalizable to other populations.

DISCUSSION

We carried out systematic studies to identify clinically useful predictors for suicide in women, an understudied population to date. Our work focuses on identifying markers involved in SI *and* suicidal behavior, including suicide completion. Markers involved in behavior may be on a continuum with some of the markers involved in ideation, varying in the degree of expression changes from less severe (ideation) to more severe (behavior). One cannot

have suicidal behavior without SI, but it may be possible to have SI without suicidal behavior.

As a first step, we sought to use a powerful but difficult to conduct within-participant design for discovery of blood biomarkers. Such a design is more informative than case–control, case–case or even identical twins designs. The power of a within-participants longitudinal design for multi-omic discovery was first illustrated by Snyder and colleagues¹² in a landmark paper with an n = 1. We also have previously demonstrated its power in an initial pilot study in male bipolar participants (n = 9 out of 75 showed a switch from a no suicidal ideation to a high suicidal ideation state),³ and then a larger studies in males with major psychiatric disorders (n = 37 out of 217).⁴ In this small (n = 12 out of 51) but very valuable pilot study in women, we followed a similar path.

Second, we conducted whole-genome gene expression discovery studies in the participants that exhibited the switches, using a longitudinal within-participant design, that factors out genetic variability and reduces environmental variability as well. We have demonstrated the power of such a design in our earlier successful pilot work on suicide biomarkers in men with an n = 9.³ Our current n = 12 is comparable (Figure 2). Genes whose levels of expression tracked SI within each participant were identified.

Third, the lists of top candidate biomarkers for SI from the discovery and prioritization step (genes with a CFG score of 4 and above, reflecting genes that have maximal experimental internal evidence from this study and/or additional external literature cross-validating evidence) were additionally validated for involvement in suicidal behavior in a cohort of demographically matched suicide completers from the coroner's office (n = 6) (Figure 2).

We ended up with 50 biomarkers that survived Bonferroni correction (49 genes; one gene, JUN, had two different probesets that validated). Additionally, we tested 65 other biomarkers that were non-Bonferroni validated but had maximum internal score of 4 in discovery *and* a CFG score of 6 and above, which means that in addition to strong evidence in this study they also had prior independent evidence of involvement in suicide from other studies. These additional biomarkers are likely involved in suicide but did not make our Bonferroni validation cutoff due to its stringency or potential technical/postmortem artifact reasons (Table 2 and Supplementary Table S2).

Fourth, we describe the use in a female population of the simple and comprehensive phenomic (clinical) risk assessment scale, CFI-S scale,⁴ as well as of the companion app to it for use by clinicians and individuals (Supplementary Figure S2). CFI-S was developed independently of any data from this study, by integrating known risk factors for suicide from the clinical literature. It has a total of 20 items (scored in a binary manner-1 for present, 0 for absent, NA for information not available) that assess the influence of mental health factors, as well as of life satisfaction, physical health, environmental stress, addictions and cultural factors known to influence suicidal behavior. It also has two demographics risk factors items: age and gender. The result is a simple polyphenic risk score with an absolute range of 0-22, normalized by the number of items on which we had available information, resulting in a score in the range from 0 to 1 (Figure 3 and Supplementary Figure S2). We present data validating the CFI-S in women, in the combined discovery and test cohort of live psychiatric participants (Figure 3). We identified the chronic stress of lack of positive relationships/social isolation as the top differential item between no and high SI in women, which is consistent with biological data from the biomarker side of our study.

Fifth, we also assessed anxiety and mood, using a visual analog SASS, previously described by us,^{4,9} for which we now have developed an app version (Supplementary Figure S2). Using a PhenoChipping approach⁹ in our discovery cohort of psychiatric participants, we show that anxiety measures cluster with SI and CFI-S, and mood measures are in the opposite cluster, suggesting that our participants have high SI when they have high anxiety

| Table 5. Cross-prediction in the other | r gender | | | | | | |
|---|---|---|--|--|---|---|---|
| Gene symbol/Gene Name | Probesets | <u>Males</u> Discovery (direction of change) method/internal score (%) | <u>Males</u> Participants tested with suicidality/total | <u>Males</u> Predictions ROC/P-value | Females Discovery (direction of change) method/internal score (%) | <u>Females</u> Participants tested with suicidality/total | <u>Females</u> Predictions ROC/P-value |
| Top biomarkers from males that were co- SLC4A4 Solute carrier family 4 (sodium bicarbonate cotransporten), member 4 SKA2 Spindle and kinetochore associated complex subunit 2 | 210739_x_at 210739_x_at 225686_at | nales (1) AP/2 (71%) (71%) (0) (0) (0) (1) (1) (34%) AP/1 (42%) | SI: 33 108 Hosp: 32 157 SI: 33 108 Hosp: 32 157 | SI: 0.72/2.41E-05 Hosp: 0.44/0.87 SI: 0.69/0.0002 Hosp: 0.46/0.75 | () DE/0 (20%) (20%) (20%) (6%) | SI: 7 33 Hosp: 3 24 SI: 7 33 Hosp: 3 24 | SI: 0.62/0.15 Hosp: 0.86/0.03 SI: 0.50/0.51 Hosp: 0.78/0.07 |
| Top biomarkers from females that were com PIK3C3 Phosphatidylinositol 3-kinase, catalytic subunit type 3 CSNK1A1 Casein kinase 1, alpha 1 | o-directional in 1 232086_at 235464_at | nales (D) DE/0 (14%) (D) AP/0 (21%) | SI: 33 108 Hosp: 32 157 SI: 33 108 Hosp: 31 157 | SI: 0.62/0.01 Hosp: 0.5/0.49 SI: 0.63/0.007 Hosp: 0.5/0.53 | (D) DE/1 (49%) (D) (D) (B6%) (36%) (36%) | Si: 7 33 Hosp: 3 24 Si: 7 33 Hosp: 3 24 | Si: 0.65/0.098 Hosp: 0.9/0.011 Si: 0.56/0.316 Hosp: 0.96/0.0007 |
| Abbreviations: AP, Absent-Present; DE, dif study) that were changed in expression discovery (33.3%). However, they display i trend towards significance. | fferential expre in the same d ability to predi | ssion; ROC, receiver-operatir irection in both genders. Th :t in the other gender as wel | ng characteristic; SI, suicid nese biomarkers were dis I. SI—predicting suicidal i | lal ideation. Exampl covered in just one ideation. Hosp—pre | ss of top predictive biomarl gender, as they were in tl dicting future hospitalizatio | kers of interest from men ² and the other gender below the and no for suicidality. Bold— P -valu | l from women (current oriori set threshold for Le is significant. Italic— |

and low mood (Figure 2). We would also like to include in the future measures of psychosis, and of stress, to be more comprehensive.

Sixth, we examined how the biomarkers identified by us are able to predict *state* (SI) in a larger independent cohort of women psychiatric participants (n = 33 participants).

Seventh, we examined whether the biomarkers are able to predict *trait* (future hospitalizations for suicidal behavior) in women psychiatric participants (n = 24).

Last but not least, we demonstrate how our apriori primary end point, a comprehensive universal predictor for suicide (UP-Suicide), composed of the combination of the Bonferroni validated biomarkers (n = 50), along with the scores from CFI-S and SASS, predicts state (SI) and trait (future psychiatric hospitalizations for suicidality).

The rationale for identifying blood biomarkers as opposed to brain biomarkers is a pragmatic one—the brain cannot be readily accessed in live individuals. Other peripheral fluids, such as cerebrospinal fluid, require more invasive and painful procedures. Nevertheless, it is likely that many of the peripheral blood transcriptomic changes are not necessarily mirroring what is happening in the brain, and vice-versa. The keys to find peripheral biomarkers⁵ are, first, to have a powerful discovery approach, such as our within-participant design, that closely tracks the phenotype you are trying to measure and reduces noise. Second, crossvalidating and prioritizing the results with other lines of evidence, such as brain gene expression and genetic data, are important in order to establish relevance to disease and generalizability of findings. Third, it is important to validate for behavior in an independent cohort with a robust and relevant phenotype, in these case suicide completers. Fourth, testing for predictive ability in independent/prospective cohorts is a must (Supplementary Figure S1).

Biomarkers that survive such a rigorous stepwise discovery, prioritization, validation and testing process are likely directly relevant to the disorder studied. As such, we endeavored to study their biology, whether they are involved in other psychiatric disorders or are relatively specific for suicide, and whether they are modulated by existing drugs in general, and drugs known to treat suicidality in particular.

We have identified a series of biomarkers that seem to be changed in opposite direction in suicide vs in treatments with omega-3 fatty acids, lithium and clozapine (Supplementary Table S4). These biomarkers could potentially be used to stratify patients to different treatment approaches, and monitor their response. BCL2, JUN, GHA1, ENTPD1, ITIH5, MBNL1 and SSBP2 are changed in expression by two of these three treatments, suggesting that they may be core to the anti-suicidal mechanism of these drugs. Interestingly, MBNL1, which is decreased in expression in suicidality, was identified as increased in expression in longevity/healthy aging.³⁴ BCL2, CAT and JUN may be useful blood pharmacogenomic markers of response to lithium. CD84, MBNL1 and RAB22A may be useful blood pharmacogenomic markers of response to clozapine. NDRG1, FOXP1, AFF3, ATXN1, CSNK1A1, ENTPD1, ITIH5, PRDX3 and SSBP2 may be useful blood pharmacogenomic markers of response to omega-3 fatty acids. Three existing drugs used for other indications have been identified as targeting the top suicide biomarkers identified by us (Supplementary Table S4), and could potentially be re-purposed for testing in treatment of acute suicidality: anakinra (inhibiting ILR1), enzastaurin (inhibiting AKT3) and tesevatinib (inhibiting EPHB4). Additionally, Connectivity Map³⁵ analyses (Supplementary Table S6) identified novel compounds that induce gene expression signatures that are the opposite of those present in suicide, and might generate leads and/or be tested for use to treat/prevent suicidality, including mifepristone, LY294002, acetylsalicylic acid, estradiol, buspirone, corticosterone, metformin, diphenhydramine, haloperidol and fluoxetine (Supplementary Table S6).



| Predictors | Visit 1 High SI HAMD-SI 3 (T- 14 months) % | + 1 H | Visit 2 High SI HAMD-SI 2 (T- 10 months) % | + 1 H | Visit 3 No SI HAMD-SI 0 (T- 5 months) % | + 4 H | T Suicide | | 98 - 86 - | 1 1 7 | Moo | | | | ø | Ŷ | | | An | diety | | | | 6 | | ohchp32 |
|-------------|--|-------------|--|-------------|--|----------|--------------|----------|--------------|----------|---------|------|----------------|----|------|------|------|---------|--------|-------|----|------------|----------|------------------------|-------|---------|
| EPB41L5 | 39.03 | | 19.68 | | 100 | | | | 74 - | | - | | | | 0 | Ŧơ | 12 | 52 | X | PE | ZX | <u> </u> | XO | 98 | | |
| HAVCR2 | 62.85 | | 34.2 | | 17.67 | | | | | | | ++- | | - | ¥ | -9 | | | | 100 | | | Ø\$ | XXX | _ | |
| ARHGAP15 | 29.17 | | 33.26 | | 25.67 | | | | 62 - | | | | | | - | | | | ×., | - | | 69 | X | | 9 | 2 |
| HTRA1 | 100 | | 40.46 | | 20.6 | | | <u>-</u> | | | | +++- | | Q | 1.41 | | | | | | | | | A XX | | - |
| PER1 | 69.72 | | 26.62 | | 20.98 | | | ъ | 50 - | | | | 2 | | | 1 | | 26 | | | | | O | KAN | | 5 |
| PDXDC1 | 17.75 | | 62.26 | | 100 | | | | | | | | 14 | | | | | | | | | | | × Se | | |
| PIK3C3 | 81.07 | | 65.73 | | 56.85 | | | | 38 - | | | X | 1. | | 1 | بەرج | | 1.0 | | 294 | | | | \mathbf{o} | | |
| GTF3C2 | 42.63 | | 51.89 | | 81.08 | | | | | | | Æ | | | | | | 1 | lest : | 100 | | | 100 | 14.5 | | |
| ALDH3A2 | 81.47 | | 66.03 | | 55.81 | | | | 26 | | | | 4 4 - 3 | | | | 3.20 | 1. | 5 | 1.92 | | 92 P | 150 | | _ | |
| BCL2 | 71.02 | | 40.43 | | 61.61 | | | | ~] | | | Sur. | | | | | 1 | | | | | I ALA | 5P | | | |
| MOB3B | 86.13 | | 65.50 | | 23.66 | | | | 14 | | | 41 | | | | | 20 | - 1 × 2 | | | | 2 | 2 | 5 | | |
| DPCD | 33.51 | | 46.59 | | 44.6 | | | | 1 | | | | 150 | | A | | | | | -0- | | 5 | 1 | $\mathbf{Q}\mathbf{Q}$ | | |
| GTF3C3 | 23.14 | | 62.60 | | 17.21 | | | | 2 | | | 11 | ~ | | | 0 | 0 | | | - | | | | | | |
| ASPH | 57.87 | | 16.57 | | 7.95 | | | | - 1 | | | | 0 | TT | | 223 | | 20 | | | | | | | | |
| KLHL28 | 59.17 | | 86.01 | | 37.19 | | | | | | OKOT 47 | 10' | / | / | / | / | | / | / | | / | | | / | / | |
| UIMC1 | 46.25 | | 60.38 | | 13.84 | | | | 11098 | BT 16200 | 00 | - | | 1 | | - | | | | | 1 | | | | | - |
| SNX27 | 40.27 | | 100 | | 20.41 | | | | -1 | 10 | | z | | 14 | | 20 | 38 | | 50 | | 62 | 74 | | 86 | | 98 |
| ACTR3 | 78.33 | | 80.32 | | 61.09 | | | | | | | | | | | | | | | | | SI | | | | |
| NUDT6 | 65.18 | | 80.59 | | 73.34 | | | | | | | | | | | | | | | | | | | ~ | | |
| LRRC8B | 86.34 | | 89.48 | | 70.00 | | | | | | | | | | | | | | | | | - F | ligh 3 | SI | | |
| CSNK1A1 | 93.4 | | 93.83 | | 78.25 | | | | | | | | | | | | | | | | | - 💻 h | ntern | nedia | te Sl | |
| LARP4 | 90.63 | | 91.63 | | 71.60 | | | | | | | | | | | | | | | | | N | lo SI | | | |
| ZNF548 | 83.18 | | 69.06 | | 34.55 | | | | | | | | | | | | | | | | | | | | | |
| BioM18 | 82.99 | | 32.54 | | 17.85 | | | | | | | | | | | | | | | | | | | | | |
| BioM32 | 95.40 | | 85.90 | | 29.51 | | | | | | | | | | | | | | | | | | | | | |
| BioM50 | 100 | | 62.49 | | 21.16 | | | | | | | | | | | | | | | | | | | | | |
| Anxiety | 96.00 | | 84.18 | | 59.80 | | | | | | | | | | | | | | | | | | | | | |
| CFI-S | 87.15 | | 79.83 | | 65.19 | | | | | | | | | | | | | | | | | | | | | |
| Mood | 83.61 | | 50.86 | | 21.43 | | | | | | | | | | | | | | | | | | | | | |
| SASS | 97.13 | | 72.27 | | 42.75 | | | | | | | | | | | | | | | | | | | | | |
| CFI-S +SASS | 100 | | 72.24 | | 40.62 | | | | | | | | | | | | | | | | | | | | | |
| UP-Suicide | 100 | | 72.14 | | 36.80 | | | | | | | | | | | | | | | | | | | | | |

Figure 5. Study participant who committed suicide. Subject phchp328 was a 38-year-old divorced Caucasian female with a long history of MDD, PTSD, BP and polysubstance abuse/dependence. She had multiple psychiatric hospitalizations due to suicidal ideation (n = 21) and due to suicidal attempts (n = 3), in the 5 years before her suicide. She committed suicide by overdose with pills, leaving behind a suicide note addressed to her mother. (a) Percentile for scores on top predictors in all the female subjects in this study (n = 105 for biomarkers and n = 88for apps and UP-Suicide). Her panel of Bonferroni validated biomarkers (BioM50) score, apps score (CFI-S+SASS), and UP-Suicide predictor score at a study visit (Visit 1) were at the 100% of the scores of all the psychiatric participant visits tested in this current study. Of note, that testing was conducted during an inpatient hospitalization due to suicidal ideation. While her scores did improve at subsequent outpatient testing visits (Visits 2 and 3), this high watermark score indicated her high risk. After the last testing visit in our study, she had four subsequent psychiatric hospitalizations: three due to suicidal ideation, one for opioid withdrawal/detox (the last one), ending 2 weeks before date of committing suicide (T). For decreased biomarkers, a higher percentile corresponds to lower expression values. Only 5 of the 32 predictors (biomarkers, clinical, combined) were discordant between the highest and lowest SI visit (italicized). In all, 17 of the 32 predictors (bold) were stepwise decreased corresponding to her SI scores. One of the biomarkers (HTRA1) was in the 100% of the subjects tested, as was the panel of 50 validated markers (BioM-50), the combination of the clinical measures/apps (CFI-S+SASS), and the combined biomarker panels and clinical/ apps predictor (UP-Suicide). (b) Tri-dimensional representation of the percentilized scores of the combination of the two apps, CFI-S and SASS (Anxiety and Mood) of all the female participant visits tested in the current study (n = 87) and all the male participant visits in our previous work (n = 317). A tri-dimensional scatter plot was created using Partek. Tri-dimensional 95% confidence intervals were inserted as ellipsoids, color coded blue, yellow and red for No SI, Intermediate SI and High SI, respectively. Subject phchp328visit1 had the highest Euclidian D (distance from origin), as indicated by the arrow. This is the only subject that completed suicide as far as we know, as of the end of this study in November 2015. BP, bipolar disorder; MDD, major depressive disorder; PTSD, post-traumatic stress disorder.

Of note, a number of biomarkers from the current study in women reproduce and are co-directional with our previous findings in men (Table 5, Table 2 and Supplementary Table S2), whereas others had changes in opposite directions (Table 2 and Supplementary Table S2), underlying the issue of biological context and differences in suicidality between the two genders. This avenue merits attention in the field, and detailed future comparative studies, as do studies by diagnostic groups.

Before any testing, we planned to use a comprehensive combination of genomic data (specifically, the top validated biomarkers) and phenomic data (specifically, the CFI-S and the SASS) as the primary end point measure, a broad-spectrum universal predictor (UP-Suicide) for state SI and trait future hospitalizations. It has not escaped our attention that certain single biomarkers, particular phenotypic items, or combinations thereof seem to perform better than the UP-Suicide in one or another type of prediction (see Table 4). However, since such

markers and combinations were not chosen by us apriori and such insights derive from testing, we cannot exclude a fit to cohort effect for them and reserve judgement as to their robustness as predictors until further testing in additional independent cohorts, by us and others. What we can put forward for now based on the current work is the UP-Suicide, which seems to be a robust predictor across different scenarios and diagnostic groups.

Our study has a number of limitations. All this work was carried out in psychiatric patients, a high-risk group, and it remains to be seen how such predictors apply to non-psychiatric participants. For the UP-Suicide testing, the prevalence rate for suicidality in our test cohorts was 21% (7 out of 33 for SI and 5 out of 24 for future hospitalizations) (Table 4). Of note, this rate was remarkably similar to our previous work in men.⁴ It is to be noted that the incidence of suicidality in the general population is lower, for example at 1.5% in adolescents in an European cohort³⁶ and estimates of 0.2-2% in the United States,³⁷ which underlines the rationale

of using a very high-risk group like we did for magnifying and enabling signal detection with a relatively small *N*. Over 40% of the live participants from the discovery cohort (5 out of 12) and independent test cohort (14 out of 33) are non-VA, and all the suicide completers used for validation are from the general population, not VA, so we believe our results have broader relevance. Studies with larger numbers and longer follow-up, currently ongoing, as well as studies in different clinical settings, may provide more generalizability.

The current studies were carried out exclusively in females. Similar work is needed in larger meta-analyses across gender, in participants with and without psychiatric disorders, to find generalizable predictors. Conversely, a narrow focus by gender, diagnosis (or lack of), and perhaps age, may be needed to find more individualized predictors. Such work is ongoing in our group.

In conclusion, we have advanced the biological understanding of suicidality in women, highlighting behavioral and biological mechanisms related to inflammation, neurotrophic factors, circadian clock, stress response and apoptosis. Biomarkers that may track treatment response to lithium and intriguingly, omega-3 fatty acids, have been identified. Of equal importance, we developed instruments (biomarkers and apps) for predicting suicidality, that do not require asking the person assessed if they have suicidal thoughts, as individuals who are truly suicidal often do not share that information with people close to them or with clinicians. We propose that the widespread use of such risk prediction tests as part of routine or targeted health-care assessments will lead to early disease interception followed by preventive lifestyle modifications or treatment. Given the magnitude and urgency of the problem, the importance of efforts to implement such tools cannot be overstated. We note that we have sadly lost one study participant to suicide (Figure 5), that in retrospect was highlighted by UP-Suicide as being the highest risk participant in our study.

Note

Supplementary information is also available from the Niculescu Laboratory website (www.neurophenomics.info).

CONFLICT OF INTEREST

ABN is listed as an inventor on a patent application being filed by Indiana University.

ACKNOWLEDGMENTS

This work is, in essence, a field-wide collaboration. We acknowledge our debt of gratitude for the efforts and results of the many other groups, cited in our paper, who have conducted and published studies (clinical, genetic and biological) in suicidality. With their arduous and careful work, a convergent approach such as ours is possible. We thank David Welsh for advice on clock genes, Joseph Niezer and Tammy Jones for helpful clinical discussions, as well as Meghan Carpenter and Jay Natarajan for help with building literature databases. We also would particularly like to thank the participants who participated in these studies, their families and their caregivers. Without their contribution, such work to advance the understanding of suicide would not be possible. This work was supported by an NIH Directors' New Innovator Award (1DP2OD007363) and a VA Merit Award (2I01CX000139) to ABN.

AUTHOR CONTRIBUTIONS

ABN designed the study and wrote the manuscript. DFL, EN, HLN, HD, PLP, TL and ECS analyzed the data. NV and FNK performed database work. HW, EB and DLG organized, conducted and scored testing in psychiatric participants. AB, MY, AS, GES and ABN organized and carried out postmortem samples collection. TG, NJS, SMK and DRS conducted microarray experiments and provided input on data analyses. All authors discussed the results and commented on the manuscript.

REFERENCES

- 1 Hawton K. Sex and suicide. Gender differences in suicidal behaviour. Br J Psychiatry2000; 177: 484-485.
- 2 Niculescu AB, Levey DF, Phalen PL, Le-Niculescu H, Dainton HD, Jain N *et al.* Understanding and predicting suicidality using a combined genomic and clinical risk assessment approach. *Mol Psychiatry* 2015; **20**: 1266–1285.
- 3 Le-Niculescu H, Levey DF, Ayalew M, Palmer L, Gavrin LM, Jain N *et al.* Discovery and validation of blood biomarkers for suicidality. *Mol Psychiatry* 2013; **18**: 1249–1264.
- 4 Niculescu AB, Levey DF, Phalen PL, Le-Niculescu H, Dainton HD, Jain N et al. Understanding and predicting suicidality using a combined genomic and clinical risk assessment approach. *Mol Psychiatry* 2015; 20: 1266–1285.
- 5 Niculescu AB, Levey D, Le-Niculescu H, Niculescu E, Kurian SM, Salomon D. Psychiatric blood biomarkers: avoiding jumping to premature negative or positive conclusions. *Mol Psychiatry* 2015; 20: 286–288.
- 6 Niculescu AB, Le-Niculescu H. Convergent Functional Genomics: what we have learned and can learn about genes, pathways, and mechanisms. *Neuropsychopharmacology* 2010; **35**: 355–356.
- 7 Zhang EE, Liu AC, Hirota T, Miraglia LJ, Welch G, Pongsawakul PY et al. A genomewide RNAi screen for modifiers of the circadian clock in human cells. Cell 2009; 139: 199–210.
- 8 McCarthy MJ, Welsh DK. Cellular circadian clocks in mood disorders. J Biol Rhythms 2012; 27: 339-352.
- 9 Niculescu AB, Lulow LL, Ogden CA, Le-Niculescu H, Salomon DR, Schork NJ et al. PhenoChipping of psychotic disorders: a novel approach for deconstructing and quantitating psychiatric phenotypes. Am J Med Genet B Neuropsychiatr Genet 2006; 141B: 653–662.
- 10 Borges G, Angst J, Nock MK, Ruscio AM, Kessler RC. Risk factors for the incidence and persistence of suicide-related outcomes: a 10-year follow-up study using the National Comorbidity Surveys. J Affect Disord 2008; 105: 25–33.
- 11 Nock MK. Future directions for the study of suicide and self-injury. J Clin Child Adolesc Psychol **53**2012; **41**: 255–259.
- 12 Chen R, Mias GI, Li-Pook-Than J, Jiang L, Lam HY, Miriami E *et al.* Personal omics profiling reveals dynamic molecular and medical phenotypes. *Cell* 2012; **148**: 1293–1307.
- 13 Sequeira A, Morgan L, Walsh DM, Cartagena PM, Choudary P, Li J et al. Gene expression changes in the prefrontal cortex, anterior cingulate cortex and nucleus accumbens of mood disorders subjects that committed suicide. PLoS One 2012; 7: e35367.
- 14 Falcone T, Fazio V, Lee C, Simon B, Franco K, Marchi N *et al*. Serum S100B: a potential biomarker for suicidality in adolescents? *PLoS One* 2010; **5**: e11089.
- 15 Guintivano J, Brown T, Newcomer A, Jones M, Cox O, Maher BS et al. Identification and replication of a combined epigenetic and genetic biomarker predicting suicide and suicidal behaviors. Am J Psychiatry 2014; 171: 1287–1296.
- 16 Kaminsky Z, Wilcox HC, Eaton WW, Van Eck K, Kilaru V, Jovanovic T *et al.* Epigenetic and genetic variation at SKA2 predict suicidal behavior and post-traumatic stress disorder. *Transl Psychiatry* 2015; 5: e627.
- 17 Mann JJ, Currier D. Medication in Suicide Prevention Insights from Neurobiology of Suicidal Behavior, In:Dwivedi Y(ed) The Neurobiological Basis of Suicide: Boca Raton, FL, USA, 2012.
- 18 Sublette ME, Hibbeln JR, Galfalvy H, Oquendo MA, Mann JJ. Omega-3 polyunsaturated essential fatty acid status as a predictor of future suicide risk. Am J Psychiatry 2006; 163: 1100–1102.
- 19 Lewis MD, Hibbeln JR, Johnson JE, Lin YH, Hyun DY, Loewke JD. Suicide deaths of active-duty US military and omega-3 fatty-acid status: a case-control comparison. *J Clin Psychiatry* 2011; **72**: 1585–1590.
- 20 Hennings JM, Uhr M, Klengel T, Weber P, Putz B, Touma C et al. RNA expression profiling in depressed patients suggests retinoid-related orphan receptor alpha as a biomarker for antidepressant response. *Transl Psychiatry* 2015; 5: e538.
- 21 Martins-de-Souza D, Maccarrone G, Ising M, Kloiber S, Lucae S, Holsboer F *et al.* Blood mononuclear cell proteome suggests integrin and Ras signaling as critical pathways for antidepressant treatment response. *Biol Psychiatry* 2014; **76**: e15–e17.
- 22 Le-Niculescu H, Kurian SM, Yehyawi N, Dike C, Patel SD, Edenberg HJ *et al.* Identifying blood biomarkers for mood disorders using convergent functional genomics. *Mol Psychiatry* 2009; **14**: 156–174.
- 23 Kurian SM, Le-Niculescu H, Patel SD, Bertram D, Davis J, Dike C *et al.* Identification of blood biomarkers for psychosis using convergent functional genomics. *Mol Psychiatry* 2011; **16**: 37–58.
- 24 Kelleher I, Lynch F, Harley M, Molloy C, Roddy S, Fitzpatrick C *et al.* Psychotic symptoms in adolescence index risk for suicidal behavior: findings from 2 population-based case-control clinical interview studies. *Arch Gen Psychiatry* 2012; 69: 1277–1283.
- 25 Le-Niculescu H, McFarland MJ, Ogden CA, Balaraman Y, Patel S, Tan J et al. Phenomic, convergent functional genomic, and biomarker studies in a



stress-reactive genetic animal model of bipolar disorder and co-morbid alcoholism. Am J Med Genet B Neuropsychiatr Genet 2008; **147B**: 134–166.

- 26 Goodwin RD, Marusic A. Association between short sleep and suicidal ideation and suicide attempt among adults in the general population. *Sleep* 2008; **31**: 1097–1101.
- 27 Schoenbaum M, Kessler RC, Gilman SE, Colpe LJ, Heeringa SG, Stein MB et al. Predictors of suicide and accident death in the Army Study to Assess Risk and Resilience in Servicemembers (Army STARRS): results from the Army Study to Assess Risk and Resilience in Servicemembers (Army STARRS). JAMA Psychiatry 2014; 71: 493–503.
- 28 Posner K, Brown GK, Stanley B, Brent DA, Yershova KV, Oquendo MA et al. The Columbia-Suicide Severity Rating Scale: initial validity and internal consistency findings from three multisite studies with adolescents and adults. Am J Psychiatry 2011; 168: 1266–1277.
- 29 Gaiteri C, Guilloux JP, Lewis DA, Sibille E. Altered gene synchrony suggests a combined hormone-mediated dysregulated state in major depression. *PLoS One* 2010; 5: e9970.
- 30 Sainz J, Mata I, Barrera J, Perez-Iglesias R, Varela I, Arranz MJ *et al.* Inflammatory and immune response genes have significantly altered expression in schizophrenia. *Mol Psychiatry* 2013; **18**: 1056–1057.
- 31 Sokolov BP, Jiang L, Trivedi NS, Aston C. Transcription profiling reveals mitochondrial, ubiquitin and signaling systems abnormalities in postmortem brains from subjects with a history of alcohol abuse or dependence. J Neurosci Res 2003; 72: 756–767.
- 32 Yu Z, Ono C, Kim HB, Komatsu H, Tanabe Y, Sakae N *et al.* Four mood stabilizers commonly induce FEZ1 expression in human astrocytes. *Bipolar Disord* 2011; **13**: 486–499.
- 33 Le-Niculescu H, Case NJ, Hulvershorn L, Patel SD, Bowker D, Gupta J et al. Convergent functional genomic studies of omega-3 fatty acids in stress reactivity, bipolar disorder and alcoholism. Transl Psychiatry 2011; 1: e4.
- 34 Sood S, Gallagher IJ, Lunnon K, Rullman E, Keohane A, Crossland H et al. A novel multi-tissue RNA diagnostic of healthy ageing relates to cognitive health status. *Genome Biol* 2015; 16: 185.

- 35 Lamb J, Crawford ED, Peck D, Modell JW, Blat IC, Wrobel MJ et al. The Connectivity Map: using gene-expression signatures to connect small molecules, genes, and disease. Science 2006; 313: 1929–1935.
- 36 Wasserman D, Hoven CW, Wasserman C, Wall M, Eisenberg R, Hadlaczky G et al. School-based suicide prevention programmes: the SEYLE cluster-randomised, controlled trial. Lancet 2015; 385: 1536–1544.
- 37 Nock MK, Borges G, Bromet EJ, Cha CB, Kessler RC, Lee S. Suicide and suicidal behavior. *Epidemiol Rev* 2008; **30**: 133–154.
- 38 Butler AW, Breen G, Tozzi F, Craddock N, Gill M, Korszun et al. A genomewide linkage study on suicidality in major depressive disorder confirms evidence for linkage to 2p12. Am J Med Genet B Neuropsychiatr Genet 2010; 153B: 1465–1473.
- 39 Smalheiser NR, Lugli G, Rizavi HS, Torvik VI, Turecki G, Dwivedi Y. MicroRNA expression is down-regulated and reorganized in prefrontal cortex of depressed suicide subjects. *PLoS One* 2012; 7: e33201.
- 40 Fiori LM, Bureau A, Labbe A, Croteau J, Noel S, Merette C et al. Global gene expression profiling of the polyamine system in suicide completers. Int J Neuropsychopharmacol 2011; 14: 595–605.
- 41 Dick DM, Meyers J, Aliev F, Nurnberger J Jr., Kramer J, Kuperman S et al. Evidence for genes on chromosome 2 contributing to alcohol dependence with conduct disorder and suicide attempts. Am J Med Genet B Neuropsychiatr Genet 2010; 153B: 1179–1188.
- 42 Hesselbrock V, Dick D, Hesselbrock M, Foroud T, Schuckit M, Edenberg H *et al.* The search for genetic risk factors associated with suicidal behavior. *Alcohol Clin Exp Res* 2004; **28**: 70 S–76 S.
- 43 Menke A, Domschke K, Czamara D, Klengel T, Hennings J, Lucae S et al. Genomewide association study of antidepressant treatment-emergent suicidal ideation. *Neuropsychopharmacology* 2012; 37: 797–807.
- 44 Sequeira A, Gwadry FG, Ffrench-Mullen JM, Canetti L, Gingras Y, Casero RA Jr. *et al.* Implication of SSAT by gene expression and genetic variation in suicide and major depression. *Arch Gen Psychiatry* 2006; **63**: 35–48.

Supplementary Information accompanies the paper on the Molecular Psychiatry website (http://www.nature.com/mp)

18

Supplementary Information:



Figure S1 Sequential flow of biomarker discovery, prioritization, validation and testing.

Figure S2. SASS and CFI-S questionnaires and apps.

Simplified Affective State Scale (SASS)

For each item, mark the scale with a vertical line where you think you are at this moment in time, compared to lowest and highest you ever remember being:

Mood Subscale

| 1) | Моос | I |
|----|------|---|
|----|------|---|

How good is your mood right now?

| [| 1 |
|--------|--------------|
| Lowest | J Highest |

2) Motivation to do things

How is your motivation, your drive, your determination to do things right now?

| [|] |
|--------|---------|
| Lowest | Highest |

3) Movement activity

How high is your physical energy and the amount of moving about that you feel like doing right now?

| Γ | 1 |
|--------|---------|
| Lowest | Highest |

4) Thinking activity

How high is your mental energy and thinking activity going on in your mind right now?

| [| [| -] |
|---|-------|---------|
| Ĺ | owest | Highest |

5) Self-esteem

How good do you feel about yourself and your accomplishments right now?

| [|] |
|--------|---------|
| Lowest | Highest |

6) Interest in pleasurable activities

How high is your interest to do things that are fun and enjoyable right now?

| [|] |
|--------|---------|
| Lowest | Highest |

7) Appetite

How high is your appetite and desire for food right now?

| [|] |
|--------|---------|
| Lowest | Highest |

Anxiety Subscale

1) Anxiety

| How | anxious | are | you | right | now? |
|-----|---------|-----|----------|-------|------|
| - | | | J | | - |

| [|] |
|--------|---------|
| Lowest | Highest |

2) Uncertainty

How uncertain about things do you feel right now?

| [|] |
|--------|---------|
| Lowest | Highest |

3) Fear

How frightened about things do you feel right now?

| [| -] |
|---|---------|
| Lowest | Highest |
| 4) Anger | |
| How angry about things do you feel right now? | |
| [|] |
| Lowest | Highest |

Comments (optional): Describe events or actions that you think are influencing how you feel now. Describe any additional feelings you might have at this moment in time:

Convergent Functional Information for Suicide (CFI-S) Scale. Items are scored 1 for Yes, 0 for No. Total Score has a maximum possible of 22. Final Score (normalized) is Total Score divided by number of items that were scored, as for some items information might not be available (NA), so they are not scored.

| Itomo | | Vac | No | | Domain | Type |
|-------|---|-----|----|----|-------------------------|--|
| items | | res | NO | NA | Domain | I ype Increased Reasons (IR) Decreased Barriers |
| 1. | Psychiatric illness diagnosed and treated | | | | Mental Health | IR |
| 2. | With poor treatment compliance | | | | Mental Health | DB |
| 3. | Family history of suicide in blood relatives | | | | Mental Health | IR |
| 4. | Personally knowing somebody who committed suicide | | | | Cultural Factors | DB |
| 5. | History of abuse: physical, sexual, emotional, neglect | | | | Life Satisfaction | IR |
| 6. | Acute/severe medical illness, including acute pain ("I just can't stand this pain anymore.") (within last 3 months) | | | | Physical Health | IR |
| 7. | Acute stress: Losses, grief (within last 3 months) | | | | Environmental Stress | IR |
| 8. | Chronic stress: perceived uselessness, not feeling needed, burden to extended kin. | | | | Environmental Stress | IR |
| 9. | History of excessive introversion, conscientiousness (including planned suicide attempts) | | | | Mental Health | IR |
| 10. | Dissatisfaction with life at this moment in time | | | | Life Satisfaction | IR |
| 11. | Lack of hope for the future | | | | Life Satisfaction | IR |
| 12. | Current substance abuse | | | | Addictions | DB |
| 13. | Past history of suicidal acts/gestures | | | | Mental Health | DB |
| 14. | Lack of religious beliefs | | | | Cultural Factors | DB |
| 15. | Acute stress: Rejection (within last 3 months) | | | | Environmental Stress | IR |
| 16. | Chronic stress: lack of positive relationships, social isolation | | | | Environmental Stress | DB |
| 17. | History of excessive extroversion and impulsive behaviors (including rage, anger, physical fights, seeking revenge) | | | | Mental Health | DB |
| 18. | Lack of coping skills when faced with stress (cracks under pressure) | | | | Mental Health | DB |
| 19. | Lack of children. If has children, not in touch /not helping take care of them. | | | | Life Satisfaction | DB |

| 20. History of command hallucinations of self- directed violence | | Mental Health | IR |
|---|--|---------------|----|
| 21. Age: Older >60 or Younger <25 | | Age | IR |
| 22. Gender: Male | | Gender | DB |

SASS App

| # 🖻 🖉 💉 🔶 🤶 | at 28% 📕 5:28 PM | 47 🖻 🖻 🖍 | 🛜 🚛 27% 📕 5:28 PM | 47 🖻 🖉 🖊 | 🛜 🚛 27% 📕 5:29 PM |
|-------------------------|------------------|---|---|---|--|
| 💹 SASS | | < 💹 SASS - Enter | Ratings | < 💹 SASS - Ente | er Ratings |
| Simplified Affective S | State Scale | Simplified Affective | State Scale | Anxiety Subscale | |
| Lab Version | | | Subject ID: 001 | For each item, slide to you are at this mome and highest you ever | he scale to where you think nt in time, compared to lowest remember being: |
| Current Subject 12. 001 | | Mood Subscale | | 1) Anxiety: 82/100 | |
| Mood and Anx | iety | For each item, slide the you are at this moment | scale to where you think in time, compared to lowest | How anxious are you | right now? |
| Enter Ratings | | and highest you ever re | member being: | Lowest | Highest |
| 🗠 View Ratings | | How good is your mood | l right now? | 2) Uncertainty: 66/ | /100 things do you feel right now? |
| Send Ratings | | Lowest | Highest | | |
| H Evport Datingo | | 2) Motivation to do t | hings: 20/100 | Lowest | Highest |
| E Export Ratings | | How is your motivation, determination to do thir | , your drive, your ngs right now? | 3) Fear: 80/100 How frightened abou | t thinas do vou feel right now? |
| 🖋 Set Subject ID | | | | | |
| | | Lowest | Highest | Lowest | Highest |
| | | Movement activity How high is your physic moving about that you | y: 41/100 cal energy and the amount of feel like doing right now? | 4) Anger: 37/100 How angry about thin | ngs do you feel right now? |
| | | Lowest | Highest | Lowest | Highest |
| | | 4) Thinking activity: | unset | 3 | <u></u> |

CFI-S App

| r 🖉 | 🛜 📲 71% 🖬 12:10 PN | 1 50° 🖍 | ار. ار | 71% 😼 | 12:11 PM | 50" 💉 | 🛜 📶 70% 🖬 12:13 PM |
|--|-----------------------------------|---|---|-------|--|-------|--------------------|
| Suicide Risk A | ssessment | Cons Suicide risk a | ssessm | ent | | CFI-S | |
| Current Subject ID: 001 Last CFI-S Assessment | t: 11:47 AM, 04/20/2015 | Ask and answer questions. If you a question, you question text for | the fol u don't can tap r more | | CFI-S Score = 0.64 (64% of possible points) | | |
| Set Subject ID | | Item 1. | | | | | |
| Belect saved Su | bject ID | Do you have a mood disorder? | Yes | No | Not sure | | |
| Perform CFI-S A | Perform CFI-S Assessment | | _ | + | | | |
| 🗠 View past asses | ssment results | 4 | | | | | |
| X Take CFI-S witho | X Take CFI-S without saving score | | Yes | No | Not sure | | |
| | | Commente | | | | | |
| Export via excel | Export via email | comments. | | | | | |
| | | Do you have any other kind of psychiatric diagnosis? | Yes | No | Not sure | | |

Comments

| Participant ID visit | Veteran Status | Diagnosis | Age | Gender | Ethnicity | HAMD S |
|----------------------|----------------|-----------|-----|--------|---------------------|--------|
| phchp034v1 | NON-VA | BP | 51 | F | Asian American | 0 |
| phchp034v2 | NON-VA | BP | 52 | F | Asian American | 3 |
| phchp043v1 | NON-VA | BP | 30 | F | Caucasian | 2 |
| phchp043v2 | NON-VA | BP | 31 | F | Caucasian | 0 |
| phchp043v3 | NON-VA | BP | 31 | F | Caucasian | 0 |
| phchp055v1 | | BP | 46 | F | Caucasian | 4 |
| phchp055v2 | | BP | 46 | F | Caucasian | 0 |
| phchp055v3 | | BP | 46 | F | Caucasian | 0 |
| phchp097v1 | NON-VA | SZA | 25 | F | Caucasian | 0 |
| phchp097v2 | NON-VA | SZA | 26 | F | Caucasian | 2 |
| phchp131v1 | | SZ | 54 | F | African American | 3 |
| phchp131v3 | | SZ | 56 | F | African American | 0 |
| phchp170v1 | NON-VA | MDD | 26 | F | Caucasian | 2 |
| phchp170v2 | NON-VA | MDD | 26 | F | Caucasian | 0 |
| phchp170v3 | NON-VA | MDD | 26 | F | Caucasian | 0 |
| phchp223v1 | NON-VA | SZA | 60 | F | Caucasian | 2 |
| phchp223v2 | NON-VA | SZA | 60 | F | Caucasian | 0 |
| phchp223v3 | NON-VA | SZA | 61 | F | Caucasian | 0 |
| phchp318v1 | | MDD | 57 | F | Caucasian | 2 |
| phchp318v2 | | MDD | 57 | F | Caucasian | 0 |
| phchp328v1 | | MDD | 37 | F | Caucasian | 3 |
| phchp328v2 | | MDD | 38 | F | Caucasian | 2 |
| phchp328v3 | | MDD | 38 | F | Caucasian | 0 |
| phchp332v1 | | SZA | 47 | F | African American | 4 |
| phchp332v2 | | SZA | 48 | F | African American | 0 |
| phchp332v3 | | SZA | 48 | F | American | 0 |
| phchp334v1 | | BP | 50 | F | Caucasian | 4 |
| phchp334v2 | | BP | 50 | F | Caucasian | 0 |
| phchp334v3 | | BP | 51 | F | Caucasian | 0 |
| phchp340v1 | | MDD | 51 | F | Caucasian | 2 |
| phchp340v2 | | MDD | 51 | F | Caucasian | 0 |

Table S1. Detailed Demographics

Coroner's Office Validation Cohort –Toxicology

| Cohort 2: Coroner's Office Validation Cohort -gene expression data (n=6) | | | | | | | | | | |
|--|-----------------------|-----|--------|------------------|--------------------------|--|--|--|--|--|
| Subject ID visit | Psych ¹ Dx | Age | Gender | Ethnicity | Cause of Death | | | | | |
| INBRAIN020 | Depression | 55 | F | Caucasian | Single GSW to chest | | | | | |
| INBRAIN026 | None | 57 | F | Caucasian | Single GSW to head | | | | | |
| INBRAIN029 | PTSD | 36 | F | Caucasian | Asphyxiation (duct tape) | | | | | |
| INBRAIN032 | Bipolar | 44 | F | Caucasian | Single GSW to head | | | | | |
| INBRAIN034 | Depression | 50 | F | Caucasian | Single GSW to chest | | | | | |
| INBRAIN050 | Depression | 19 | F | African American | Single GSW under chin | | | | | |

| Coroner's Office Validation Cohort - Toxicology | | | | | | | | |
|---|---|--|--|--|--|--|--|--|
| Subject ID visit | Toxicology | | | | | | | |
| INBRAIN020 | clonazepam 6.7 7-aminoclonazepam 32.9 duloxetine 68.7 trazodone 0.21 | | | | | | | |
| INBRAIN026 | CAFFEINE POSITIVE | | | | | | | |
| INBRAIN029 | NA | | | | | | | |
| INBRAIN032 | CAFFEINE POSITIVE | | | | | | | |
| INBRAIN034 | Oxazepam 54.5 Temazepam 395 Gabapentin 1 Zolpidem 571 Temazepam >2500 Oxazepam>2500 Hydrocodone 88 Hydromorphine 161 | | | | | | | |
| INBRAIN050 | NA | | | | | | | |

| | Cohort 3: Test | Cohort for | Suicida | l Ideation | (n=33) (74 visits) | |
|-------------------------|----------------|------------|---------|------------|--------------------|---------|
| Participant ID visit | Veteran Status | Diagnosis | Age | Gender | Ethnicity | HAMD SI |
| phchp018v1 | NON-VA | SZA | 54 | F | Caucasian | 0 |
| phchp028v1 | NON-VA | BP | 50 | F | Asian | 1 |
| phchp028v2 | NON-VA | BP | 50 | F | Asian | 1 |
| phchp035v1 | NON-VA | BP | 36 | F | Caucasian | 0 |
| phchp035v2 | NON-VA | BP | 37 | F | Caucasian | 0 |
| phchp035v3 | NON-VA | BP | 37 | F | Caucasian | 0 |
| phchp037v1 | NON-VA | BP | 52 | F | Caucasian | 0 |
| phchp063v1 | NON-VA | SZ | 46 | F | African American | 0 |
| phchp071v1 | NON-VA | SZA | 50 | F | African American | 0 |
| phchp074v1 | | SZA | 46 | F | African American | 0 |
| phchp074v2 | | SZA | 46 | F | African American | 0 |
| phchp074v3 | | SZA | 46 | F | African American | 0 |
| phchp076v1 | | SZA | 41 | F | African American | 2 |
| phchp076v2 | | SZA | 41 | F | African American | 1 |
| phchp076v3 | | SZA | 41 | F | African American | 1 |
| phchp084v1 | | BP | 49 | F | Caucasian | 0 |
| phchp084v2 | | BP | 49 | F | Caucasian | 0 |
| phchp084v3 | | BP | 50 | F | Caucasian | 0 |
| phchp106v1 | | BP | 28 | F | Mixed | 0 |
| phchp106v2 | | BP | 28 | F | Mixed | 0 |
| phchp106v3 | | BP | 29 | F | Mixed | 0 |
| phchp130v1 | | MDD | 42 | F | Caucasian | 0 |
| phchp130v2 | | MDD | 42 | F | Caucasian | 0 |
| phchp130v3 | | MDD | 42 | F | Caucasian | 0 |
| phchp141v1 | | BP | 47 | F | Caucasian | 1 |
| phchp141v2 | | BP | 47 | F | Caucasian | 0 |
| phchp141v3 | | BP | 47 | F | Caucasian | 1 |
| phchp156v1 | | BP | 35 | F | Caucasian | 2 |
| phchp160v1 | NON-VA | SZA | 41 | F | Caucasian | 0 |
| phchp160v2 | NON-VA | SZA | 41 | F | Caucasian | 0 |
| phchp160v3 | NON-VA | SZA | 41 | F | Caucasian | 0 |
| phchp164v1 | | MDD | 48 | F | Caucasian | 0 |
| phchp164v2 | | MDD | 49 | F | Caucasian | 0 |
| phchp164v3 | | MDD | 49 | F | Caucasian | 0 |
| phchp172v1 | NON-VA | BP | 24 | F | Caucasian | 0 |
| phchp172v2 | NON-VA | BP | 24 | F | Caucasian | 0 |
| phchp172v3 | NON-VA | BP | 25 | F | Caucasian | 0 |

| phchp177v1 | | SZ | 39 | F | Caucasian | 0 |
|------------|--------|-----|----|---|------------------|---|
| phchp177v2 | | SZ | 39 | F | Caucasian | 0 |
| phchp180v1 | NON-VA | BP | 47 | F | Caucasian | 0 |
| phchp180v2 | NON-VA | BP | 47 | F | Caucasian | 0 |
| phchp180v3 | NON-VA | BP | 47 | F | Caucasian | 0 |
| phchp181v1 | NON-VA | BP | 28 | F | Caucasian | 0 |
| phchp181v3 | NON-VA | BP | 28 | F | Caucasian | 0 |
| phchp181v4 | NON-VA | BP | 29 | F | Caucasian | 0 |
| phchp204v1 | NON-VA | BP | 49 | F | Caucasian | 0 |
| phchp204v2 | NON-VA | BP | 49 | F | Caucasian | 0 |
| phchp204v3 | NON-VA | BP | 49 | F | Caucasian | 0 |
| phchp232v1 | NON-VA | SZA | 38 | F | Caucasian | 0 |
| phchp232v2 | NON-VA | SZA | 38 | F | Caucasian | 0 |
| phchp232v3 | NON-VA | SZA | 38 | F | Caucasian | 0 |
| phchp239v1 | NON-VA | SZA | 54 | F | African American | 0 |
| phchp239v2 | NON-VA | SZA | 54 | F | African American | 0 |
| phchp239v3 | NON-VA | SZA | 54 | F | African American | 0 |
| phchp240v1 | | MDD | 55 | F | Caucasian | 0 |
| phchp240v2 | | MDD | 55 | F | Caucasian | 0 |
| phchp240v3 | | MDD | 56 | F | Caucasian | 0 |
| phchp254v1 | | MDD | 49 | F | Caucasian | 0 |
| phchp254v2 | | MDD | 49 | F | Caucasian | 0 |
| phchp254v3 | | MDD | 50 | F | Caucasian | 0 |
| phchp258v1 | | BP | 52 | F | Caucasian | 0 |
| phchp258v2 | | BP | 52 | F | Caucasian | 0 |
| phchp285v1 | | BP | 56 | F | Caucasian | 0 |
| phchp285v2 | | BP | 56 | F | Caucasian | 1 |
| phchp291v1 | | BP | 45 | F | Caucasian | 0 |
| phchp291v2 | | BP | 46 | F | Caucasian | 0 |
| phchp291v3 | | BP | 47 | F | Caucasian | 0 |
| phchp294v1 | NON-VA | BP | 20 | F | Caucasian | 2 |
| phchp307v1 | | MDD | 53 | F | Caucasian | 2 |
| phchp330v1 | | BP | 45 | F | Caucasian | 3 |
| phchp338v1 | | BP | 51 | F | Caucasian | 0 |
| phchp338v2 | | BP | 51 | F | Caucasian | 0 |
| phchp353v1 | | MDD | 45 | F | Caucasian | 2 |
| phchp355v1 | | MDD | 50 | F | Caucasian | 3 |
| | | | | | | |

| Participant ID visit | Diagnosis Age | | Gender | Ethnicity | Years Followed | Number Futur Hospitaliz Due to Sui | of All re ations cidality | Hospitalizations Frequency Due to Suicidality | |
|-------------------------|---------------|----|--------|---------------------|-------------------|---|------------------------------------|---|---------|
| | | | | | | SI | SA | SI | SA |
| phchp055v1 | BP | 46 | F | Caucasian | 3.482192 | 0 | 1 | 0 | 0.28717 |
| phchp055v2 | BP | 46 | F | Caucasian | 3.175342 | 0 | 0 | 0 | 0 |
| phchp055v3 | BP | 46 | F | Caucasian | 2.893151 | 0 | 0 | 0 | 0 |
| phchp074v1 | SZA | 46 | F | African American | 1.882192 | 0 | 0 | 0 | 0 |
| phchp074v2 | SZA | 46 | F | African American | 1.583562 | 0 | 0 | 0 | 0 |
| phchp074v3 | SZA | 46 | F | African American | 1.326027 | 0 | 0 | 0 | 0 |
| phchp076v1 | SZA | 41 | F | African American | 7.490411 | 2 | 0 | 0.267008 | 0 |
| phchp076v2 | SZA | 41 | F | American | 7.210959 | 1 | 0 | 0.138678 | 0 |
| phchp076v3 | SZA | 41 | F | American | 6.991781 | 1 | 0 | 0.143025 | 0 |
| phchp084v1 | BP | 49 | F | Caucasian | 7.032877 | 0 | 0 | 0 | 0 |
| phchp084v2 | BP | 49 | F | Caucasian | 6.835616 | 0 | 0 | 0 | 0 |
| phchp084v3 | BP | 50 | F | Caucasian | 6.567123 | 0 | 0 | 0 | 0 |
| phchp106v1 | BP | 28 | F | Mixed | 5.446575 | 0 | 0 | 0 | 0 |
| phchp106v2 | BP | 28 | F | Mixed | 5.205479 | 0 | 0 | 0 | 0 |
| phchp106v3 | BP | 29 | F | Mixed | 4.961644 | 0 | 0 | 0 | 0 |
| phchp130v1 | MDD | 42 | F | Caucasian | 4.939726 | 0 | 0 | 0 | 0 |
| phchp130v2 | MDD | 42 | F | Caucasian | 4.641096 | 0 | 0 | 0 | 0 |
| phchp130v3 | MDD | 42 | F | Caucasian | 4.386301 | 0 | 0 | 0 | 0 |
| phchp131v1 | SZ | 54 | F | African American | 1.671233 | 0 | 0 | 0 | 0 |
| phchp131v2 | SZ | 55 | F | African American | 1.358904 | 0 | 0 | 0 | 0 |
| phchp131v3 | SZ | 56 | F | African American | 1.112329 | 0 | 0 | 0 | 0 |
| phchp141v1 | BP | 47 | F | Caucasian | 4.60274 | 0 | 0 | 0 | 0 |
| phchp141v2 | BP | 47 | F | Caucasian | 4.336986 | 0 | 0 | 0 | 0 |
| phchp141v3 | BP | 47 | F | Caucasian | 4.090411 | 0 | 0 | 0 | 0 |
| phchp156v1 | BP | 35 | F | Caucasian | 1.778082 | 0 | 0 | 0 | 0 |
| phchp164v1 | MDD | 48 | F | Caucasian | 3.906849 | 0 | 0 | 0 | 0 |
| phchp164v2 | MDD | 49 | F | Caucasian | 3.578082 | 0 | 0 | 0 | 0 |
| phchp164v3 | MDD | 49 | F | Caucasian | 3.309589 | 0 | 0 | 0 | 0 |
| phchp177v1 | SZ | 39 | F | Caucasian | 3.912329 | 0 | 0 | 0 | 0 |
| phchp177v2 | SZ | 39 | F | Caucasian | 3.613699 | 0 | 0 | 0 | 0 |
| phchp240v1 | MDD | 55 | F | Caucasian | 3.252055 | 0 | 0 | 0 | 0 |
| phchp240v2 | MDD | 55 | F | Caucasian | 2.641096 | 0 | 0 | 0 | 0 |

| phchp240v3 | MDD | 56 | F | Caucasian | 2.282192 | 0 | 0 | 0 | 0 |
|------------|-----|----|---|---------------------|----------|---|---|----------|---|
| phchp254v1 | MDD | 49 | F | Caucasian | 2.353425 | 0 | 0 | 0 | 0 |
| phchp254v2 | MDD | 49 | F | Caucasian | 1.739726 | 0 | 0 | 0 | 0 |
| phchp254v3 | MDD | 50 | F | Caucasian | 1.336986 | 0 | 0 | 0 | 0 |
| phchp258v1 | BP | 52 | F | Caucasian | 2.863014 | 0 | 0 | 0 | 0 |
| phchp258v2 | BP | 52 | F | Caucasian | 2.252055 | 0 | 0 | 0 | 0 |
| phchp291v1 | BP | 45 | F | Caucasian | 2.468493 | 0 | 0 | 0 | 0 |
| phchp291v2 | BP | 46 | F | Caucasian | 2.084932 | 0 | 0 | 0 | 0 |
| phchp291v3 | BP | 47 | F | Caucasian | 0.391781 | 0 | 0 | 0 | 0 |
| phchp318v1 | MDD | 57 | F | Caucasian | 2.369863 | 0 | 0 | 0 | 0 |
| phchp318v2 | MDD | 57 | F | Caucasian | 0.660274 | 0 | 0 | 0 | 0 |
| phchp328v1 | MDD | 37 | F | Caucasian | 1.30411 | 5 | 0 | 3.834034 | 0 |
| phchp328v2 | MDD | 38 | F | Caucasian | 1.008219 | 4 | 0 | 3.967391 | 0 |
| phchp328v3 | MDD | 38 | F | Caucasian | 0.613699 | 3 | 0 | 4.888393 | 0 |
| phchp330v1 | BP | 45 | F | Caucasian | 1.2 | 0 | 0 | 0 | 0 |
| phchp332v1 | SZA | 47 | F | African American | 0.871233 | 2 | 0 | 2.295597 | 0 |
| phchp332v2 | SZA | 48 | F | African American | 0.619178 | 2 | 0 | 3.230088 | 0 |
| phchp332v3 | SZA | 48 | F | African American | 0.561644 | 0 | 0 | 0 | 0 |
| phchp334v1 | BP | 50 | F | Caucasian | 1.065753 | 2 | 0 | 1.876607 | 0 |
| phchp334v2 | BP | 50 | F | Caucasian | 0.816438 | 2 | 0 | 2.449664 | 0 |
| phchp334v3 | BP | 51 | F | Caucasian | 0.534247 | 0 | 0 | 0 | 0 |
| phchp338v1 | BP | 51 | F | Caucasian | 0.89863 | 0 | 0 | 0 | 0 |
| phchp338v2 | BP | 51 | F | Caucasian | 0.556164 | 0 | 0 | 0 | 0 |
| phchp340v1 | MDD | 51 | F | Caucasian | 0.923288 | 0 | 0 | 0 | 0 |
| phchp340v2 | MDD | 51 | F | Caucasian | 0.627397 | 0 | 0 | 0 | 0 |
| phchp353v1 | MDD | 45 | F | Caucasian | 0.29863 | 0 | 0 | 0 | 0 |
| phchp355v1 | MDD | 50 | F | Caucasian | 0.539726 | 0 | 0 | 0 | 0 |

Table S2. Top candidate biomarker genes -evidence for involvement in suicidality.

The top 49 genes (50 probesets) from validation (Bonferroni significant), as well as 65 genes that were top scoring in both discovery (internal score of 4) and prioritization (CFG score of 6 and above) but were non Bonferroni validated. <u>Underlined gene symbol</u> means co-directionality of the exact same probeset with biomarkers findings from our previous work in males (Niculescu et al. 2015)². 82 out of 115 probesets were co-directional (71%). *Italic- nominally significant*. **Bold p-value is Bonferroni significant after validation in suicide completers.**

| Gene Symbol/Gene Name | Probesets | Discovery (Change) Method/ Score | Prior human genetic evidence | Prior human Brain expression evidence | Prior human peripheral expression evidence | Prioritizati on Total CFG Score For Suicide | Validation ANOVA p-value |
|---|----------------------------|---|---------------------------------------|--|--|---|--------------------------------|
| | | Valid | ated Biomarker | s (Bonferroni) (49 genes, 50 | probesets) | | |
| BCL2 B-cell CLL/Lymphoma 2 | 203684_s_at | (D) DE/2 | Linkage ³ | (D) PFC ⁴ | (D) Blood⁵ | 9 | 3.95E-06 |
| GSK3B glycogen synthase kinase 3 beta | 226183_at | (D) DE/1 | Suicide ⁶ | (D) PFC ⁷⁸ | (I) Blood⁵ | 9 | 2.26E-05 |
| ALDH3A2 aldehyde dehydrogenase 3 family, member A2 | 202053_s_at | (D) DE/2 | | (I) BA4, BA44, THALAMUS ⁹ | (D) Blood ⁵ | 8 | 1.62E-06 |
| AP1S2 adaptor-related protein complex 1, sigma 2 subunit | 203299_s_at | (D) DE/1 | Linkage | (I) BA 8/9 ; (D) BA 44, BA 11 Suicide ¹⁰ | (D) Blood ⁵ | 8 | 2.52E-05 |
| CAT catalase | 238363_at | (D) DE/2 | | (D) BA47 ¹¹ | (I) Blood ⁵ | 8 | 5.04E-07 |
| JUN jun proto- oncogene | 201466_s_at 201465_s_at | (I) DE/2 DE/1 | | (D) HIP ¹² | (I) Blood ⁵ | 8 7 | 1.14E-11 1.72E-14 |
| C18orf54 chromosome 18 open reading frame 54 | 244324_at | (D) DE/1 | | (D) HIP ¹² | (I) Blood ⁵ | 7 | 2.79E-06 |
| LINC00342 long intergenic non-protein coding RNA 342 | 1560661_x_at | (D) DE/2 | Linkage | (D) DLFPC ¹⁴ | | 7 | 1.67E-06 |
| MOB3B MOB kinase activator 3B | 229568_at | (D) DE/1 | | (I) ACC ¹⁴ | (I) Blood⁵ | 7 | 4.69E-06 |
| NDRG1 N-myc downstream regulated 1 | 200632_s_at | (I) DE/1 | | (I) NAC ¹⁴ | (I) Blood ⁵ | 7 | 3.07E-07 |
| PER1 period circadian clock 1 | 202861_at | (I) DE/1 | | (D) DLFPC ¹⁴ | (D) Blood⁵ | 7 | 5.32E-12 |
| Ras association (RalGDS | 1552482_at | (I) DE/1 | | (I) BA11 ¹⁵ | (I) Blood⁵ | 7 | 7.44E-10 |
| SPON1 spondin 1, extracellular matrix protein | 213993_at | (I) DE/1 | | (D) PFC ¹⁶ (I) DLFPC ¹⁴ | (I) Blood⁵ | 7 | 1.02E-05 |
| FOXP1 forkhead box P1 | 223937_at | (I) DE/4 | | | (D) Blood ⁵ | 6 | 7.03E-07 |
| HAVCR2 hepatitis A virus cellular receptor 2 | 1555629_at | (I) DE/4 | | | (D) Blood ⁵ | 6 | 1.69E-12 |
| PIP5K1B phosphatidylinosito I-4-phosphate 5- | 205632_s_at | (D) DE/4 | | | (I) Blood⁵ | 6 | 1.83E-05 |

| kinase, type I, beta | | | | | | | |
|--|--------------|-------------|-----------------------|--|---------------------------|---|----------|
| ARHGAP15 Rho GTPase activating protein 15 | 1561489_at | (I) DE/1 | Suicide ¹³ | | (I) Blood ⁵ | 5 | 3.05E-06 |
| GJA1 gap junction protein, alpha 1, 43kDa | 201667_at | (I) DE/1 | | (D) HIP ¹² PFC ^{16 17} | | 5 | 1.96E-06 |
| HES1 hes family bHLH transcription factor 1 | 203394_s_at | (I) AP/1 | | (D) DLPFC, AMY ¹⁸ | | 5 | 7.65E-10 |
| HTRA1 HtrA serine peptidase 1 | 201185_at | (I) AP/1 | | (I) NAC ¹⁴ | | 5 | 3.17E-07 |
| PRCP prolylcarboxypeptid ase (angiotensinase C) | 242636_at | (D) DE/1 | | (D) HIP ¹² | | 5 | 2.36E-08 |
| TIMP1 TIMP metallopeptidase inhibitor 1 | 201666_at | (I) DE/1 | | (I) HIP ¹⁹ (D) PFC ¹⁶ | | 5 | 7.00E-07 |
| CD200R1 CD200 receptor 1 | 1553395_a_at | (D) DE/2 | | | (D) Blood⁵ | 4 | 1.45E-05 |
| CD84 CD84 molecule | 230391_at | (D) DE/2 | | | (D) Blood ⁵ | 4 | 1.74E-05 |
| CEP44 centrosomal protein 44kDa | 231850_x_at | (D) DE/4 | | | | 4 | 6.71E-08 |
| CROT carnitine O- octanoyltransferase | 231102_at | (D) DE/2 | | | (I) Blood⁵ | 4 | 7.62E-06 |
| DCAF5 DDB1 and CUL4 associated factor 5 | 224696_s_at | (D) DE/2 | | | (I) Blood ⁵ | 4 | 1.37E-05 |
| DTWD2 DTW domain containing 2 | 231277_x_at | (D) DE/2 | | | (I) Blood⁵ | 4 | 1.87E-09 |
| EPB41L5 erythrocyte membrane protein band 4.1 like 5 | 229292_at | (I) DE/1 | Linkage | | (I) Blood | 4 | 4.58E-14 |
| ERP27 endoplasmic reticulum protein 27 | 227450_at | (D) DE/2 | | | (D) Blood ⁵ | 4 | 9.54E-08 |
| FAM173B family with sequence similarity 173, member B | 225670_at | (D) DE/2 | | | (D) Blood ⁵ | 4 | 2.25E-05 |
| GANC glucosidase, alpha; neutral C | 235714_at | (D) DE/2 | | | (I) Blood ⁵ | 4 | 1.40E-08 |
| GTF3C2 general transcription factor IIIC, polypeptide 2, beta 110kDa | 210620_s_at | (D) DE/2 | | | (D) Blood ⁵ | 4 | 1.68E-07 |
| IL1R1 interleukin 1 receptor, type I | 215561_s_at | (I) AP/1 | Linkage | | (D) Blood ⁵ | 4 | 5.47E-08 |
| INO80D | 227924_at | (D) | | | (D) | 4 | 6.58E-06 |

| INO80 complex subunit D | | DE/2 | | Blood ⁵ | | |
|--|-------------|-------------|---|---------------------------|---|----------|
| INPP4A inositol polyphosphate-4- phosphatase, type I, 107kDa | 235695_at | (D) DE/1 | Linkage | (D) Blood ⁵ | 4 | 1.79E-05 |
| ITLN1 intelectin 1 (galactofuranose binding) | 223597_at | (I) DE/2 | | (I) Blood⁵ | 4 | 6.69E-07 |
| JRK Jrk homolog (mouse) | 37872_at | (D) AP/2 | | (D) Blood⁵ | 4 | 4.25E-06 |
| KCTD5 potassium channel tetramerization domain containing 5 | 218474_s_at | (D) DE/2 | | (D) Blood ⁵ | 4 | 2.05E-07 |
| KIR2DL4 killer cell immunoglobulin- like receptor, two domains, long cytoplasmic tail, 4 | 208426_x_at | (I) DE/2 | | (D) Blood ⁵ | 4 | 1.61E-11 |
| METTL15 methyltransferase like 15 | 238773_at | (D) DE/2 | | (D) Blood ⁵ | 4 | 2.16E-06 |
| NUDT10 nudix (nucleoside diphosphate linked moiety X)-type motif 10 | 241596_at | (I) DE/2 | | (D) Blood ⁵ | 4 | 7.99E-07 |
| PDXDC1 pyridoxal- dependent decarboxylase domain containing 1 | 1560013_at | (I) DE/2 | | (I) Blood ⁵ | 4 | 1.03E-05 |
| PIK3C3 phosphatidylinosito I 3-kinase, catalytic subunit type 3 | 232086_at | (D) DE/1 | Suicide, Antidepres sants ²¹ | (I) Blood ⁵ | 4 | 3.14E-08 |
| RBM48 RNA binding motif protein 48 | 232661_s_at | (D) DE/2 | | (I) Blood ⁵ | 4 | 7.89E-07 |
| SMARCA2 SWI/SNF Related, Matrix Associated, Actin Dependent Regulator of Chromatin, Subfamily A, Member 2 | 206543_at | (D) DE/1 | Linkage 3 | (D) Blood ⁵ | 4 | 2.46E-05 |
| UCHL5 ubiquitin carboxyl- terminal hydrolase L5 | 1570145_at | (D) DE/2 | | (I) Blood ⁵ | 4 | 9.05E-11 |
| VPS53 vacuolar protein sorting 53 homolog (S. cerevisiae) | 235882_at | (D) DE/2 | | (I) Blood ⁵ | 4 | 3.41E-09 |
| ZNF302 zinc finger protein 302 | 228392_at | (D) DE/2 | | (D) Blood⁵ | 4 | 7.64E-06 |

| Top Discovery and Prioritization Biomarkers(Non Bonferroni Validated, 65 genes) | | | | | | | | | | | |
|---|-------------|-------------|--|--------------------------|---------------------------|----|------------|--|--|--|--|
| <mark>CLTA</mark> clathrin, light chain A | 216296_at | (I) DE/4 | | (I) PFC ²² | (I) Blood ⁵ | 10 | | | | | |
| FAM214A family with sequence similarity 214, member A | 236237_at | (I) DE/4 | | (I) ACC ¹⁴ | (I) Blood ⁵ | 10 | | | | | |
| HSPD1 heat shock 60kDa protein 1 (chaperonin) | 241716_at | (I) DE/4 | | (I) AMY ²³ | (D) Blood ⁵ | 10 | 0.021922 | | | | |
| ZMYND8 zinc finger, MYND- type containing 8 | 214795_at | (I) AP/4 | | (I) ACC ¹⁴ | (I) Blood ⁵ | 10 | | | | | |
| AK2 adenylate kinase 2 | 212172_at | (I) AP/4 | Suicide ²⁴ | | (D) Blood⁵ | 8 | | | | | |
| CAPZA2 capping protein (actin filament) muscle Z-line, alpha 2 | 201238_s_at | (D) DE/4 | | (I) PFC ²³ | | 8 | 0.116785 | | | | |
| LRRC8B leucine rich repeat containing 8 family, member B | 212976_at | (D) DE/4 | | (I) PFC ¹⁵ | | 8 | 0.231881 | | | | |
| PPM1B protein phosphatase, Mg2+ | 209296_at | (D) DE/4 | | (I) NAC ¹⁴ | | 8 | 0.002299 | | | | |
| ACTR3 ARP3 actin-related protein 3 homolog (yeast) | 213102_at | (D) DE/4 | Linkage | | (I) Blood ⁵ | 7 | 0.0045239 | | | | |
| AFF3 AF4/FMR2 family, member 3 | 244696_at | (I) AP/4 | Linkage | | (D) Blood ⁵ | 7 | | | | | |
| MRPS5 mitochondrial ribosomal protein S5 | 237560_at | (I) AP/4 | Linkage 3 {Willour, 2007 #37863} | | (D) Blood ⁵ | 7 | | | | | |
| SH2D1A SH2 domain containing 1A | 211211_x_at | (D) DE/4 | Linkage 9 {Zubenko, 2004 #37861} | | (D) Blood⁵ | 7 | | | | | |
| AKT3 v-akt murine thymoma viral oncogene homolog 3 | 240568_at | (I) AP/4 | | | (D) Blood ⁵ | 6 | | | | | |
| ALG13 ALG13, UDP-N- acetylglucosaminyltr ansferase subunit | 205584_at | (D) DE/4 | | | (I) Blood ⁵ | 6 | 0.046957 | | | | |
| ARHGAP35 Rho GTPase activating protein 35 | 229397_s_at | (D) DE/4 | | | (D) Blood ⁵ | 6 | 0.00160014 | | | | |
| ARID4B AT rich interactive domain 4B (RBP1- like) | 221230_s_at | (D) DE/4 | | | (I) Blood ⁵ | 6 | | | | | |
| ASPH aspartate beta- | | (1) | | | (I) Blood⁵ | 6 | 0.01087 | | | | |

| hydroxylase | 242037_at | DE/4 | | | | |
|--|------------------|-------------|--|---------------------------|---|----------|
| ATXN1 ataxin 1 | 1565804_at | (I) DE/4 | | (I) Blood ⁵ | 6 | |
| BRE Brain and reproductive organ- expressed (TNFRSF1A modulator) | 1556817_a_a t | (I) AP/4 | | (I) Blood⁵ | 6 | |
| CHMP2B charged multivesicular body protein 2B | 202538_s_at | (D) DE/4 | | (I) Blood ⁵ | 6 | 0.022703 |
| <u>CLPB</u> ClpB caseinolytic peptidase B homolog (E. coli) | 1566581_at | (I) AP/4 | | (D) Blood ⁵ | 6 | 0.025268 |
| CSNK1A1 casein kinase 1, alpha 1 | 235464_at | (D) DE/4 | | (D) Blood ⁵ | 6 | |
| DPCD deleted in primary ciliary dyskinesia homolog (mouse) | 226009_at | (I) DE/4 | | (D) Blood ⁵ | 6 | |
| ECSIT ECSIT signalling integrator | 218225_at | (I) DE/4 | | (D) Blood ⁵ | 6 | |
| ENTPD1 ectonucleoside triphosphate diphosphohydrolase 1 | 243111_at | (I) AP/4 | | (I) Blood ⁵ | 6 | |
| EPHB4 EPH receptor B4 | 202894_at | (I) DE/4 | | (D) Blood ⁵ | 6 | |
| ETNK1 ethanolamine kinase 1 | 224453_s_at | (D) AP/4 | | (D) Blood ⁵ | 6 | |
| FANCI Fanconi anemia, complementation group I | 213008_at | (I) DE/4 | | (I) Blood ⁵ | 6 | 0.000897 |
| FBXL3 F-box and leucine- rich repeat protein 3 | 225132_at | (D) DE/4 | | (I) Blood ⁵ | 6 | 0.00127 |
| GTF3C3 general transcription factor IIIC, polypeptide 3, 102kDa | 1555439_at | (I) AP/4 | | (I) Blood ⁵ | 6 | NC |
| HERC4 HECT and RLD domain containing E3 ubiquitin protein ligase 4 | 225988_at | (D) DE/4 | | (D) Blood⁵ | 6 | 0.042192 |
| ITIH5 inter-alpha-trypsin inhibitor heavy chain family, member 5 | 1553243_at | (I) AP/4 | | (I) Blood ⁵ | 6 | |
| JMJD1C jumonji domain containing 1C | 221763_at | (D) DE/4 | | (I) Blood ⁵ | 6 | 0.191525 |
| KLHL28 kelch-like family member 28 | 220374_at | (I) AP/4 | | (I) Blood ⁵ | 6 | |
|--|------------------|----------------------------|--|---------------------------|---|----------|
| LARP4 La ribonucleoprotein domain family, member 4 | 214155_s_at | (D) DE/4 | | (D) Blood ⁵ | 6 | 0.014911 |
| MBNL1 muscleblind-like splicing regulator 1 | 201153_s_at | (D) DE/4 | | (D) Blood ⁵ | 6 | 0.009769 |
| MEX3C mex-3 RNA binding family member C | 222567_s_at | (D) DE/4 | | (D) Blood ⁵ | 6 | 0.00603 |
| <u>MR1</u> major histocompatibility complex, class I- related | 207566_at | (I) DE/4 | | (D) Blood ⁵ | 6 | |
| NUDT6 nudix (nucleoside diphosphate linked moiety X)-type motif 6 | 220183_s_at | (D) AP/4 | | (D) Blood ⁵ | 6 | |
| PHC3 polyhomeotic homolog 3 (Drosophila) | 1552644_a_a t | (D) DE/4 (I) DE/1 | | (I) Blood ⁵ | 6 | |
| PIAS1 protein inhibitor of activated STAT, 1 | 1558418_at | (I) DE/4 | | (I) Blood ⁵ | 6 | |
| PPHLN1 periphilin 1 | 234459_at | (I) DE/4 | | (I) Blood⁵ | 6 | |
| PRDX3 peroxiredoxin 3 | 201619_at | (D) DE/4 | | (I) Blood ⁵ | 6 | 0.000225 |
| PVT1 Pvt1 oncogene (non- protein coding) | 1562153_a_a t | (D) DE/4 | | (D) Blood ⁵ | 6 | 0.000433 |
| RAB22A RAB22A, member RAS oncogene family | 218360_at | (D) DE/4 | | (I) Blood ⁵ | 6 | |
| RDH13 retinol dehydrogenase 13 (all-trans/9-cis) | 225449_at | (I) AP/4 | | (D) Blood ⁵ | 6 | |
| SBNO1 strawberry notch homolog 1 (Drosophila) | 229528_at | (I) DE/4 | | (I) Blood ⁵ | 6 | |
| SLC35B3 solute carrier family 35 (adenosine 3'- phospho 5'- phosphosulfate transporter), member B3 | 231003_at | (D) DE/4 | | (I) Blood ⁵ | 6 | 3.34E-05 |
| SNRNP27 small nuclear ribonucleoprotein 27kDa (U4 | 212440_at | (D) DE/4 | | (D) Blood ⁵ | 6 | |
| <u>SNX27</u> | 244349_at | (I) | | (1) | 6 | |

| sorting nexin family member 27 | | AP/4 | | Blood⁵ | | |
|---|------------------|-------------|--|---------------------------|---|----------|
| <u>SSBP2</u> single-stranded DNA binding protein 2 | 1557814_a_a t | (I) AP/4 | | (I) Blood ⁵ | 6 | |
| <u>STRN</u> striatin, calmodulin binding protein | 1569813_at | (I) AP/4 | | (I) Blood ⁵ | 6 | |
| TTC7A tetratricopeptide repeat domain 7A | 224924_at | (I) DE/4 | | (I) Blood⁵ | 6 | |
| UIMC1 ubiquitin interaction motif containing 1 | 233596_at | (I) DE/4 | | (I) Blood ⁵ | 6 | |
| USP6NL USP6 N-terminal like | 204761_at | (D) DE/4 | | (D) Blood ⁵ | 6 | 0.007614 |
| WAC WW domain containing adaptor with coiled-coil | 230154_at | (D) DE/4 | | (D) Blood⁵ | 6 | 8.53E-05 |
| WAPAL wings apart-like homolog (Drosophila) | 212267_at | (D) DE/4 | | (D) Blood⁵ | 6 | 0.002521 |
| ZBP1 Z-DNA binding protein 1 | 208087_s_at | (I) DE/4 | | (D) Blood ⁵ | 6 | |
| ZFAND5 zinc finger, AN1-type domain 5 | 210275_s_at | (D) DE/4 | | (D) Blood⁵ | 6 | 0.042362 |
| ZNF117 zinc finger protein 117 | 207605_x_at | (D) DE/4 | | (D) Blood ⁵ | 6 | |
| ZNF141 zinc finger protein 141 | 206931_at | (D) DE/4 | | (D) Blood ⁵ | 6 | |
| ZNF548 zinc finger protein 548 | 1553718_at | (D) DE/4 | | (D) Blood⁵ | 6 | 0.000461 |
| ZNF596 zinc finger protein 596 | 240324_at | (I) AP/4 | | (I) Blood ⁵ | 6 | |
| AP3S2 adaptor-related protein complex 3, sigma 2 subunit | 213215_at | (I) DE/4 | | | 4 | |
| SSR1 signal sequence receptor, alpha | 200890_s_at | (D) DE/4 | | | 4 | 0.000923 |

Table S3. Top candidate biomarker genes – evidence for involvement in other psychiatric and

non-psychiatric disorders (aging, pain). <u>Underlined gene symbol means concordant with findings from our previous</u> <u>mood and psychosis biomarker studies (mood-opposite direction, psychosis-same direction)</u>. Alc- alcoholism; BP- Bipolar; SZschizophrenia. ASD- Autism spectrum disorders; ALZ- Alzheimer; PTSD-Post Traumatic Stress Disorder.

| Gene Symbol/Gene Name | Probesets | Disc over y (Cha nge) Met hod/ Scor e | Prioriti zation CFG Score For Suicid e | Validation ANOVA p-value | Circadian clock function | Prior human genetic evidence | Prior human Brain expression evidence | Prior human peripheral expression evidence | CFG Score For Other Disorde rs |
|--|-------------|---|--|--------------------------------|--------------------------------|---|--|--|---|
| | | | Vali | dated Biomarke | rs (Bonferroni) | (49 genes, 50 pr | obesets) | | |
| BCL2 B-cell CLL/Lymphoma 2 | 203684_s_at | (D) DE/2 | 9.00 | 3.95E-06 | | Anxiety ²⁵ BP ^{26 27} BP, SZ ²⁸ | (I) Aging PFC ²⁹ (D) BP FC ³⁰ PTSD DLPFC ³¹ | (I) Alc Blood ³² Pain Vertebral disc ³³ (D) BP lymphoblast ²⁶ Mood stabilizers Blood ³⁴ | 8.00 |
| GSK3B glycogen synthase kinase 3 beta | 226183_at | (D) DE/1 | 9.00 | 2.26E-05 | Clock Immediate Input | BP ^{35 36 37} MDD ₃₈ Mood Stabilizers ³ ⁹ MDD ^{40 41} SZ ^{42 43} | (D) Alc HTH ⁴⁴ BP Brain ⁴⁵ DLPFC ⁴⁶ ⁴⁷ ACC ⁴⁶ SZ HIP ⁴⁸ ⁴⁹ DLPFC ⁵⁰ ⁴³ Thalamus ⁵¹ Temporal Cortex ⁵² (I) MDD HTH (I) ⁴⁴ ACC, DLPFC ⁴⁶ | (I) MDD Fibroblast ⁵³ (D) Mood stabilizers platelets ⁵⁴ Mild Cognitive Impairment Blood ⁵⁵ BP platelets ⁵⁴ | 8.00 |
| ALDH3A2 aldehyde dehydrogenase 3 family, member A2 | 202053_s_at | (D) DE/2 | 8.00 | 1.62E-06 | | | (D) BP Brain ⁴⁵ | | 4.00 |
| AP152 adaptor-related protein complex 1, sigma 2 subunit | 203299_s_at | (D) DE/1 | 8.00 | 2.52E-05 | | | (D) BP Brain ^{45 56} SZ,SZA DLPFC ⁵⁷ | | 4.00 |
| CAT catalase | 238363_at | (D) DE/2 | 8.00 | 5.04E-07 | | | (I) Mood Disorders NOS ACC ⁵⁸ PTSD DLPFC BA46 31 BP ACC , DLPFC ⁴⁶ | (I) BP Plasma ⁵⁹ (D) SZ Red Blood Cell ⁶⁰ SZ Fibroblasts ⁶¹ | 8.00 |

| | | | | | | | (D) MDD BA47 ¹¹ ; | | |
|---|-----------------------------|---------------------|------------|----------------------|----------------------------|--|--|---|------|
| JUN jun proto- oncogene | 201466_s_at 201465_s_at, | (I) DE/2 DE/1 | 8.0 7.0 | 1.14E-11 1.72E-14 | | | (I) MDD BA2 ⁶² AMY ⁶³ SZ cerebellar vermis ⁶⁴ middle temporal gyrus ⁶⁵ thalamus ₆₆ | SZ Fibroblasts 67 Neurological Pain vertebral disc 33 (D) Stress, Lithium Leukocytes 68 SZ Blood ⁶⁷ | 6.00 |
| C18orf54 chromosome 18 open reading frame 54 | 244324_at | (D) DE/1 | 7.00 | 2.79E-06 | | | | | 0.00 |
| LINC00342 long intergenic non-protein coding RNA 342 | 1560661_x_at | (D) DE/2 | 7.00 | 1.67E-06 | | | | | 0.00 |
| MOB3B MOB kinase activator 3B | 229568_at | (D) DE/1 | 7.00 | 4.69E-06 | | | | | 0.00 |
| NDRG1 N-myc downstream regulated 1 | 200632_s_at | (I) DE/1 | 7.00 | 3.07E-07 | Clock Distant Output | | SZ ACC (BA 24) 56 (I) SZ APFC ⁶⁹ | | 4.00 |
| PER1 period circadian clock 1 | 202861_at | (I) DE/1 | 7.00 | 5.32E-12 | Clock Core | ASD 70 Depression 71 Stress/Alc ⁷ | (Unspecified) MDD DLPFC ⁷³ (D) BP ACC ⁴⁴ (I) SZ middle temporal gyrus ⁶⁵ | (I) BP buccal mucosa cells ⁷⁴ MDD leukocytes 75 (D) SZ Lymphocyte 76 Alc Blood ⁷⁷ | 8.00 |
| RAPH1 Ras association (RalGDS | 1552482_at | (I) DE/1 | 7.00 | 7.44E-10 | Clock Distant Output | | (I) MDD BA11 ¹⁵ | (D) MDD Blood ^{78 79} (I) (MDD) Fibroblast ⁵³ | 6.00 |
| SPON1 | 213994_s_at | (D) | 7.00 | 1.02E-05 | | | | (I) | 8.00 |

| spondin 1, extracellular matrix protein | | DE/1 | | | | Antidepres sants ⁸⁰ | (D) SZ PFC (BA 46/10) ¹⁶ | PTSD Blood ⁸¹ (D) SZ Fibroblasts 61 | |
|--|-------------|-------------|------|----------|------------------------------|--|---|---|------|
| FOXP1 forkhead box P1 | 223937_at | (I) DE/4 | 6.00 | 7.03E-07 | Clock Immediate Output | Alc 82 ASD 83 BP 84 SZ 85 | (I) MDD AMY and cingulate cortex ⁸⁶ | (D) Circadian Abnormalities Blood ⁸⁷ | 8.00 |
| HAVCR2 hepatitis A virus cellular receptor 2 | 1555629_at | (I) DE/4 | 6.00 | 1.69E-12 | | | | (I) PTSD Blood ⁸¹ SZ Blood ⁸⁸ | 2.00 |
| PIP5K1B phosphatidylinos itol-4-phosphate 5-kinase, type I, beta | 205632_s_at | (D) DE/4 | 6.00 | 1.83E-05 | | | (D) BP Brain ⁴⁵ | (D) Delusions Blood ⁸⁹ (I) SZ Fibroblasts ⁶¹ | 6.00 |
| ARHGAP15 Rho GTPase activating protein 15 | 1561489_at | (I) DE/1 | 5.00 | 3.05E-06 | | ASD 90 SZ 85 Alcohol 13 | | | 2.00 |
| GJA1 gap junction protein, alpha 1, 43kDa | 201667_at | (I) DE/1 | 5.00 | 1.96E-06 | | | (I) Alc PFC ⁹¹ frontal (D) Alc 92 MDD Locus coeruleus foreBrain 93 SZ PFC BA 46/10) 16 supragenual (BA24) ACC ⁹⁴ | (I) Neurological Pain vertebral disc ³³ | 6.00 |
| HES1 hes family bHLH transcription factor 1 | 203394_s_at | (I) AP/1 | 5.00 | 7.65E-10 | | | | | 0.00 |
| HTRA1 HtrA serine peptidase 1 | 201185_at | (I) AP/1 | 5.00 | 3.17E-07 | Clock Distant Output | | (D) Alc FC ⁹² | (I) SZ Blood ⁹⁵ | 6.00 |
| PRCP prolylcarboxype ptidase (angiotensinase C) | 242636_at | (D) DE/1 | 5.00 | 2.36E-08 | | | | (D) Chronic Stress Blood monocytes ⁹⁶ SZ Fibroblasts ⁶¹ Blood ⁸⁸ | 2.00 |

| TIMP1 TIMP metallopeptidas e inhibitor 1 | 201666_at | (I) DE/1 | 5.00 | 7.00E-07 | | | (I) AIC HIP ⁹⁷ ASD cerebral cortex ⁹⁸ BP FC ⁹⁹ MDD HIP ¹⁹ DLPFC ¹⁰⁰ (D) BP PFC BA 46/10 ¹⁶ BP,MDD Pituitary ¹⁰¹ AIC Frontal, motor cortex ¹⁰² | (I) SZ Plasma (I) ¹⁰³ (Unspecified) Antidepressants BLOOD ¹⁰⁴ | 6.00 |
|--|--------------|-------------|------|----------|----------------------------|---|---|---|------|
| CD200R1 CD200 receptor | 1553395_a_at | (D) DE/2 | 4.00 | 1.45E-05 | | ASD, SZ ¹⁰⁵ | | | 2.00 |
| CD84 CD84 molecule | 230391_at | (D) DE/2 | 4.00 | 1.74E-05 | | | | (I) BP Whole Blood ¹⁰⁶ Psychosis Blood ⁸⁹ (D) ALZ BMC ¹⁰⁷ Circadian abnormalities Whole Blood 87 | 2.00 |
| CEP44 centrosomal protein 44kDa | 231850_x_at | (D) DE/4 | 4.00 | 6.71E-08 | | | | | 0.00 |
| CROT carnitine O- octanoyltransfer ase | 231102_at | (D) DE/2 | 4.00 | 7.62E-06 | Clock Distant Output | Personality Disorder, Cynicism ¹⁰⁸ | | | 2.00 |
| DCAF5 DDB1 and CUL4 associated factor 5 | 224696_s_at | (D) DE/2 | 4.00 | 1.37E-05 | | | | (D) Circadian abnormalities Whole Blood 87 | 2.00 |
| DTWD2 DTW domain containing 2 | 231277_x_at | (D) DE/2 | 4.00 | 1.87E-09 | | | | | 0.00 |
| EPB41L5 erythrocyte membrane protein band 4.1 like 5 | 229292_at | (I) DE/1 | 4.00 | 4.58E-14 | | | | | 0.00 |
| ERP27 endoplasmic reticulum protein 27 | 227450_at | (D) DE/2 | 4.00 | 9.54E-08 | | | | | 0.00 |
| FAM173B family with sequence similarity 173, | 225670_at | (D) DE/2 | 4.00 | 2.25E-05 | | | (D) Alcohol ₉₇ | | 4.00 |

| member B | | | | | | | | |
|--|-------------|-------------|------|----------|-----------------------------|---|---|------|
| GANC glucosidase, alpha; neutral C | 235714_at | (D) DE/2 | 4.00 | 1.40E-08 | ASD 109 | | | 2.00 |
| GTF3C2 general transcription factor IIIC, polypeptide 2, beta 110kDa | 210620_s_at | (D) DE/2 | 4.00 | 1.68E-07 | | (D) MDD AMY, cingulate cortex | | 4.00 |
| IL1R1 interleukin 1 receptor, type I | 215561_s_at | (I) AP/1 | 4.00 | 5.47E-08 | Aic 110 | (1) Alcohol NAC ¹¹¹ HIP ⁹⁷ BP Brain ⁴⁵ FC ¹¹² (D) BP,SZ DLPFC ¹¹³ SZ PFC ¹¹⁴ SZ PFC ¹¹⁴ | (I) SZ serum ¹¹⁵ 116 Psychological Distress peripheral Blood cells ¹¹⁷ Stress Leukocyte ¹¹⁸ MDD 119 (D) SZ PBMC ¹²⁰ | 7.00 |
| INO80D INO80 complex subunit D | 227924_at | (D) DE/2 | 4.00 | 6.58E-06 | | | | 0.00 |
| INPP4A inositol polyphosphate- 4-phosphatase, type I, 107kDa | 235695_at | (D) DE/1 | 4.00 | 1.79E-05 | Bipolar Psychosis 121 | (D) BP Brain ⁴⁵ (I) SZ supragenual (BA24) ACC 94 | (D) BP Lymphocyte | 8.00 |
| ITLN1 intelectin 1 (galactofuranose binding) | 223597_at | (I) DE/2 | 4.00 | 6.69E-07 | | | | 0.00 |
| JRK Jrk homolog (mouse) | 37872_at | (D) AP/2 | 4.00 | 4.25E-06 | | | | 0.00 |
| KCTD5 potassium channel tetramerization domain containing 5 | 218474_s_at | (D) DE/2 | 4.00 | 2.05E-07 | | | (I) BP Whole Blood ¹⁰⁶ | 2.00 |
| KIR2DL4 killer cell immunoglobulin- like receptor, two domains, long cytoplasmic tail, 4 | 208426_x_at | (I) DE/2 | 4.00 | 1.61E-11 | | | SZ Blood ⁹⁵ (I) Delusions Blood ⁸⁹ Tourette Syndrome Blood ¹²³ | 2.00 |
| methyltransferas | 238773_at | (D) DE/2 | 4.00 | 2.16E-06 | | | | 0.00 |

| e like 15 | | | | | | | | | |
|---|-------------|-------------|-----------|----------------|--------------|--|--|--|------|
| NUDT10 nudix (nucleoside diphosphate linked moiety X)- type motif 10 | 241596_at | (I) DE/2 | 4.00 | 7.99E-07 | | | | (I) Hallucinations Blood ⁸⁹ | 2.00 |
| PDXDC1 pyridoxal- dependent decarboxylase domain containing 1 | 1560013_at | (I) DE/2 | 4.00 | 1.03E-05 | | SZ 124 | | | 2.00 |
| PIK3C3 phosphatidylinos itol 3-kinase, catalytic subunit type 3 | 232086_at | (D) DE/1 | 4.00 | 3.14E-08 | | BP 125 SZ 126 BP, SZ 28, 127 | (D) MDD AMY, ACC | | 6.00 |
| RBM48 RNA binding motif protein 48 | 232661_s_at | (D) DE/2 | 4.00 | 7.89E-07 | | | | | 0.00 |
| SMARCA2 SWI/SNF Related, Matrix Associated, Actin Dependent Regulator of Chromatin, Subfamily A, Member 2 | 206543_at | (D) DE/1 | 4.00 | 2.46E-05 | | SZ 128 129 130 Aging 131 <i>CNV</i> SZ 132 | (I) BP FC ⁹⁹ SZ DLPFC ¹³³ DLPFC BA46 ¹³⁴ (D) SZ PFC ¹²⁹ BP Brain ⁴⁵ | (I) BP Lymphocyte 76 | 8.00 |
| UCHL5 ubiquitin carboxyl- terminal hydrolase L5 | 1570145_at | (D) DE/2 | 4.00 | 9.05E-11 | | | (D) BP Brain ⁴⁵ | (I) Antidepressants Blood ¹³⁵ | 5.00 |
| VPS53 vacuolar protein sorting 53 homolog (S. cerevisiae) | 235882_at | (D) DE/2 | 4.00 | 3.41E-09 | | | (D) BP Brain ⁴⁵ | (I) MDD Fibroblast ₅₃ | 6.00 |
| ZNF302 zinc finger protein 302 | 228392_at | (D) DE/2 | 4.00 | 7.64E-06 | | | (D) MDD AMY, cingulate cortex 86 (I) SZ DLPFC ¹³⁶ | | 4.00 |
| | 1 | op Disco | overy and | Prioritization | Biomarkers(N | lon Bonferron | i Validated, 65 genes) | | |
| <mark>CLTA</mark> clathrin, light chain A | 216296_at | (I) DE/4 | 10.00 | | | | (I) MDD FC ²² (D) BP Brain ⁴⁵ | (D) ALZ Blood ¹⁰⁷ | 6.00 |
| FAM214A family with sequence similarity 214, member A | 236237_at | (I) DE/4 | 10.00 | | | | | | 0.00 |

| HSPD1 heat shock 60kDa protein 1 (chaperonin) | 241716_at | (I) DE/4 | 10.00 | 0.021922 | | SZ ¹³⁷ | (D) Alc FC ⁹² (I) BP parietal cortex ¹³⁸ MDD AMY and cingulate cortex ⁸⁶ PTSD DLPFC ³¹ | (I) Antidepressants Blood ¹³⁵ MNC ¹³⁹ (D) Circadian Abnormalities Blood ⁸⁷ SZ Blood ¹⁴⁰ Mood Disorder NOS Fetal Brain cultured in cortisol treatment 3weeks ¹⁴¹ | 8.00 |
|--|-------------|-------------|-------|----------|------------------------------|--------------------------|--|---|------|
| ZMYND8 zinc finger, MYND-type containing 8 | 214795_at | (I) AP/4 | 10.00 | | | | (I) SZ DLPFC ¹³⁶ | | 4.00 |
| AK2 adenylate kinase 2 | 212172_at | (I) AP/4 | 8.00 | | Clock Distant Output | | (D) BP,SZ PFC (BA46) 142 | | 4.00 |
| CAPZA2 capping protein (actin filament) muscle Z-line, alpha 2 | 201238_s_at | (D) DE/4 | 8.00 | 0.116785 | | | (D) BP ACC ⁵⁶ ; Brain ⁴⁵ SZ Thalamus | (D) BP, MDD,SZ CSF ¹⁴³ PTSD Blood ⁸¹ | 6.00 |
| LRRC8B leucine rich repeat containing 8 family, member B | 212976_at | (D) DE/4 | 8.00 | 0.231881 | | | (D) BP Brain ⁴⁵ (I) BA11 ¹⁵ SZ DPFC (BA 46) ¹³⁴ | (D) Mood State Blood ¹⁴⁴ | 6.00 |
| PPM1B protein phosphatase, Mg2+ | 209296_at | (D) DE/4 | 8.00 | 0.002299 | Clock Immediat e Input | | (D) Alc FC ¹⁴⁵ | | 4.00 |
| ACTR3 ARP3 actin- related protein 3 homolog (yeast) | 213102_at | (D) DE/4 | 7.00 | 0.004524 | | | (I) BP ACC (BA 24) ⁵⁶ ; Brain SZ ACC 146 (D) BP 45 PFC ¹⁴⁷ SZ,SZA DLPFC ⁵⁷ SZA APFC ⁶⁹ | (I) BP Blood ¹⁰⁶ | 6.00 |
| AFF3 AF4/FMR2 family, member 3 | 244696_at | (I) AP/4 | 7.00 | | | SZ 85 | (D) BP Brain ⁴⁵ | (I) BP Blood ¹⁰⁶ | 8.00 |
| MRPS5 mitochondrial ribosomal | 237560_at | (I) AP/4 | 7.00 | | | | (D) Alc HIP ⁹⁷ | (I) PTSD Blood ⁸¹ | 6.00 |

| | 1 | r | | | | | | 1 | |
|--|--------------|-------------|------|----------|---------------------------------|---|--|--|------|
| protein S5 | | | | | | | | | |
| SH2D1A SH2 domain containing 1A | 211211_x_at | (D) DE/4 | 7.00 | | | | (I) BP APFC ⁶⁹ | (I) PTSD Blood ⁸¹ Antidepressants Blood ¹³⁵ | 6.00 |
| AKT3 v-akt murine thymoma viral oncogene homolog 3 | 240568_at | (I) AP/4 | 6.00 | | | SZ 148 149 137 Longevity ¹⁵⁰ | (D) BP Brain ⁴⁵ | | 6.00 |
| ALG13 ALG13, UDP-N- acetylglucosamin yltransferase subunit | 205584_at | (D) DE/4 | 6.00 | 0.046957 | | | (D) BP Brain ⁴⁵ | (I) BP Blood ¹⁰⁶ | 6.00 |
| ARHGAP35 Rho GTPase activating protein 35 | 229397_s_at | (D) DE/4 | 6.00 | 0.0016 | | | | | 0.00 |
| ARID4B AT rich interactive domain 4B (RBP1-like) | 221230_s_at | (D) DE/4 | 6.00 | | | | | | 0.00 |
| ASPH aspartate beta- hydroxylase | 242037_at | (I) DE/4 | 6.00 | 0.01087 | | | | (I) MDD Blood ¹⁵¹ | 2.00 |
| ATXN1 ataxin 1 | 1565804_at | (1) DE/4 | 6.00 | | | ADHD 152 Alc 82 BP 153 154 84 SZ 155 156 126 153 42 | (D) Alc Frontal, motor cortex | (I) Mood State Blood ¹⁴⁴ Pain vertebral disc ³³ Social Isolation leukocytes ¹⁵⁷ (D) Delusions/ Hallucinations Blood ⁸⁹ Chronic Stress BLOOD monocytes ⁹⁶ | 6.00 |
| BRE Brain and reproductive organ-expressed (TNFRSF1A modulator) | 1556817_a_at | (I) AP/4 | 6.00 | | | BP 158 Longevity ¹⁵⁹ | (D) BP Brain ⁴⁵ | | 6.00 |
| CHMP2B charged multivesicular body protein 2B | 202538_s_at | (D) DE/4 | 6.00 | 0.022703 | | | (I) MDD AMY and cingulate cortex ⁸⁶ | | 4.00 |
| CLPB ClpB caseinolytic peptidase B homolog (E. coli) | 1566581_at | (I) AP/4 | 6.00 | 0.025268 | | | | | 0.00 |
| CSNK1A1 casein kinase 1, alpha 1 | 235464_at | (D) DE/4 | 6.00 | | Clock Immedia te Input | | (D) Alc temporal cortex ¹⁶⁰ (Unspecified) MDD thalamus ⁵¹ | (I) Mood stabilizers Human astrocyte- derived cells U-87 MG (I) ¹⁶¹ (D) | 6.00 |

| | | | | | | | | Mood State | |
|---|-------------|-------------|------|----------|------------------------------|------------------------|---|--|------|
| | | | | | | | | Blood 144 | |
| DPCD deleted in primary ciliary dyskinesia homolog (mouse) | 226009_at | (I) DE/4 | 6.00 | | | | (D) BP Brain ⁴⁵ | (I) PTSD Blood ⁸¹ (D) BP Whole Blood | 6.00 |
| ECSIT ECSIT signalling integrator | 218225_at | (I) DE/4 | 6.00 | | | | (D) BP Brain ⁴⁵ | (I) BP Blood ¹⁰⁶ | 6.00 |
| ENTPD1 ectonucleoside triphosphate diphosphohydrol ase 1 | 243111_at | (I) AP/4 | 6.00 | | | | | (I) SZ Blood mononuclear cells 162 | 2.00 |
| EPHB4 EPH receptor B4 | 202894_at | (I) DE/4 | 6.00 | | | | (I) BP DPFC (BA 46) ¹⁶³ SZ DLPFC (BA 46) ¹⁶³ | | 4.00 |
| ETNK1 ethanolamine kinase 1 | 224453_s_at | (D) AP/4 | 6.00 | | | | (D) BP Brain ⁴⁵ (I) MDD AMY and cingulate cortex ⁸⁶ | | 4.00 |
| FANCI Fanconi anemia, complementatio n group I | 213008_at | (I) DE/4 | 6.00 | 0.000897 | | | (D) MDD DLPFC ¹⁶⁴ | (D) Delusions Blood ⁸⁹ | 6.00 |
| FBXL3 F-box and leucine-rich repeat protein 3 | 225132_at | (D) DE/4 | 6.00 | 0.00127 | Clock Immediat e Input | | (D) Alc superior FC ¹⁴⁵ (I) Alz Occipital lobe | (I) BP Blood ¹⁰⁶ (D) SZ Fibroblasts ₆₁ | 6.00 |
| FGFR1OP2 FGFR1 oncogene partner 2 | 223262_s_at | (D) DE/4 | 6.00 | | | | (D) BP Brain ⁴⁵ | (I) BP Blood ¹⁰⁶ | 6.00 |
| GTF3C3 general transcription factor IIIC, polypeptide 3, 102kDa | 1555439_at | (I) AP/4 | 6.00 | | | | (I) SZ PFC ¹⁶⁶ | (D) Circadian abnormalities Blood ⁸⁷ | 6.00 |
| HERC4 HECT and RLD domain containing E3 ubiquitin protein ligase 4 | 225988_at | (D) DE/4 | 6.00 | 0.042192 | | | (D) Alc HIP ⁹⁷ | (D) Delusions Blood ⁸⁹ (I) BP Blood ¹⁰⁶ | 6.00 |
| ITIH5 inter-alpha- trypsin inhibitor heavy chain family, member 5 | 1553243_at | (I) AP/4 | 6.00 | | | BP 84 Alc 167 | (D) BP Brain ⁴⁵ | (I) PTSD Blood ⁸¹ | 8.00 |
| JMJD1C jumonji domain containing 1C | 221763_at | (D) DE/4 | 6.00 | 0.191525 | | Anxiety, BP | | (I) BP Blood ¹⁰⁶ (D) PTSD Blood ⁸¹ | 4.00 |

| | 1 | | | | r | | | | |
|---|--------------|-------------|------|----------|----------------------------|------------------|--|---|------|
| KLHL28 kelch-like family member 28 | 220374_at | (I) AP/4 | 6.00 | | | | (D) Alc HIP ⁹⁷ | (I) BP Blood ¹⁰⁶ | 6.00 |
| LARP4 La ribonucleoprotei n domain family, member 4 | 214155_s_at | (D) DE/4 | 6.00 | 0.014911 | | | | (D) Mood State Blood 144 Circadian abnormalities Blood ⁸⁷ | 2.00 |
| MBNL1 muscleblind-like splicing regulator 1 | 201153_s_at | (D) DE/4 | 6.00 | 0.009769 | | BP 169 | (I) MDD AMY and cingulate cortex ⁸⁶ SZ DLPFC - BA 46 170 | (D) BP Blood ¹⁰⁶ MDD Blood ¹⁵¹ (I) Longevity ¹⁷¹ | 8.00 |
| MEX3C mex-3 RNA binding family member C | 222567_s_at | (D) DE/4 | 6.00 | 0.00603 | | | | (I) Alc Blood ³² PTSD Blood ⁸¹ (D) BP Blood ¹⁰⁶ | 2.00 |
| MIER1 mesoderm induction early response 1, transcriptional regulator | 225475_at | (D) DE/4 | 6.00 | 0.031445 | | | | | 0.00 |
| MR1 major histocompatibilit y complex, class I-related | 207566_at | (I) DE/4 | 6.00 | | | | | | 0.00 |
| NUDT6 nudix (nucleoside diphosphate linked moiety X)- type motif 6 | 220183_s_at | (D) AP/4 | 6.00 | | | | | (I) SZ serum ¹⁷² | 2.00 |
| PHC3 polyhomeotic homolog 3 (Drosophila) | 1552644_a_at | (D) DE/4 | 6.00 | | | | | | 0.00 |
| PIAS1 protein inhibitor of activated STAT, 1 | 1558418_at | (I) DE/4 | 6.00 | | Clock Distant Output | | (D) MS Subcortical, periventric ular, medial subcortical white matter ¹⁷³ | (D) Alc Blood ³² | 6.00 |
| PPHLN1 periphilin 1 | 234459_at | (I) DE/4 | 6.00 | | | | | (D) BP Whole Blood | 2.00 |
| PRDX3 peroxiredoxin 3 | 201619_at | (D) DE/4 | 6.00 | 0.000225 | | | (I) SZA APFC ⁶⁹ SZ PFC ¹⁷⁴ (D) | (D) Chronic Stress Blood monocytes ⁹⁶ | 6.00 |

| | | | | | | | Alc Superior Frontal Gyrus | | |
|---|--------------|-------------|------|----------|----------------------------|--|---|---|------|
| | | | | | | | BP Brain ⁴⁵ | | |
| | | | | | | | MDD Pituitary ¹⁰¹ | | |
| | | | | | | | BP, MDD APFC ⁶⁹ | | |
| | | | | | | | | | |
| PVT1 Pvt1 oncogene (non-protein coding) | 1562153_a_at | (D) DE/4 | 6.00 | 0.000433 | | Psychosis ¹⁷⁶ SZ,BP 177 | | | 2.00 |
| RAB22A RAB22A, member RAS oncogene family | 218360_at | (D) DE/4 | 6.00 | | | | | | 0.00 |
| RDH13 retinol dehydrogenase 13 (all-trans/9- cis) | 225449_at | (I) AP/4 | 6.00 | | | | (D) PTSD DLPFC BA46 | | 4.00 |
| SBNO1 strawberry notch homolog 1 (Drosophila) | 229528_at | (I) DE/4 | 6.00 | | | SZ 178 137 | (I) Alc superior FC 145 | (I) SZ Fibroblasts | 8.00 |
| SLC35B3 solute carrier family 35 (adenosine 3'- phospho 5'- phosphosulfate transporter), member B3 | 231003_at | (D) DE/4 | 6.00 | 3.34E-05 | Clock Distant Output | | (I) BP Brain ⁴⁵ | (D) Delusions Blood ⁸⁹ | 6.00 |
| SNRNP27 small nuclear ribonucleoprotei n 27kDa (U4 | 212440_at | (D) DE/4 | 6.00 | | | | (I) MDD AMY, cingulate cortex | | 4.00 |
| SNX27 sorting nexin family member 27 | 244349_at | (I) AP/4 | 6.00 | | | | (D) Alc HIP ⁹⁷ SZ STG ¹⁷⁹ | (I) Delusions/ Hallucinations Blood ⁸⁹ (D) BP Blood ¹⁰⁶ | 6.00 |
| SSBP2 single-stranded DNA binding protein 2 | 1557814_a_at | (I) AP/4 | 6.00 | | | | (D) BP Brain ⁴⁵ (I) MDD AMY and cingulate cortex ⁸⁶ | (D) Mood State Blood ¹⁴⁴ | 6.00 |
| STRN striatin, calmodulin binding protein | 1569813_at | (I) AP/4 | 6.00 | | | | (D) Alc HIP ⁹⁷ | (I) MDD leukocytes 180 | 6.00 |
| TTC7A tetratricopeptide repeat domain 7A | 224924_at | (I) DE/4 | 6.00 | | | MDD 40 | | | 2.00 |
| UIMC1 ubiquitin interaction motif containing 1 | 233596_at | (I) DE/4 | 6.00 | | | | | | 0.00 |

| USP6NL USP6 N-terminal like | 204761_at | (D) DE/4 | 6.00 | 0.007614 | | | (D) Mood State Blood | 2.00 |
|---|-------------|-------------|------|----------|-----------|--|---|------|
| WAC WW domain containing adaptor with coiled-coil | 230154_at | (D) DE/4 | 6.00 | 8.53E-05 | ASD 83 | (Unspecified) BP ACC (BA 24) ⁵⁶ | | 6.00 |
| WAPAL wings apart-like homolog (Drosophila) | 212267_at | (D) DE/4 | 6.00 | 0.002521 | | | (I) Mood stabilizers SK-N-AS cells 181 | 2.00 |
| ZBP1 Z-DNA binding protein 1 | 208087_s_at | (I) DE/4 | 6.00 | | | (I) Alc HIP ⁹⁷ | (I) SZ LCLs ¹⁸² Blood leukocytes (Stress, PTSD, Post- Traumatic Stress Disorder) 0 | 6.00 |
| ZFAND5 zinc finger, AN1- type domain 5 | 210275_s_at | (D) DE/4 | 6.00 | 0.042362 | | | | 0.00 |
| ZNF117 zinc finger protein 117 | 207605_x_at | (D) DE/4 | 6.00 | | | (I) MDD FC ¹⁸³ | | 4.00 |
| ZNF141 zinc finger protein 141 | 206931_at | (D) DE/4 | 6.00 | | | | | 0.00 |
| ZNF548 zinc finger protein 548 | 1553718_at | (D) DE/4 | 6.00 | 0.000461 | | | | 0.00 |
| ZNF596 zinc finger protein 596 | 240324_at | (I) AP/4 | 6.00 | | | | (D) Mood State Blood ¹⁴⁴ | 2.00 |

Table S4. Top candidate biomarker genes - drugs that modulate these markers in

the opposite direction. FC- frontal cortex. HIP-Hippocampus. AMY- amygdala. VT-ventral tegmentum. <u>Underlined-potential pharmacogenomics marker.</u>

| Gene Symbol/ Gene Name | Discov ery (Chang e) Metho d/ Score | Prioritizat ion Total CFG Score For Suicide | Validation ANOVA p-value | Modulated by Omega-3 | Modulated by Lithium | Modulated by Clozapine | Other Drugs |
|--|---|---|--------------------------------|--|---|--------------------------------|---|
| | | 0 | ut of Validated | Biomarkers (Bonf | erroni) (49 genes, | , 50 probesets) | |
| BCL2 B-cell CLL | (D) DE/2 | 9.00 | 3.95E-06 | | (I) FC 184 (I) cerebellar granule cells 185 (I) Human Blood ³⁴ (I) Astrocyte 186 (I) HIP ¹⁸⁷ (I) Dentate gyrus, HIP ¹⁸⁸ | (I) Hip ¹⁸⁹ | oblimersen,rasagiline,(-)- gossypol,navitoclax,gemcitabine/pacl itaxel,bortezomib/paclitaxel,ABT- 199,paclitaxel/trastuzumab,paclitaxel /pertuzumab/trastuzumab,lapatinib/ paclitaxel,doxorubicin/paclitaxel,epir ubicin/paclitaxel,paclitaxel/topoteca n,paclitaxel |
| GSK3B glycogen synthase kinase 3 beta | (D) DE/1 | 9.00 | 2.26E-05 | | (I) FC ¹⁹⁰ | | enzastaurin |
| CAT catalase | (D) DE/2 | 8.00 | 5.04E-07 | | BP (I) Plasma ⁵⁹ | | fomepizole |
| JUN jun proto- oncogene | (I) DE/2 DE/1 | 8.00 | 1.14E-11 1.72E-14 | | (D) leukocytes ⁶⁸ | (D) FC ¹⁹¹ | |
| MOB3B MOB kinase activator 3B | (D) DE/1 | 7.00 | 4.69E-06 | (I) PFC (females) ¹⁹² | | | |
| NDRG1 N-myc downstream regulated 1 | (I) DE/1 | 7.00 | 3.07E-07 | (D) Blood ¹⁹² | | | |
| SPON1 spondin 1, extracellular matrix protein | (D) DE/1 | 7.00 | 1.02E-05 | | | (I) VT ¹⁹³ | |
| FOXP1 forkhead box P1 | (I) DE/4 | 6.00 | 7.03E-07 | (D) Blood ¹⁹² | | | |
| HAVCR2 hepatitis A virus cellular receptor 2 | (I) DE/4 | 6.00 | 1.69E-12 | | | (D) PFC ¹⁹⁴ | |
| GJA1 gap junction protein, alpha 1, 43kDa | (I) DE/1 | 5.00 | 1.96E-06 | (D) HIP (females) ¹⁹² | | (D) VT ¹⁹³ | |
| CD84 CD84 molecule | (D) DE/2 | 4.00 | 1.74E-05 | | | (I) Blood ¹⁹³ | |
| DCAF5 DDB1 and | (D) DE/2 | 4.00 | 1.37E-05 | | | (I) VT | |

| | | | | | | 193 | | | | | |
|--|--|-------|----------|--|--|---------------------------------|-------------|--|--|--|--|
| CUL4 associated | | | | | | 195 | | | | | |
| GANC glucosidase, alpha; neutral C | (D) DE/2 | 4.00 | 1.40E-08 | | | | miglitol | | | | |
| IL1R1 interleukin 1 receptor, type I | (I) AP/1 | 4.00 | 5.47E-08 | | | | anakinra | | | | |
| INPP4A inositol polyphosphate -4- phosphatase, type I, 107kDa | (D) DE/1 | 4 | 1.79E-05 | | | (I) VT ¹⁹³ | | | | | |
| JRK Jrk homolog (mouse) | (D) AP/2 | 4.00 | 4.25E-06 | (I) Brain ¹⁹⁵ | | | | | | | |
| PDXDC1 pyridoxal- dependent decarboxylase domain containing 1 | (I) DE/2 | 4.00 | 1.03E-05 | | | (D) VT ¹⁹³ | | | | | |
| SMARCA2 SWI/SNF Related, Matrix Associated, Actin Dependent Regulator of Chromatin, Subfamily A, Member 2 | (D) DE/1 | 4.00 | 2.46E-05 | (I) HIP (males) ¹⁹² | | | | | | | |
| | Out of Top Discovery and Prioritization Biomarkers(Non Bonferroni Validated, 65 genes) | | | | | | | | | | |
| CLTA clathrin, light chain A | (I) DE/4 | 10.00 | | | | (D) FC ¹⁹¹ | | | | | |
| PPM1B protein phosphatase, Mg2+ | (D) DE/4 | 8.00 | 0.002299 | | | (I) VT ¹⁹³ | | | | | |
| AFF3 AF4/FMR2 family, member 3 | (I) AP/4; (I) DE/1 | 7.00 | | (D) Blood ¹⁹² | | | | | | | |
| WAC WW domain containing adaptor with coiled-coil | (D) DE/4 | 7.00 | 8.53E-05 | | | (I) VT ¹⁹³ | | | | | |
| AKT3 v-akt murine thymoma viral oncogene homolog 3 | (I) AP/4 | 6.00 | | | | | enzastaurin | | | | |
| ARID4B AT rich interactive domain 4B (RBP1-like) | (D) DE/4 | 6.00 | | (I) HIP (males) ¹⁹² | | | | | | | |
| ATXN1 ataxin 1 | (I) DE/4 | 6.00 | | (D) Blood ¹⁹² | | | | | | | |
| BRE Brain and reproductive organ- expressed (TNFRSF1A | (I) AP/4 | 6.00 | | | | (D) VT ¹⁹³ | | | | | |

| modulator) | | | | | | | |
|--|-------------|------|----------|--|---|----------------------------------|----------------------|
| CSNK1A1 casein kinase 1, alpha 1 | (D) DE/4 | 6.00 | | (I) Blood ¹⁹² | | | |
| ENTPD1 ecton ucleoside triphosphate diphosphohydr olase 1 | (I) AP/4 | 6.00 | | (D) Blood ¹⁹² | | (D) PFC ¹⁹⁴ | |
| EPHB4 EPH receptor B4 | (I) DE/4 | 6.00 | | | | | tesevatinib |
| ETNK1 ethanolamine kinase 1 | (D) AP/4 | 6.00 | | (I) PFC (males) ¹⁹² | | | |
| ITIH5 inter-alpha- trypsin inhibitor heavy chain family, member 5 | (I) AP/4 | 6.00 | | (D) Blood ¹⁹² | | (D) PFC ¹⁹⁴ | |
| LARP4 La ribonucleoprot ein domain family, member 4 | (D) DE/4 | 6.00 | 0.014911 | | | (I) VT ¹⁹³ | |
| MBNL1 muscleblind- like splicing regulator 1 | (D) DE/4 | 6.00 | 0.009769 | (I) HIP (males) ¹⁹² | | (I) Blood ¹⁹³ | |
| MR1 major histocompatibi lity complex, class I-related | (I) DE/4 | 6.00 | | | | | antiLymphocyte serum |
| PRDX3 peroxiredoxin 3 | (D) DE/4 | 6.00 | 0.000225 | (I) Blood ¹⁹² | | | |
| RAB22A RAB22A, member RAS oncogene family | (D) DE/4 | 6.00 | | | | (I) Blood ¹⁹³ | |
| SNX27 sorting nexin family member 27 | (I) AP/4 | 6.00 | | | | (D) AMY ¹⁹³ | |
| SSBP2 single- stranded DNA binding protein 2 | (I) AP/4 | 6.00 | | (D) Blood ¹⁹² | | (D) VT ¹⁹³ | |
| WAPAL wings apart- like homolog (Drosophila) | (D) DE/4 | 6.00 | 0.002521 | | (I) SK-N-AS cells (ATCC derived from a human neuroblastoma cell ¹⁸¹ | (I) VT ¹⁹³ | |

 Table S5 Biological Pathways and Diseases.
 Suicidal ideation markers non-validated for behavior in completers (n=886) vs.

 suicidal ideation markers that were stepwise validated for behavior in completers (n=595).

| Α. | | Ingenuity Pathways | 5 | | KEGG Pat | hways | | GeneGO Pathways | | |
|----------------------------------|---|--|-----------------|------------------|---|----------------|-----------------------------------|--|--------|---------------|
| | # | Top Canonical Pathways | P- Val ue | Ratio | Pathway Name | Ra tio | Enric hmen t p- value | Process Networks | Ratio | p- value |
| | 1 | PI3K Signaling in B Lymphocytes | 6.05 E-13 | 20.3 % 27/133 | Amoebiasis | 17/ 36 8 | 2.95E- 05 | Immune response_BCR pathway | 30/137 | 5.123E- 09 |
| Non- Validated Stepwise in | 2 | B Cell Receptor Signaling | 3.08 E-11 | 16.2 % 29/179 | Glioma | 15/ 30 0 | 3.69E- 05 | Cytoskeleton_Regulati on of cytoskeleton rearrangement | 33/183 | 1.357E- 07 |
| (n=882 genes) | 3 | Role of NFAT in Cardiac Hypertrophy | 3.91 E-10 | 15.1 % 28/186 | Pancreatic cancer | 15/ 36 6 | 0.000 3 | Signal transduction_WNT signaling | 31/177 | 6.413E- 07 |
| for IDEATION only | 4 | Role of Macrophages, Fibroblasts and Endothelial Cells in Rheumatoid Arthritis | 1.05 E-09 | 11.9 % 36/302 | Focal adhesion | 24/ 77 1 | 0.000 318 | Signal transduction_Neurope ptide signaling pathways | 28/155 | 1.189E- 06 |
| | 5 | Amyotrophic Lateral Sclerosis Signaling | 2.78 E-09 | 18.7 % 20/107 | Phosphatidylinosit ol signaling system | 12/ 25 1 | 0.000 324 | Cell cycle_G1-S Growth factor regulation | 32/195 | 1.875E- 06 |
| | # | Top Canonical Pathways | P- Val ue | Ratio | Pathway Name | Ra tio | Enric hmen t p- value | Process Networks | Ratio | p- value |
| | 1 | Glucocorticoid Receptor Signaling | 2.86 E-06 | 7.8 % 22/281 | Morphine addiction | 9/2 49 | 0.000 6493 | Reproduction_Gonado tropin regulation | 24/199 | 9.843E- 07 |
| Validation Stepwise in | 2 | IGF-1 Signaling | 7.18 E-06 | 12.1 % 12/99 | Colorectal cancer | 9/2 87 | 0.001 6932 | Reproduction_GnRH signaling pathway | 20/166 | 8.256E- 06 |
| Completers (n=589 genes) | 3 | Renin-Angiotensin Signaling | 8.72 E-06 | 11.0 % 13/118 | Cocaine addiction | 6/1 55 | 0.003 7291 | Reproduction_Progest erone signaling | 23/214 | 1.194E- 05 |
| Biomarkers for | 4 | Protein Kinase A Signaling | 1.02 E-05 | 6.5 % 26/398 | Insulin signaling pathway | 12/ 53 5 | 0.004 7284 | Signal transduction_NOTCH signaling | 24/236 | 1.962E- 05 |
| IDEATION and BEHAVIOR | 5 | Melanocyte Development and Pigmentation Signaling | 1.02 E-05 | 12.8 % 11/86 | Inositol phosphate metabolism | 6/1 93 | 0.010 1986 | Signal transduction_Androge n receptor signaling cross-talk | 12/72 | 2.241E- 05 |

| Β. | | Ingenuit | ty | | GeneGO | | | |
|--|---|-------------------------------------|----------------------|-------------|---|-----------|----------|--|
| | | Diseases and Disorders | P-Value | # Molecules | Diseases | pValue | Ratio | |
| Non- Validated | 1 | Cancer | 1.33E-04E - 2.55E-23 | 440 | Mental Disorders | 1.44E-25 | 166/1610 | |
| Stepwise in Completers (n=886 genes) Biomarkers for IDEATION only | 2 | Organismal Injury and Abnormalities | 1.33E-04E - 2.55E-23 | 440 | Psychiatry and Psychology | 3.23E-24 | 182/1904 | |
| | 3 | Gastrointestinal Disease | 9.09E-05 - 2.12E-18 | 333 | Central Nervous System Diseases | 1.43E-22 | 247/3060 | |
| | 4 | Reproductive System Disease | 2.80E-05 - 7.72E-18 | 244 | Neurodegenerative Diseases | 1.98E-22 | 189/2087 | |
| | 5 | Infectious Diseases | 3.72E-05 - 6.69E-15 | 109 | Depressive Disorder, Major | 1.31E-21 | 80/543 | |
| | | Diseases and Disorders | P-Value | # Molecules | Diseases | pValue | Ratio | |
| Validation | 1 | Cancer | 6.51E-04 - 6.47E-17 | 489 | Breast Neoplasms | 2.361E-15 | 359/8894 | |
| Stepwise in Completers | 2 | Organismal Injury and Abnormalities | 6.92E-04 - 6.47E-17 | 494 | Breast Diseases | 2.407E-15 | 359/8895 | |
| genes) | 3 | Gastrointestinal Disease | 6.27E-04 - 6.91E-10 | 354 | Psychiatry and Psychology | 3.842E-14 | 115/1904 | |
| Biomarkers | 4 | Reproductive System Disease | 2.60E-04 - 1.51E-08 | 237 | Pathological Conditions, Signs and Symptoms | 1.247E-13 | 208/4433 | |
| for IDEATION and BEHAVIOR | 5 | Infectious Diseases | 6.92E-04 - 9.45E-8 | 104 | Mental Disorders | 1.833E-13 | 101/1610 | |

Table S6 Drugs that have similar and opposite gene expression profile to our suicide biomarkers.

Connectivity Map (cmap) (Broad/MIT)¹⁹⁶ results. Cmap comprises a collection of genome-wide transcriptional expression data from cultured human cells treated with bioactive small molecules and simple pattern-matching algorithms that together enable the discovery of functional connections between drugs, genes and diseases through the transitory feature of common gene-expression changes ¹⁹⁶, ¹⁹⁷. Score of 1 means maximum similarity, score of -1 means maximum opposite effect. Red (most)/pink (other commonly used medications) that mimic effects of suicidality, i.e. may induce suicidality. **Green (most)/light green other commonly used medications) that do the opposite to suicide, i.e. may be tested for or used to generate leads to treat/prevent suicidality.** A. Validated Bonferroni biomarkers. B. Top biomarkers from validation, as well as discovery and prioritization (Table S2). C. Validated nominally significant biomarkers.

| rank | batch | cmap name | dose | cell | score |
|------|-------|--------------|-------|------|--------|
| 1 | 683 | lycorine | 12 µM | PC3 | 1 |
| 3 | 645 | lycorine | 12 µM | HL60 | 0.947 |
| 6 | 726 | digoxigenin | 10 µM | MCF7 | 0.924 |
| 7 | 715 | digoxin | 5 µM | PC3 | 0.923 |
| 10 | 767 | fluphenazine | 10 µM | MCF7 | 0.914 |
| 12 | 506 | thioridazine | 10 µM | MCF7 | 0.9 |
| 14 | 504 | felodipine | 10 µM | MCF7 | 0.889 |
| 17 | 636 | tamoxifen | 7 μΜ | MCF7 | 0.86 |
| 22 | 502 | felodipine | 10 µM | MCF7 | 0.854 |
| | | | | | |
| 6081 | 622 | mifepristone | 9 µM | HL60 | -0.797 |
| 6097 | 665 | lansoprazole | 11 µM | HL60 | -0.888 |
| 6098 | 658 | nafcillin | 9 µM | HL60 | -0.895 |
| 6100 | 665 | betulin | 9 µM | HL60 | -1 |

A. Validated Bonferroni Significant Biomarkers (49 Genes)

B. Top Biomarkers (114 Genes)

| rank | batch | cmap name | dose | cell | score |
|------|-------|-----------------------------|-------|------|--------|
| 1 | 631 | 7-aminocephalosporanic acid | 15 µM | HL60 | 1 |
| 7 | 647 | methotrexate | 9 µM | MCF7 | 0.902 |
| 9 | 661 | ribavirin | 16 µM | HL60 | 0.894 |
| 10 | 664 | fluticasone | 8 µM | HL60 | 0.888 |
| 15 | 1074 | pioglitazone | 10 µM | MCF7 | 0.859 |
| 20 | 659 | ganciclovir | 16 µM | HL60 | 0.834 |
| 21 | 645 | flunisolide | 9 µM | HL60 | 0.834 |
| 35 | 695 | simvastatin | 10 µM | MCF7 | 0.805 |
| | | | | | |
| 6049 | 650 | troglitazone | 10 µM | HL60 | -0.8 |
| 6059 | 635 | rifampicin | 5 µM | HL60 | -0.812 |
| 6061 | 732 | ondansetron | 12 µM | PC3 | -0.813 |
| 6062 | 636 | tetracycline | 8 µM | MCF7 | -0.817 |

| 6063 | 665 | lansoprazole | 11 µM | HL60 | -0.821 |
|------|-----|----------------------|--------|------|--------|
| 6064 | 707 | dicloxacillin | 8 µM | MCF7 | -0.824 |
| 6067 | 630 | buspirone | 9 µM | HL60 | -0.83 |
| 6072 | 650 | estradiol | 100 nM | HL60 | -0.839 |
| 6080 | 650 | acetylsalicylic acid | 100 µM | HL60 | -0.868 |
| 6083 | 750 | LY-294002 | 10 µM | HL60 | -0.881 |
| 6092 | 694 | minoxidil | 19 µM | MCF7 | -0.92 |
| 6097 | 650 | LY-294002 | 10 µM | HL60 | -0.96 |
| 6100 | 694 | zalcitabine | 19 µM | MCF7 | -1 |

C. Validated Nominally Significant Biomarkers (396 genes)

| rank | batch | cmap name | dose | cell | score |
|------|-------|------------------|--------|------|--------|
| 1 | 665 | pivampicillin | 9 µM | HL60 | 1 |
| 6 | 648 | metoprolol | 6 µM | HL60 | 0.902 |
| 18 | 630 | cefalexin | 11 µM | HL60 | 0.852 |
| 20 | 749 | dexpropranolol | 14 µM | HL60 | 0.843 |
| 23 | 750 | valproic acid | 200 µM | HL60 | 0.831 |
| | | | | | |
| 6079 | 634 | fluoxetine | 12 µM | HL60 | -0.772 |
| 6082 | 602 | haloperidol | 10 µM | HL60 | -0.791 |
| 6085 | 629 | diphenhydramine | 14 µM | HL60 | -0.799 |
| 6091 | 630 | prochlorperazine | 7 μΜ | HL60 | -0.832 |
| 6092 | 629 | metformin | 24 µM | HL60 | -0.837 |
| 6095 | 665 | lansoprazole | 11 µM | HL60 | -0.873 |
| 6098 | 631 | corticosterone | 12 µM | HL60 | -0.919 |
| 6100 | 649 | atractyloside | 5 µM | HL60 | -1 |

Literature Cited

- 1. Vargas JL, Sainz M, Roldan C, Alvarez I, de la Torre A. Analysis of electrical thresholds and maximum comfortable levels in cochlear implant patients. *Auris, nasus, larynx* 2013; **40**(3): 260-265.
- 2. Niculescu AB, Levey DF, Phalen PL, Le-Niculescu H, Dainton HD, Jain N *et al.* Understanding and predicting suicidality using a combined genomic and clinical risk assessment approach. *Mol Psychiatry* 2015; **20**(11): 1266-1285.
- 3. Butler AW, Breen G, Tozzi F, Craddock N, Gill M, Korszun A *et al.* A genomewide linkage study on suicidality in major depressive disorder confirms evidence for linkage to 2p12. *Am J Med Genet B Neuropsychiatr Genet* 2010; **153B**(8): 1465-1473.
- Smalheiser NR, Lugli G, Rizavi HS, Torvik VI, Turecki G, Dwivedi Y. MicroRNA expression is down-regulated and reorganized in prefrontal cortex of depressed suicide subjects. *PLoS One* 2012; 7(3): e33201.
- 5. Niculescu AB, Levey DF, Phalen PL, Le-Niculescu H, Dainton HD, Jain N *et al.* Understanding and predicting suicidality using a combined genomic and clinical risk assessment approach. *Molecular psychiatry* 2015.
- 6. Jimenez E, Arias B, Mitjans M, Goikolea JM, Roda E, Saiz PA *et al.* Genetic variability at IMPA2, INPP1 and GSK3beta increases the risk of suicidal behavior in bipolar patients. *Eur Neuropsychopharmacol* 2013; **23**(11): 1452-1462.
- 7. Ren X, Rizavi HS, Khan MA, Dwivedi Y, Pandey GN. Altered Wnt signalling in the teenage suicide brain: focus on glycogen synthase kinase-3beta and beta-catenin. *The international journal of neuropsychopharmacology / official scientific journal of the Collegium Internationale Neuropsychopharmacologicum* 2013; **16**(5): 945-955.
- 8. Pandey GN, Dwivedi Y, Rizavi HS, Teppen T, Gaszner GL, Roberts RC *et al.* GSK-3beta gene expression in human postmortem brain: regional distribution, effects of age and suicide. *Neurochem Res* 2009; **34**(2): 274-285.
- 9. Fiori LM, Bureau A, Labbe A, Croteau J, Noel S, Merette C *et al.* Global gene expression profiling of the polyamine system in suicide completers. *Int J Neuropsychopharmacol* 2011; **14**(5): 595-605.
- 10. Fiori LM, Zouk H, Himmelman C, Turecki G. X chromosome and suicide. *Molecular psychiatry* 2011; **16**(2): 216-226.

- 11. Klempan TA, Sequeira A, Canetti L, Lalovic A, Ernst C, ffrench-Mullen J *et al.* Altered expression of genes involved in ATP biosynthesis and GABAergic neurotransmission in the ventral prefrontal cortex of suicides with and without major depression. *Molecular psychiatry* 2009; **14**(2): 175-189.
- 12. Labonte B, Suderman M, Maussion G, Lopez JP, Navarro-Sanchez L, Yerko V *et al.* Genome-wide methylation changes in the brains of suicide completers. *Am J Psychiatry* 2013; **170**(5): 511-520.
- 13. Dick DM, Meyers J, Aliev F, Nurnberger J, Jr., Kramer J, Kuperman S *et al.* Evidence for genes on chromosome 2 contributing to alcohol dependence with conduct disorder and suicide attempts. *American journal of medical genetics Part B, Neuropsychiatric genetics : the official publication of the International Society of Psychiatric Genetics* 2010; **153B**(6): 1179-1188.
- 14. Sequeira A, Morgan L, Walsh DM, Cartagena PM, Choudary P, Li J *et al.* Gene expression changes in the prefrontal cortex, anterior cingulate cortex and nucleus accumbens of mood disorders subjects that committed suicide. *PloS one* 2012; **7**(4): e35367.
- 15. Sequeira A, Gwadry FG, Ffrench-Mullen JM, Canetti L, Gingras Y, Casero RA, Jr. *et al.* Implication of SSAT by gene expression and genetic variation in suicide and major depression. *Arch Gen Psychiatry* 2006; **63**(1): 35-48.
- 16. Kim S, Choi KH, Baykiz AF, Gershenfeld HK. Suicide candidate genes associated with bipolar disorder and schizophrenia: an exploratory gene expression profiling analysis of post-mortem prefrontal cortex. *BMC Genomics* 2007; **8**: 413.
- 17. Ernst C, Nagy C, Kim S, Yang JP, Deng X, Hellstrom IC *et al.* Dysfunction of astrocyte connexins 30 and 43 in dorsal lateral prefrontal cortex of suicide completers. *Biol Psychiatry* 2011; **70**(4): 312-319.
- 18. Monsalve EM, Garcia-Gutierrez MS, Navarrete F, Giner S, Laborda J, Manzanares J. Abnormal expression pattern of Notch receptors, ligands, and downstream effectors in the dorsolateral prefrontal cortex and amygdala of suicidal victims. *Mol Neurobiol* 2014; **49**(2): 957-965.
- 19. Hoyo-Becerra C, Huebener A, Trippler M, Lutterbeck M, Liu ZJ, Truebner K *et al.* Concomitant interferon alpha stimulation and TLR3 activation induces neuronal expression of depression-related genes that are elevated in the brain of suicidal persons. *PloS one* 2013; **8**(12): e83149.
- 20. Hesselbrock V, Dick D, Hesselbrock M, Foroud T, Schuckit M, Edenberg H *et al.* The search for genetic risk factors associated with suicidal behavior. *Alcohol Clin Exp Res* 2004; **28**(5 Suppl): 70S-76S.

- 21. Menke A, Domschke K, Czamara D, Klengel T, Hennings J, Lucae S *et al.* Genome-wide association study of antidepressant treatment-emergent suicidal ideation. *Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology* 2012; **37**(3): 797-807.
- 22. Zhurov V, Stead JD, Merali Z, Palkovits M, Faludi G, Schild-Poulter C *et al.* Molecular pathway reconstruction and analysis of disturbed gene expression in depressed individuals who died by suicide. *PLoS One* 2012; **7**(10): e47581.
- Kekesi KA, Juhasz G, Simor A, Gulyassy P, Szego EM, Hunyadi-Gulyas E *et al.* Altered functional protein networks in the prefrontal cortex and amygdala of victims of suicide. *PLoS One* 2012; 7(12): e50532.
- 24. Coon H, Darlington T, Pimentel R, Smith KR, Huff CD, Hu H *et al.* Genetic risk factors in two Utah pedigrees at high risk for suicide. *Translational psychiatry* 2013; **3**: e325.
- 25. Sipila T, Kananen L, Greco D, Donner J, Silander K, Terwilliger JD *et al.* An association analysis of circadian genes in anxiety disorders. *Biological psychiatry* 2010; **67**(12): 1163-1170.
- 26. Machado-Vieira R, Pivovarova NB, Stanika RI, Yuan P, Wang Y, Zhou R *et al.* The Bcl-2 gene polymorphism rs956572AA increases inositol 1,4,5-trisphosphate receptor-mediated endoplasmic reticulum calcium release in subjects with bipolar disorder. *Biological psychiatry* 2011; **69**(4): 344-352.
- 27. Soeiro-de-Souza MG, Salvadore G, Moreno RA, Otaduy MC, Chaim KT, Gattaz WF *et al.* Bcl-2 rs956572 polymorphism is associated with increased anterior cingulate cortical glutamate in euthymic bipolar I disorder. *Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology* 2013; **38**(3): 468-475.
- 28. Yu H, Bi W, Liu C, Zhao Y, Zhang D, Yue W. A hypothesis-driven pathway analysis reveals myelinrelated pathways that contribute to the risk of schizophrenia and bipolar disorder. *Progress in neuro-psychopharmacology & biological psychiatry* 2014; **51:** 140-145.
- 29. Erraji-Benchekroun L, Underwood MD, Arango V, Galfalvy H, Pavlidis P, Smyrniotopoulos P *et al.* Molecular aging in human prefrontal cortex is selective and continuous throughout adult life. *Biological psychiatry* 2005; **57**(5): 549-558.
- 30. Kim HW, Rapoport SI, Rao JS. Altered expression of apoptotic factors and synaptic markers in postmortem brain from bipolar disorder patients. *Neurobiology of disease* 2010; **37**(3): 596-603.

- 31. Su YA, Wu J, Zhang L, Zhang Q, Su DM, He P *et al.* Dysregulated mitochondrial genes and networks with drug targets in postmortem brain of patients with posttraumatic stress disorder (PTSD) revealed by human mitochondria-focused cDNA microarrays. *Int J Biol Sci* 2008; **4**(4): 223-235.
- 32. Beech RD, Qu J, Leffert JJ, Lin A, Hong KA, Hansen J *et al.* Altered expression of cytokine signaling pathway genes in peripheral blood cells of alcohol dependent subjects: preliminary findings. *Alcoholism, clinical and experimental research* 2012; **36**(9): 1487-1496.
- Gruber HE, Hoelscher GL, Ingram JA, Hanley EN, Jr. Genome-wide analysis of pain-, nerve- and neurotrophin -related gene expression in the degenerating human annulus. *Molecular pain* 2012; 8: 63.
- 34. Lowthert L, Leffert J, Lin A, Umlauf S, Maloney K, Muralidharan A *et al.* Increased ratio of antiapoptotic to pro-apoptotic Bcl2 gene-family members in lithium-responders one month after treatment initiation. *Biology of mood & anxiety disorders* 2012; **2**(1): 15.
- 35. Szczepankiewicz A, Skibinska M, Hauser J, Slopien A, Leszczynska-Rodziewicz A, Kapelski P *et al.* Association analysis of the GSK-3beta T-50C gene polymorphism with schizophrenia and bipolar disorder. *Neuropsychobiology* 2006; **53**(1): 51-56.
- 36. Lachman HM, Pedrosa E, Petruolo OA, Cockerham M, Papolos A, Novak T *et al.* Increase in GSK3beta gene copy number variation in bipolar disorder. *American journal of medical genetics Part B, Neuropsychiatric genetics : the official publication of the International Society of Psychiatric Genetics* 2007; **144B**(3): 259-265.
- 37. Jimenez E, Arias B, Mitjans M, Goikolea JM, Roda E, Ruiz V *et al.* Association between GSK3beta gene and increased impulsivity in bipolar disorder. *Eur Neuropsychopharmacol* 2014; **24**(4): 510-518.
- 38. Kripke DF, Nievergelt CM, Tranah GJ, Murray SS, Rex KM, Grizas AP *et al.* FMR1, circadian genes and depression: suggestive associations or false discovery? *J Circadian Rhythms* 2013; **11**(1): 3.
- 39. McCarthy MJ, Wei H, Marnoy Z, Darvish RM, McPhie DL, Cohen BM *et al.* Genetic and clinical factors predict lithium's effects on PER2 gene expression rhythms in cells from bipolar disorder patients. *Translational psychiatry* 2013; **3**: e318.
- 40. Lewis CM, Ng MY, Butler AW, Cohen-Woods S, Uher R, Pirlo K *et al.* Genome-wide association study of major recurrent depression in the U.K. population. *Am J Psychiatry* 2010; **167**(8): 949-957.

- 41. Inkster B, Nichols TE, Saemann PG, Auer DP, Holsboer F, Muglia P *et al.* Association of GSK3beta polymorphisms with brain structural changes in major depressive disorder. *Archives of general psychiatry* 2009; **66**(7): 721-728.
- 42. Mozhui K, Wang X, Chen J, Mulligan MK, Li Z, Ingles J *et al.* Genetic regulation of Nrxn1 [corrected] expression: an integrative cross-species analysis of schizophrenia candidate genes. *Translational psychiatry* 2011; **1**: e25.
- 43. Blasi G, Napolitano F, Ursini G, Di Giorgio A, Caforio G, Taurisano P *et al.* Association of GSK-3beta genetic variation with GSK-3beta expression, prefrontal cortical thickness, prefrontal physiology, and schizophrenia. *The American journal of psychiatry* 2013; **170**(8): 868-876.
- 44. Gonzalez R, Bernardo C, Cruz D, Walss-Bass C, Thompson PM. The relationships between clinical characteristics, alcohol and psychotropic exposure, and circadian gene expression in human postmortem samples of affective disorder and control subjects. *Psychiatry Res* 2014; **218**(3): 359-362.
- 45. Chen H, Wang N, Zhao X, Ross CA, O'Shea KS, McInnis MG. Gene expression alterations in bipolar disorder postmortem brains. *Bipolar disorders* 2013; **15**(2): 177-187.
- 46. Vawter MP, Tomita H, Meng F, Bolstad B, Li J, Evans S *et al.* Mitochondrial-related gene expression changes are sensitive to agonal-pH state: implications for brain disorders. *Molecular psychiatry* 2006; **11**(7): 615, 663-679.
- 47. Nakatani N, Hattori E, Ohnishi T, Dean B, Iwayama Y, Matsumoto I *et al.* Genome-wide expression analysis detects eight genes with robust alterations specific to bipolar I disorder: relevance to neuronal network perturbation. *Human molecular genetics* 2006; **15**(12): 1949-1962.
- 48. Torrey EF, Barci BM, Webster MJ, Bartko JJ, Meador-Woodruff JH, Knable MB. Neurochemical markers for schizophrenia, bipolar disorder, and major depression in postmortem brains. *Biol Psychiatry* 2005; **57**(3): 252-260.
- 49. Nadri C, Dean B, Scarr E, Agam G. GSK-3 parameters in postmortem frontal cortex and hippocampus of schizophrenic patients. *Schizophrenia research* 2004; **71**(2-3): 377-382.
- 50. Kozlovsky N, Shanon-Weickert C, Tomaskovic-Crook E, Kleinman JE, Belmaker RH, Agam G. Reduced GSK-3beta mRNA levels in postmortem dorsolateral prefrontal cortex of schizophrenic patients. *J Neural Transm* 2004; **111**(12): 1583-1592.

- 51. Chu TT, Liu Y, Kemether E. Thalamic transcriptome screening in three psychiatric states. *Journal* of human genetics 2009; **54**(11): 665-675.
- 52. Polesskaya OO, Sokolov BP. Differential expression of the "C" and "T" alleles of the 5-HT2A receptor gene in the temporal cortex of normal individuals and schizophrenics. *Journal of neuroscience research* 2002; **67**(6): 812-822.
- 53. Garbett KA, Vereczkei A, Kalman S, Wang L, Korade Z, Shelton RC *et al.* Fibroblasts from patients with major depressive disorder show distinct transcriptional response to metabolic stressors. *Translational psychiatry* 2015; **5**: e523.
- 54. Pandey GN, Ren X, Rizavi HS, Dwivedi Y. Glycogen synthase kinase-3beta in the platelets of patients with mood disorders: effect of treatment. *Journal of psychiatric research* 2010; **44**(3): 143-148.
- 55. Marksteiner J, Humpel C. Glycogen-synthase kinase-3beta is decreased in peripheral blood mononuclear cells of patients with mild cognitive impairment. *Exp Gerontol* 2009; **44**(6-7): 370-371.
- 56. Zhao Z, Xu J, Chen J, Kim S, Reimers M, Bacanu SA *et al.* Transcriptome sequencing and genomewide association analyses reveal lysosomal function and actin cytoskeleton remodeling in schizophrenia and bipolar disorder. *Molecular psychiatry* 2015; **20**(5): 563-572.
- 57. Arion D, Corradi JP, Tang S, Datta D, Boothe F, He A *et al.* Distinctive transcriptome alterations of prefrontal pyramidal neurons in schizophrenia and schizoaffective disorder. *Molecular psychiatry* 2015.
- 58. Deo AJ, Huang YY, Hodgkinson CA, Xin Y, Oquendo MA, Dwork AJ *et al*. A large-scale candidate gene analysis of mood disorders: evidence of neurotrophic tyrosine kinase receptor and opioid receptor signaling dysfunction. *Psychiatr Genet* 2013; **23**(2): 47-55.
- 59. de Sousa RT, Zarate CA, Jr., Zanetti MV, Costa AC, Talib LL, Gattaz WF *et al.* Oxidative stress in early stage Bipolar Disorder and the association with response to lithium. *Journal of psychiatric research* 2014; **50:** 36-41.
- 60. Raffa M, Fendri C, Ben Othmen L, Slama H, Amri M, Kerkeni A *et al.* The reduction of superoxide dismutase activity is associated with the severity of neurological soft signs in patients with schizophrenia. *Progress in neuro-psychopharmacology & biological psychiatry* 2012; **39**(1): 52-56.

- 61. Brennand KJ, Simone A, Jou J, Gelboin-Burkhart C, Tran N, Sangar S *et al.* Modelling schizophrenia using human induced pluripotent stem cells. *Nature* 2011; **473**(7346): 221-225.
- 62. Aston C, Jiang L, Sokolov BP. Transcriptional profiling reveals evidence for signaling and oligodendroglial abnormalities in the temporal cortex from patients with major depressive disorder. *Mol Psychiatry* 2005; **10**(3): 309-322.
- 63. Sibille E, Wang Y, Joeyen-Waldorf J, Gaiteri C, Surget A, Oh S *et al.* A molecular signature of depression in the amygdala. *The American journal of psychiatry* 2009; **166**(9): 1011-1024.
- 64. Todorova VK, Elbein AD, Kyosseva SV. Increased expression of c-Jun transcription factor in cerebellar vermis of patients with schizophrenia. *Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology* 2003; **28**(8): 1506-1514.
- 65. Aston C, Jiang L, Sokolov BP. Microarray analysis of postmortem temporal cortex from patients with schizophrenia. *Journal of neuroscience research* 2004; **77**(6): 858-866.
- 66. Kyosseva SV. Differential expression of mitogen-activated protein kinases and immediate early genes fos and jun in thalamus in schizophrenia. *Progress in neuro-psychopharmacology & biological psychiatry* 2004; **28**(6): 997-1006.
- 67. Cattane N, Minelli A, Milanesi E, Maj C, Bignotti S, Bortolomasi M *et al*. Altered gene expression in schizophrenia: findings from transcriptional signatures in fibroblasts and blood. *PloS one* 2015; **10**(2): e0116686.
- Watanabe S, Iga J, Nishi A, Numata S, Kinoshita M, Kikuchi K *et al.* Microarray analysis of global gene expression in leukocytes following lithium treatment. *Human psychopharmacology* 2014; 29(2): 190-198.
- 69. Gottschalk MG, Wesseling H, Guest PC, Bahn S. Proteomic enrichment analysis of psychotic and affective disorders reveals common signatures in presynaptic glutamatergic signaling and energy metabolism. *The international journal of neuropsychopharmacology / official scientific journal of the Collegium Internationale Neuropsychopharmacologicum* 2014; **18**(2).
- 70. Nicholas B, Rudrasingham V, Nash S, Kirov G, Owen MJ, Wimpory DC. Association of Per1 and Npas2 with autistic disorder: support for the clock genes/social timing hypothesis. *Molecular psychiatry* 2007; **12**(6): 581-592.

- 71. Utge SJ, Soronen P, Loukola A, Kronholm E, Ollila HM, Pirkola S *et al.* Systematic analysis of circadian genes in a population-based sample reveals association of TIMELESS with depression and sleep disturbance. *PloS one* 2010; **5**(2): e9259.
- 72. Dong L, Bilbao A, Laucht M, Henriksson R, Yakovleva T, Ridinger M *et al.* Effects of the circadian rhythm gene period 1 (per1) on psychosocial stress-induced alcohol drinking. *The American journal of psychiatry* 2011; **168**(10): 1090-1098.
- 73. Li JZ, Bunney BG, Meng F, Hagenauer MH, Walsh DM, Vawter MP *et al.* Circadian patterns of gene expression in the human brain and disruption in major depressive disorder. *Proceedings of the National Academy of Sciences of the United States of America* 2013; **110**(24): 9950-9955.
- 74. Novakova M, Prasko J, Latalova K, Sladek M, Sumova A. The circadian system of patients with bipolar disorder differs in episodes of mania and depression. *Bipolar disorders* 2015; **17**(3): 303-314.
- 75. Gouin JP, Connors J, Kiecolt-Glaser JK, Glaser R, Malarkey WB, Atkinson C *et al.* Altered expression of circadian rhythm genes among individuals with a history of depression. *Journal of affective disorders* 2010; **126**(1-2): 161-166.
- 76. Middleton FA, Pato CN, Gentile KL, McGann L, Brown AM, Trauzzi M *et al.* Gene expression analysis of peripheral blood leukocytes from discordant sib-pairs with schizophrenia and bipolar disorder reveals points of convergence between genetic and functional genomic approaches. *Am J Med Genet B Neuropsychiatr Genet* 2005; **136**(1): 12-25.
- 77. Huang MC, Ho CW, Chen CH, Liu SC, Chen CC, Leu SJ. Reduced expression of circadian clock genes in male alcoholic patients. *Alcoholism, clinical and experimental research* 2010; **34**(11): 1899-1904.
- 78. Pajer K, Andrus BM, Gardner W, Lourie A, Strange B, Campo J *et al.* Discovery of blood transcriptomic markers for depression in animal models and pilot validation in subjects with early-onset major depression. *Translational psychiatry* 2012; **2**: e101.
- 79. Redei EE, Andrus BM, Kwasny MJ, Seok J, Cai X, Ho J *et al.* Blood transcriptomic biomarkers in adult primary care patients with major depressive disorder undergoing cognitive behavioral therapy. *Translational psychiatry* 2014; **4**: e442.
- 80. Ising M, Lucae S, Binder EB, Bettecken T, Uhr M, Ripke S *et al.* A genomewide association study points to multiple loci that predict antidepressant drug treatment outcome in depression. *Arch Gen Psychiatry* 2009; **66**(9): 966-975.

- Mehta D, Klengel T, Conneely KN, Smith AK, Altmann A, Pace TW *et al.* Childhood maltreatment is associated with distinct genomic and epigenetic profiles in posttraumatic stress disorder.
 Proceedings of the National Academy of Sciences of the United States of America 2013; **110**(20): 8302-8307.
- 82. Juraeva D, Treutlein J, Scholz H, Frank J, Degenhardt F, Cichon S *et al.* XRCC5 as a risk gene for alcohol dependence: evidence from a genome-wide gene-set-based analysis and follow-up studies in Drosophila and humans. *Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology* 2015; **40**(2): 361-371.
- 83. Iossifov I, O'Roak BJ, Sanders SJ, Ronemus M, Krumm N, Levy D *et al.* The contribution of de novo coding mutations to autism spectrum disorder. *Nature* 2014; **515**(7526): 216-221.
- 84. Nurnberger JI, Jr., Koller DL, Jung J, Edenberg HJ, Foroud T, Guella I *et al.* Identification of pathways for bipolar disorder: a meta-analysis. *JAMA psychiatry* 2014; **71**(6): 657-664.
- 85. Aberg KA, McClay JL, Nerella S, Clark S, Kumar G, Chen W *et al.* Methylome-wide association study of schizophrenia: identifying blood biomarker signatures of environmental insults. *JAMA psychiatry* 2014; **71**(3): 255-264.
- 86. Gaiteri C, Guilloux JP, Lewis DA, Sibille E. Altered gene synchrony suggests a combined hormonemediated dysregulated state in major depression. *PloS one* 2010; **5**(4): e9970.
- 87. Moller-Levet CS, Archer SN, Bucca G, Laing EE, Slak A, Kabiljo R *et al.* Effects of insufficient sleep on circadian rhythmicity and expression amplitude of the human blood transcriptome. *Proceedings of the National Academy of Sciences of the United States of America* 2013; **110**(12): E1132-1141.
- 88. Glatt SJ, Stone WS, Nossova N, Liew CC, Seidman LJ, Tsuang MT. Similarities and differences in peripheral blood gene-expression signatures of individuals with schizophrenia and their first-degree biological relatives. *Am J Med Genet B Neuropsychiatr Genet* 2011; **156B**(8): 869-887.
- Kurian SM, Le-Niculescu H, Patel SD, Bertram D, Davis J, Dike C *et al.* Identification of blood biomarkers for psychosis using convergent functional genomics. *Molecular psychiatry* 2011; 16(1): 37-58.
- 90. Wong CC, Meaburn EL, Ronald A, Price TS, Jeffries AR, Schalkwyk LC *et al.* Methylomic analysis of monozygotic twins discordant for autism spectrum disorder and related behavioural traits. *Molecular psychiatry* 2014; **19**(4): 495-503.

- 91. Iwamoto K, Bundo M, Yamamoto M, Ozawa H, Saito T, Kato T. Decreased expression of NEFH and PCP4/PEP19 in the prefrontal cortex of alcoholics. *Neuroscience research* 2004; **49**(4): 379-385.
- 92. Lewohl JM, Wang L, Miles MF, Zhang L, Dodd PR, Harris RA. Gene expression in human alcoholism: microarray analysis of frontal cortex. *Alcohol Clin Exp Res* 2000; **24**(12): 1873-1882.
- 93. Bernard R, Kerman IA, Thompson RC, Jones EG, Bunney WE, Barchas JD *et al.* Altered expression of glutamate signaling, growth factor, and glia genes in the locus coeruleus of patients with major depression. *Molecular psychiatry* 2011; **16**(6): 634-646.
- 94. Focking M, Lopez LM, English JA, Dicker P, Wolff A, Brindley E *et al.* Proteomic and genomic evidence implicates the postsynaptic density in schizophrenia. *Molecular psychiatry* 2015; **20**(4): 424-432.
- Sainz J, Mata I, Barrera J, Perez-Iglesias R, Varela I, Arranz MJ *et al.* Inflammatory and immune response genes have significantly altered expression in schizophrenia. *Mol Psychiatry* 2013; 18(10): 1056-1057.
- 96. Miller GE, Chen E, Sze J, Marin T, Arevalo JM, Doll R *et al.* A functional genomic fingerprint of chronic stress in humans: blunted glucocorticoid and increased NF-kappaB signaling. *Biological psychiatry* 2008; **64**(4): 266-272.
- 97. McClintick JN, Xuei X, Tischfield JA, Goate A, Foroud T, Wetherill L *et al.* Stress-response pathways are altered in the hippocampus of chronic alcoholics. *Alcohol* 2013; **47**(7): 505-515.
- 98. Voineagu I, Wang X, Johnston P, Lowe JK, Tian Y, Horvath S *et al.* Transcriptomic analysis of autistic brain reveals convergent molecular pathology. *Nature* 2011; **474**(7351): 380-384.
- 99. Bezchlibnyk YB, Wang JF, McQueen GM, Young LT. Gene expression differences in bipolar disorder revealed by cDNA array analysis of post-mortem frontal cortex. *Journal of neurochemistry* 2001; **79**(4): 826-834.
- Kang HJ, Adams DH, Simen A, Simen BB, Rajkowska G, Stockmeier CA *et al.* Gene expression profiling in postmortem prefrontal cortex of major depressive disorder. *J Neurosci* 2007; 27(48): 13329-13340.

- 101. Stelzhammer V, Alsaif M, Chan MK, Rahmoune H, Steeb H, Guest PC *et al.* Distinct proteomic profiles in post-mortem pituitary glands from bipolar disorder and major depressive disorder patients. *Journal of psychiatric research* 2015; **60**: 40-48.
- 102. Leclercq C, Ferro-Luzzi A. Total and domestic consumption of salt and their determinants in three regions of Italy. *Eur J Clin Nutr* 1991; **45**(3): 151-159.
- 103. Domenici E, Wille DR, Tozzi F, Prokopenko I, Miller S, McKeown A *et al.* Plasma protein biomarkers for depression and schizophrenia by multi analyte profiling of case-control collections. *PLoS One* 2010; **5**(2): e9166.
- 104. Guilloux JP, Bassi S, Ding Y, Walsh C, Turecki G, Tseng G *et al.* Testing the predictive value of peripheral gene expression for nonremission following citalopram treatment for major depression. *Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology* 2015; **40**(3): 701-710.
- 105. Ersland KM, Christoforou A, Stansberg C, Espeseth T, Mattheisen M, Mattingsdal M *et al.* Genebased analysis of regionally enriched cortical genes in GWAS data sets of cognitive traits and psychiatric disorders. *PloS one* 2012; **7**(2): e31687.
- Beech RD, Lowthert L, Leffert JJ, Mason PN, Taylor MM, Umlauf S *et al.* Increased peripheral blood expression of electron transport chain genes in bipolar depression. *Bipolar disorders* 2010; 12(8): 813-824.
- 107. Maes OC, Xu S, Yu B, Chertkow HM, Wang E, Schipper HM. Transcriptional profiling of Alzheimer blood mononuclear cells by microarray. *Neurobiology of aging* 2007; **28**(12): 1795-1809.
- 108. Merjonen P, Keltikangas-Jarvinen L, Jokela M, Seppala I, Lyytikainen LP, Pulkki-Raback L *et al.* Hostility in adolescents and adults: a genome-wide association study of the Young Finns. *Translational psychiatry* 2011; **1**: e11.
- 109. Salyakina D, Ma DQ, Jaworski JM, Konidari I, Whitehead PL, Henson R *et al.* Variants in several genomic regions associated with asperger disorder. *Autism research : official journal of the International Society for Autism Research* 2010; **3**(6): 303-310.
- 110. Saiz PA, Garcia-Portilla MP, Florez G, Corcoran P, Arango C, Morales B *et al.* Polymorphisms of the IL-1 gene complex are associated with alcohol dependence in Spanish Caucasians: data from an association study. *Alcoholism, clinical and experimental research* 2009; **33**(12): 2147-2153.

- 111. Flatscher-Bader T, van der Brug M, Hwang JW, Gochee PA, Matsumoto I, Niwa S *et al.* Alcoholresponsive genes in the frontal cortex and nucleus accumbens of human alcoholics. *Journal of neurochemistry* 2005; **93**(2): 359-370.
- 112. Rao JS, Harry GJ, Rapoport SI, Kim HW. Increased excitotoxicity and neuroinflammatory markers in postmortem frontal cortex from bipolar disorder patients. *Molecular psychiatry* 2010; **15**(4): 384-392.
- 113. Fillman SG, Sinclair D, Fung SJ, Webster MJ, Shannon Weickert C. Markers of inflammation and stress distinguish subsets of individuals with schizophrenia and bipolar disorder. *Translational psychiatry* 2014; **4**: e365.
- 114. Toyooka K, Watanabe Y, Iritani S, Shimizu E, Iyo M, Nakamura R *et al*. A decrease in interleukin-1 receptor antagonist expression in the prefrontal cortex of schizophrenic patients. *Neuroscience research* 2003; **46**(3): 299-307.
- 115. de Witte L, Tomasik J, Schwarz E, Guest PC, Rahmoune H, Kahn RS *et al.* Cytokine alterations in first-episode schizophrenia patients before and after antipsychotic treatment. *Schizophrenia research* 2014; **154**(1-3): 23-29.
- 116. Chan MK, Krebs MO, Cox D, Guest PC, Yolken RH, Rahmoune H *et al.* Development of a bloodbased molecular biomarker test for identification of schizophrenia before disease onset. *Translational psychiatry* 2015; **5**: e601.
- Morita K, Saito T, Ohta M, Ohmori T, Kawai K, Teshima-Kondo S *et al.* Expression analysis of psychological stress-associated genes in peripheral blood leukocytes. *Neurosci Lett* 2005; **381**(1-2): 57-62.
- 118. Ohmori T, Morita K, Saito T, Ohta M, Ueno S, Rokutan K. Assessment of human stress and depression by DNA microarray analysis. *J Med Invest* 2005; **52 Suppl:** 266-271.
- 119. Howren MB, Lamkin DM, Suls J. Associations of depression with C-reactive protein, IL-1, and IL-6: a meta-analysis. *Psychosomatic medicine* 2009; **71**(2): 171-186.
- 120. Bergink V, Burgerhout KM, Weigelt K, Pop VJ, de Wit H, Drexhage RC *et al.* Immune system dysregulation in first-onset postpartum psychosis. *Biological psychiatry* 2013; **73**(10): 1000-1007.

- 121. Goes FS, Hamshere ML, Seifuddin F, Pirooznia M, Belmonte-Mahon P, Breuer R *et al.* Genome-wide association of mood-incongruent psychotic bipolar disorder. *Translational psychiatry* 2012;
 2: e180.
- 122. Matigian N, Windus L, Smith H, Filippich C, Pantelis C, McGrath J *et al.* Expression profiling in monozygotic twins discordant for bipolar disorder reveals dysregulation of the WNT signalling pathway. *Molecular psychiatry* 2007; **12**(9): 815-825.
- 123. Lit L, Gilbert DL, Walker W, Sharp FR. A subgroup of Tourette's patients overexpress specific natural killer cell genes in blood: a preliminary report. *American journal of medical genetics Part B, Neuropsychiatric genetics : the official publication of the International Society of Psychiatric Genetics* 2007; **144B**(7): 958-963.
- 124. Ikeda M, Aleksic B, Kirov G, Kinoshita Y, Yamanouchi Y, Kitajima T *et al.* Copy number variation in schizophrenia in the Japanese population. *Biological psychiatry* 2010; **67**(3): 283-286.
- 125. Stopkova P, Saito T, Papolos DF, Vevera J, Paclt I, Zukov I *et al.* Identification of PIK3C3 promoter variant associated with bipolar disorder and schizophrenia. *Biological psychiatry* 2004; **55**(10): 981-988.
- 126. Glessner JT, Reilly MP, Kim CE, Takahashi N, Albano A, Hou C *et al*. Strong synaptic transmission impact by copy number variations in schizophrenia. *Proc Natl Acad Sci U S A* 2010; **107**(23): 10584-10589.
- 127. Carrard A, Salzmann A, Perroud N, Gafner J, Malafosse A, Karege F. Genetic association of the Phosphoinositide-3 kinase in schizophrenia and bipolar disorder and interaction with a BDNF gene polymorphism. *Brain and behavior* 2011; **1**(2): 119-124.
- Walsh T, McClellan JM, McCarthy SE, Addington AM, Pierce SB, Cooper GM *et al.* Rare structural variants disrupt multiple genes in neurodevelopmental pathways in schizophrenia. *Science* 2008; 320(5875): 539-543.
- 129. Koga M, Ishiguro H, Yazaki S, Horiuchi Y, Arai M, Niizato K *et al.* Involvement of SMARCA2/BRM in the SWI/SNF chromatin-remodeling complex in schizophrenia. *Human molecular genetics* 2009; **18**(13): 2483-2494.
- 130. Loe-Mie Y, Lepagnol-Bestel AM, Maussion G, Doron-Faigenboim A, Imbeaud S, Delacroix H *et al.* SMARCA2 and other genome-wide supported schizophrenia-associated genes: regulation by REST/NRSF, network organization and primate-specific evolution. *Human molecular genetics* 2010; **19**(14): 2841-2857.

- 131. Walter S, Atzmon G, Demerath EW, Garcia ME, Kaplan RC, Kumari M *et al.* A genome-wide association study of aging. *Neurobiology of aging* 2011; **32**(11): 2109 e2115-2128.
- 132. Szatkiewicz JP, O'Dushlaine C, Chen G, Chambert K, Moran JL, Neale BM *et al.* Copy number variation in schizophrenia in Sweden. *Molecular psychiatry* 2014; **19**(7): 762-773.
- 133. Vawter MP, Atz ME, Rollins BL, Cooper-Casey KM, Shao L, Byerley WF. Genome scans and gene expression microarrays converge to identify gene regulatory loci relevant in schizophrenia. *Hum Genet* 2006; **119**(5): 558-570.
- Hakak Y, Walker JR, Li C, Wong WH, Davis KL, Buxbaum JD *et al.* Genome-wide expression analysis reveals dysregulation of myelination-related genes in chronic schizophrenia.
 Proceedings of the National Academy of Sciences of the United States of America 2001; **98**(8): 4746-4751.
- 135. Hennings JM, Uhr M, Klengel T, Weber P, Putz B, Touma C *et al.* RNA expression profiling in depressed patients suggests retinoid-related orphan receptor alpha as a biomarker for antidepressant response. *Translational psychiatry* 2015; **5**: e538.
- 136. Glatt SJ, Everall IP, Kremen WS, Corbeil J, Sasik R, Khanlou N *et al.* Comparative gene expression analysis of blood and brain provides concurrent validation of SELENBP1 up-regulation in schizophrenia. *Proc Natl Acad Sci U S A* 2005; **102**(43): 15533-15538.
- 137. Schizophrenia Working Group of the Psychiatric Genomics C. Biological insights from 108 schizophrenia-associated genetic loci. *Nature* 2014; **511**(7510): 421-427.
- 138. Jurata LW, Bukhman YV, Charles V, Capriglione F, Bullard J, Lemire AL *et al.* Comparison of microarray-based mRNA profiling technologies for identification of psychiatric disease and drug signatures. *Journal of neuroscience methods* 2004; **138**(1-2): 173-188.
- 139. Martins-de-Souza D, Maccarrone G, Ising M, Kloiber S, Lucae S, Holsboer F *et al.* Blood mononuclear cell proteome suggests integrin and Ras signaling as critical pathways for antidepressant treatment response. *Biological psychiatry* 2014; **76**(7): e15-17.
- 140. Herberth M, Koethe D, Cheng TM, Krzyszton ND, Schoeffmann S, Guest PC *et al.* Impaired glycolytic response in peripheral blood mononuclear cells of first-onset antipsychotic-naive schizophrenia patients. *Molecular psychiatry* 2011; **16**(8): 848-859.

- 141. Salaria S, Chana G, Caldara F, Feltrin E, Altieri M, Faggioni F *et al.* Microarray analysis of cultured human brain aggregates following cortisol exposure: implications for cellular functions relevant to mood disorders. *Neurobiology of disease* 2006; **23**(3): 630-636.
- 142. Iwamoto K, Bundo M, Kato T. Altered expression of mitochondria-related genes in postmortem brains of patients with bipolar disorder or schizophrenia, as revealed by large-scale DNA microarray analysis. *Human molecular genetics* 2005; **14**(2): 241-253.
- 143. Maccarrone G, Ditzen C, Yassouridis A, Rewerts C, Uhr M, Uhlen M *et al.* Psychiatric patient stratification using biosignatures based on cerebrospinal fluid protein expression clusters. *Journal of psychiatric research* 2013; **47**(11): 1572-1580.
- 144. Le-Niculescu H, Kurian SM, Yehyawi N, Dike C, Patel SD, Edenberg HJ *et al.* Identifying blood biomarkers for mood disorders using convergent functional genomics. *Molecular psychiatry* 2009; **14**(2): 156-174.
- 145. Liu J, Lewohl JM, Harris RA, Iyer VR, Dodd PR, Randall PK *et al.* Patterns of gene expression in the frontal cortex discriminate alcoholic from nonalcoholic individuals. *Neuropsychopharmacology* 2006; **31**(7): 1574-1582.
- 146. Clark D, Dedova I, Cordwell S, Matsumoto I. A proteome analysis of the anterior cingulate cortex gray matter in schizophrenia. *Molecular psychiatry* 2006; **11**(5): 459-470, 423.
- 147. Nakatani N, Ohnishi T, Iwamoto K, Watanabe A, Iwayama Y, Yamashita S *et al.* Expression analysis of actin-related genes as an underlying mechanism for mood disorders. *Biochemical and biophysical research communications* 2007; **352**(3): 780-786.
- 148. Juraeva D, Haenisch B, Zapatka M, Frank J, Investigators G, Group P-GSW *et al.* Integrated pathway-based approach identifies association between genomic regions at CTCF and CACNB2 and schizophrenia. *PLoS genetics* 2014; **10**(6): e1004345.
- 149. Ripke S, O'Dushlaine C, Chambert K, Moran JL, Kahler AK, Akterin S *et al.* Genome-wide association analysis identifies 13 new risk loci for schizophrenia. *Nat Genet* 2013; **45**(10): 1150-1159.
- 150. Deelen J, Uh HW, Monajemi R, van Heemst D, Thijssen PE, Bohringer S *et al.* Gene set analysis of GWAS data for human longevity highlights the relevance of the insulin/IGF-1 signaling and telomere maintenance pathways. *Age (Dordr)* 2013; **35**(1): 235-249.
- 151. Jansen R, Penninx BW, Madar V, Xia K, Milaneschi Y, Hottenga JJ *et al.* Gene expression in major depressive disorder. *Molecular psychiatry* 2015.
- 152. Rizzi TS, Arias-Vasquez A, Rommelse N, Kuntsi J, Anney R, Asherson P *et al.* The ATXN1 and TRIM31 genes are related to intelligence in an ADHD background: evidence from a large collaborative study totaling 4,963 subjects. *American journal of medical genetics Part B, Neuropsychiatric genetics : the official publication of the International Society of Psychiatric Genetics* 2011; **156**(2): 145-157.
- 153. Fallin MD, Lasseter VK, Avramopoulos D, Nicodemus KK, Wolyniec PS, McGrath JA *et al.* Bipolar I disorder and schizophrenia: a 440-single-nucleotide polymorphism screen of 64 candidate genes among Ashkenazi Jewish case-parent trios. *American journal of human genetics* 2005; **77**(6): 918-936.
- Johnson C, Drgon T, McMahon FJ, Uhl GR. Convergent genome wide association results for bipolar disorder and substance dependence. *Am J Med Genet B Neuropsychiatr Genet* 2009; 150B(2): 182-190.
- 155. Shi J, Levinson DF, Duan J, Sanders AR, Zheng Y, Pe'er I *et al.* Common variants on chromosome 6p22.1 are associated with schizophrenia. *Nature* 2009; **460**(7256): 753-757.
- 156. Culjkovic B, Stojkovic O, Savic D, Zamurovic N, Nesic M, Major T *et al.* Comparison of the number of triplets in SCA1, MJD/SCA3, HD, SBMA, DRPLA, MD, FRAXA and FRDA genes in schizophrenic patients and a healthy population. *Am J Med Genet* 2000; **96**(6): 884-887.
- 157. Cole SW, Hawkley LC, Arevalo JM, Sung CY, Rose RM, Cacioppo JT. Social regulation of gene expression in human leukocytes. *Genome Biol* 2007; **8**(9): R189.
- 158. Cichon S, Muhleisen TW, Degenhardt FA, Mattheisen M, Miro X, Strohmaier J *et al.* Genomewide association study identifies genetic variation in neurocan as a susceptibility factor for bipolar disorder. *Am J Hum Genet* 2011; **88**(3): 372-381.
- 159. Sebastiani P, Solovieff N, Dewan AT, Walsh KM, Puca A, Hartley SW *et al*. Genetic signatures of exceptional longevity in humans. *PloS one* 2012; **7**(1): e29848.
- 160. Sokolov BP, Jiang L, Trivedi NS, Aston C. Transcription profiling reveals mitochondrial, ubiquitin and signaling systems abnormalities in postmortem brains from subjects with a history of alcohol abuse or dependence. *Journal of neuroscience research* 2003; **72**(6): 756-767.

- 161. Yu Z, Ono C, Kim HB, Komatsu H, Tanabe Y, Sakae N *et al*. Four mood stabilizers commonly induce FEZ1 expression in human astrocytes. *Bipolar disorders* 2011; **13**(5-6): 486-499.
- 162. Gardiner EJ, Cairns MJ, Liu B, Beveridge NJ, Carr V, Kelly B *et al.* Gene expression analysis reveals schizophrenia-associated dysregulation of immune pathways in peripheral blood mononuclear cells. *Journal of psychiatric research* 2013; **47**(4): 425-437.
- 163. Shao L, Vawter MP. Shared gene expression alterations in schizophrenia and bipolar disorder. *Biological psychiatry* 2008; **64**(2): 89-97.
- 164. Martins-de-Souza D, Guest PC, Harris LW, Vanattou-Saifoudine N, Webster MJ, Rahmoune H *et al.* Identification of proteomic signatures associated with depression and psychotic depression in post-mortem brains from major depression patients. *Translational psychiatry* 2012; **2**: e87.
- 165. Yokota T, Mishra M, Akatsu H, Tani Y, Miyauchi T, Yamamoto T *et al.* Brain site-specific gene expression analysis in Alzheimer's disease patients. *Eur J Clin Invest* 2006; **36**(11): 820-830.
- 166. Harris LW, Lockstone HE, Khaitovich P, Weickert CS, Webster MJ, Bahn S. Gene expression in the prefrontal cortex during adolescence: implications for the onset of schizophrenia. *BMC Med Genomics* 2009; **2**: 28.
- 167. Kalsi G, Kuo PH, Aliev F, Alexander J, McMichael O, Patterson DG *et al.* A systematic gene-based screen of chr4q22-q32 identifies association of a novel susceptibility gene, DKK2, with the quantitative trait of alcohol dependence symptom counts. *Human molecular genetics* 2010; 19(12): 2497-2506.
- 168. Kerner B, Rao AR, Christensen B, Dandekar S, Yourshaw M, Nelson SF. Rare Genomic Variants Link Bipolar Disorder with Anxiety Disorders to CREB-Regulated Intracellular Signaling Pathways. *Front Psychiatry* 2013; **4:** 154.
- 169. Hattori E, Toyota T, Ishitsuka Y, Iwayama Y, Yamada K, Ujike H *et al.* Preliminary genome-wide association study of bipolar disorder in the Japanese population. *Am J Med Genet B Neuropsychiatr Genet* 2009; **150B**(8): 1110-1117.
- 170. Dean B, Keriakous D, Scarr E, Thomas EA. Gene expression profiling in Brodmann's area 46 from subjects with schizophrenia. *Aust N Z J Psychiatry* 2007; **41**(4): 308-320.
- 171. Sood S, Gallagher IJ, Lunnon K, Rullman E, Keohane A, Crossland H *et al.* A novel multi-tissue RNA diagnostic of healthy ageing relates to cognitive health status. *Genome Biol* 2015; **16**: 185.

- 172. Jaros JA, Martins-de-Souza D, Rahmoune H, Rothermundt M, Leweke FM, Guest PC *et al.* Protein phosphorylation patterns in serum from schizophrenia patients and healthy controls. *J Proteomics* 2012; **76 Spec No.:** 43-55.
- 173. Tajouri L, Mellick AS, Tourtellotte A, Nagra RM, Griffiths LR. An examination of MS candidate genes identified as differentially regulated in multiple sclerosis plaque tissue, using absolute and comparative real-time Q-PCR analysis. *Brain Res Brain Res Protoc* 2005; **15**(2): 79-91.
- 174. Smalla KH, Mikhaylova M, Sahin J, Bernstein HG, Bogerts B, Schmitt A *et al.* A comparison of the synaptic proteome in human chronic schizophrenia and rat ketamine psychosis suggest that prohibitin is involved in the synaptic pathology of schizophrenia. *Mol Psychiatry* 2008; **13**(9): 878-896.
- 175. Etheridge N, Lewohl JM, Mayfield RD, Harris RA, Dodd PR. Synaptic proteome changes in the superior frontal gyrus and occipital cortex of the alcoholic brain. *Proteomics Clin Appl* 2009; **3**(6): 730-742.
- 176. Kanazawa T, Ikeda M, Glatt SJ, Tsutsumi A, Kikuyama H, Kawamura Y *et al.* Genome-wide association study of atypical psychosis. *American journal of medical genetics Part B, Neuropsychiatric genetics : the official publication of the International Society of Psychiatric Genetics* 2013; **162B**(7): 679-686.
- 177. Byrne EM, Psychiatric Genetics Consortium Major Depressive Disorder Working G, Raheja UK, Stephens SH, Heath AC, Madden PA *et al.* Seasonality shows evidence for polygenic architecture and genetic correlation with schizophrenia and bipolar disorder. *J Clin Psychiatry* 2015; **76**(2): 128-134.
- 178. Girard SL, Gauthier J, Noreau A, Xiong L, Zhou S, Jouan L *et al.* Increased exonic de novo mutation rate in individuals with schizophrenia. *Nature genetics* 2011; **43**(9): 860-863.
- 179. Bowden NA, Scott RJ, Tooney PA. Altered gene expression in the superior temporal gyrus in schizophrenia. *BMC Genomics* 2008; **9:** 199.
- 180. Yi Z, Li Z, Yu S, Yuan C, Hong W, Wang Z *et al.* Blood-based gene expression profiles models for classification of subsyndromal symptomatic depression and major depressive disorder. *PloS one* 2012; **7**(2): e31283.
- 181. Seelan RS, Khalyfa A, Lakshmanan J, Casanova MF, Parthasarathy RN. Deciphering the lithium transcriptome: microarray profiling of lithium-modulated gene expression in human neuronal cells. *Neuroscience* 2008; **151**(4): 1184-1197.

- 182. Sanders AR, Goring HH, Duan J, Drigalenko El, Moy W, Freda J *et al.* Transcriptome study of differential expression in schizophrenia. *Human molecular genetics* 2013; **22**(24): 5001-5014.
- 183. Shelton RC, Claiborne J, Sidoryk-Wegrzynowicz M, Reddy R, Aschner M, Lewis DA *et al.* Altered expression of genes involved in inflammation and apoptosis in frontal cortex in major depression. *Molecular psychiatry* 2011; **16**(7): 751-762.
- 184. Chen G, Zeng WZ, Yuan PX, Huang LD, Jiang YM, Zhao ZH *et al*. The mood-stabilizing agents lithium and valproate robustly increase the levels of the neuroprotective protein bcl-2 in the CNS. *Journal of neurochemistry* 1999; **72**(2): 879-882.
- 185. Chen RW, Chuang DM. Long term lithium treatment suppresses p53 and Bax expression but increases Bcl-2 expression. A prominent role in neuroprotection against excitotoxicity. *J Biol Chem* 1999; **274**(10): 6039-6042.
- 186. Keshavarz M, Emamghoreishi M, Nekooeian AA, J JW, Zare HR. Increased bcl-2 Protein Levels in Rat Primary Astrocyte Culture Following Chronic Lithium Treatment. *Iran J Med Sci* 2013; **38**(3): 255-262.
- 187. Chen G, Rajkowska G, Du F, Seraji-Bozorgzad N, Manji HK. Enhancement of hippocampal neurogenesis by lithium. *Journal of neurochemistry* 2000; **75**(4): 1729-1734.
- 188. Hammonds MD, Shim SS. Effects of 4-week treatment with lithium and olanzapine on levels of brain-derived neurotrophic factor, B-cell CLL/lymphoma 2 and phosphorylated cyclic adenosine monophosphate response element-binding protein in the sub-regions of the hippocampus. *Basic & clinical pharmacology & toxicology* 2009; **105**(2): 113-119.
- 189. Bai O, Zhang H, Li XM. Antipsychotic drugs clozapine and olanzapine upregulate bcl-2 mRNA and protein in rat frontal cortex and hippocampus. *Brain Res* 2004; **1010**(1-2): 81-86.
- 190. Fatemi SH, Reutiman TJ, Folsom TD. Chronic psychotropic drug treatment causes differential expression of Reelin signaling system in frontal cortex of rats. *Schizophr Res* 2009; **111**(1-3): 138-152.
- 191. MacDonald ML, Eaton ME, Dudman JT, Konradi C. Antipsychotic drugs elevate mRNA levels of presynaptic proteins in the frontal cortex of the rat. *Biological psychiatry* 2005; **57**(9): 1041-1051.

- 192. Le-Niculescu H, Case NJ, Hulvershorn L, Patel SD, Bowker D, Gupta J *et al.* Convergent functional genomic studies of omega-3 fatty acids in stress reactivity, bipolar disorder and alcoholism. *Translational psychiatry* 2011; **1**: e4.
- 193. Le-Niculescu H, Balaraman Y, Patel S, Tan J, Sidhu K, Jerome RE *et al.* Towards understanding the schizophrenia code: an expanded convergent functional genomics approach. *American journal of medical genetics Part B, Neuropsychiatric genetics : the official publication of the International Society of Psychiatric Genetics* 2007; **144B**(2): 129-158.
- Jakovcevski M, Bharadwaj R, Straubhaar J, Gao G, Gavin DP, Jakovcevski I *et al.* Prefrontal cortical dysfunction after overexpression of histone deacetylase 1. *Biological psychiatry* 2013; 74(9): 696-705.
- 195. Hammamieh R, Chakraborty N, Gautam A, Miller SA, Muhie S, Meyerhoff J *et al.* Transcriptomic analysis of the effects of a fish oil enriched diet on murine brains. *PloS one* 2014; **9**(3): e90425.
- Lamb J, Crawford ED, Peck D, Modell JW, Blat IC, Wrobel MJ *et al.* The Connectivity Map: using gene-expression signatures to connect small molecules, genes, and disease. *Science* 2006; 313(5795): 1929-1935.
- 197. Lamb J. The Connectivity Map: a new tool for biomedical research. *Nat Rev Cancer* 2007; **7**(1): 54-60.